prednisone has been researched along with Metastase in 429 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Excerpt | Relevance | Reference |
---|---|---|
"The addition of radium-223 to abiraterone acetate plus prednisone or prednisolone did not improve symptomatic skeletal event-free survival in patients with castration-resistant prostate cancer and bone metastases, and was associated with an increased frequency of bone fractures compared with placebo." | 9.30 | Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. ( Boegemann, M; Heidenreich, A; Higano, C; Kakehi, Y; Karyakin, O; Kimura, G; Krissel, H; Matsubara, N; Matveev, V; Miller, K; Nahas, WC; Ng, QS; Nolè, F; Parker, C; Piulats, JM; Rosenbaum, E; Saad, F; Shen, J; Smith, M; Teufel, M; Tombal, B; Wagner, V; Zhang, A; Zucca, LE, 2019) |
"Cabazitaxel significantly improves overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) progressing during or after docetaxel, but is associated with a higher rate of grade ≥3 neutropenia compared with docetaxel." | 9.22 | Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. ( de Bono, J; de Wit, R; Liewen, H; Meisel, A; Sartor, O; Stenner-Liewen, F; Vogt, DR; von Felten, S, 2016) |
"In patients with mCRPC progressing after docetaxel chemotherapy, abiraterone acetate and prednisone yielded clinically meaningful improvements in patient-reported fatigue compared with prednisone alone." | 9.17 | Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. ( Cleeland, C; de Bono, JS; Fizazi, K; Gagnon, DD; Hao, Y; Haqq, CM; Kheoh, T; Mainwaring, P; Molina, A; North, S; Rothman, M; Scher, HI; Sternberg, CN, 2013) |
"When administered as a single agent to previously treated patients with advanced breast cancer, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has good activity." | 9.08 | A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand. ( Ackland, S; Bishop, JF; Dewar, J; Goldstein, D; Gurney, H; Kennedy, I; Levi, J; Olver, I; Stephenson, J; Tattersall, MH; Toner, G; Walpole, E, 1997) |
"Sixty-seven patients with advanced breast cancer were prospectively entered into a Phase II trial of cyclophosphamide 100 mg/m2 orally on days 1-14, methotrexate 40 mg/m2 intravenously (i." | 9.07 | A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer. ( Bishop, JF; Dipell, JF; Jeal, P; Laidlaw, CR; Olver, IN; Rischin, D; Zimet, A, 1992) |
"The prospective controlled phase III clinical trial compared the therapeutic value of the cis-platinum - adriamycin - cyclophosphamide combination (CAP) and that of the combination of cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisolone (CMFVP) in untreated metastatic breast cancer." | 9.05 | CAP (cyclophosphamide, adriamycin, platinum) vs CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study. ( Cervek, J; Kolarić, K; Roth, A; Vukas, D, 1984) |
"To evaluate the association of the use of concomitant BRIs with overall survival (OS) and time to first SRE among patients with mCRPC and bone metastases receiving abiraterone acetate with prednisone as first-line therapy." | 8.02 | Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy. ( Alimohamed, NS; Bengala, C; Bryce, AH; Cigliola, A; Crivelli, F; Francini, E; Francini, G; Garcia-Foncillas, J; Gonzalez-Velez, M; Harshman, LC; Heng, DYC; Higano, CS; Lee-Ying, R; Montagnani, F; Moreno-Candilejo, I; Nuzzo, PV; Petrioli, R; Rosellini, P; Rubio-Perez, J; Shaw, GK; Sweeney, CJ; Zhang, L, 2021) |
"Thirty-seven men with symptomatic bone metastases from prostate cancer that had progressed following earlier treatment with estrogens and/or orchidectomy were treated with low-dose prednisone (7." | 7.67 | Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. ( Gospodarowicz, M; Meakin, W; Panzarella, T; Rider, W; Stewart, L; Tannock, I, 1989) |
"Forty-nine postmenopausal patients with advanced breast cancer were treated with a nonsteroidal antiestrogen, Nafoxidine." | 7.66 | Clinical trial of nafoxidine in advanced breast cancer. ( De Jager, RL; Krakoff, IH; Steinbaum, FL, 1978) |
"Prednisone was given orally at 60 mg/m(2) per day for five consecutive days within each 28-day cycle." | 6.75 | A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. ( Conley, BA; Dancey, J; Doroshow, JH; Figg, WD; Gardner, ER; Gutierrez, ME; Kummar, S; Melillo, G; Murgo, AJ; Sausville, EA, 2010) |
"Concerning bone metastases there was no difference between the two schedules in response rate, nor in the median remission duration (CAP 11, FAC 10 months)." | 6.66 | Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5-fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study. ( Kolarić, K; Potrebica, V; Vukas, D, 1989) |
"The addition of radium-223 to abiraterone acetate plus prednisone or prednisolone did not improve symptomatic skeletal event-free survival in patients with castration-resistant prostate cancer and bone metastases, and was associated with an increased frequency of bone fractures compared with placebo." | 5.30 | Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. ( Boegemann, M; Heidenreich, A; Higano, C; Kakehi, Y; Karyakin, O; Kimura, G; Krissel, H; Matsubara, N; Matveev, V; Miller, K; Nahas, WC; Ng, QS; Nolè, F; Parker, C; Piulats, JM; Rosenbaum, E; Saad, F; Shen, J; Smith, M; Teufel, M; Tombal, B; Wagner, V; Zhang, A; Zucca, LE, 2019) |
"Men with mHNPC having ≥2 of 3 high-risk factors (Gleason score ≥8, ≥3 bone lesions or measurable visceral metastases) randomly received abiraterone acetate 1000-mg+ prednisone 5-mg+ADT (AAP group) or ADT+Placebos (Placebo group)." | 5.27 | Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study. ( Enjo, K; Fizazi, K; Fukasawa, S; Kawaguchi, K; Matsubara, N; Noguchi, H; Suzuki, H; Todd, M; Tran, N, 2018) |
"Cabazitaxel significantly improves overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) progressing during or after docetaxel, but is associated with a higher rate of grade ≥3 neutropenia compared with docetaxel." | 5.22 | Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. ( de Bono, J; de Wit, R; Liewen, H; Meisel, A; Sartor, O; Stenner-Liewen, F; Vogt, DR; von Felten, S, 2016) |
"The present multicenter phase II trial evaluated the safety and efficacy of pegylated liposomal doxorubicin (PLD) instead of conventional doxorubicin in standard R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine [Oncovin], and prednisone) therapy for elderly patients with diffuse large B-cell lymphoma." | 5.20 | Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. ( Astrow, AB; Durand, JB; Ewer, MS; Fanale, M; Fayad, LE; Fisch, MJ; Fowler, N; Hagemeister, FB; Huang, X; Kwak, LW; Lenihan, DJ; McLaughlin, P; Neelapu, SS; Oki, Y; Pro, B; Rodriguez, MA; Romaguera, J; Samaniego, F; Wang, M; Younes, A, 2015) |
"In patients with mCRPC progressing after docetaxel chemotherapy, abiraterone acetate and prednisone yielded clinically meaningful improvements in patient-reported fatigue compared with prednisone alone." | 5.17 | Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. ( Cleeland, C; de Bono, JS; Fizazi, K; Gagnon, DD; Hao, Y; Haqq, CM; Kheoh, T; Mainwaring, P; Molina, A; North, S; Rothman, M; Scher, HI; Sternberg, CN, 2013) |
"The association of cycle 1 neutropenia with overall survival (OS) was examined post hoc in a randomized phase II trial of 221 men with mCRPC who received docetaxel-prednisone combined with placebo or AT-101 (bcl-2 inhibitor); weekly blood cell counts were performed during the first cycle." | 5.16 | Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. ( Berry, WR; Galsky, MD; Leopold, L; Pond, GR; Sonpavde, G; Wood, BA, 2012) |
"To investigate the use of docetaxel 75 mg/m(2) intravenously every 3 weeks plus prednisone 5 mg orally twice daily in men with metastatic hormone-refractory prostate cancer (HRPC) progressing after first-line mitoxantrone/prednisone (MP), the primary outcome being progression-free survival with prostatic-specific antigen (PSA) and pain response, toxicity and quality of life (QoL) also assessed." | 5.13 | The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. ( Cheng, T; Ernst, S; Karakiewicz, P; North, S; Perrotte, P; Ruether, D; Saad, F; Winquist, E, 2008) |
"When administered as a single agent to previously treated patients with advanced breast cancer, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has good activity." | 5.08 | A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand. ( Ackland, S; Bishop, JF; Dewar, J; Goldstein, D; Gurney, H; Kennedy, I; Levi, J; Olver, I; Stephenson, J; Tattersall, MH; Toner, G; Walpole, E, 1997) |
"One hundred ninety-five women (141 eligible) whose disease was in CR or in CR except for bone metastases following six cycles (6 months) of doxorubicin-containing induction treatment were randomized to receive cyclophosphamide, methotrexate, fluorouracil, prednisone, tamoxifen, and halotestin [CMF(P)TH] or observation." | 5.08 | Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. ( Abeloff, MD; Cummings, FJ; Falkson, G; Gelman, RS; Osborne, CK; Pandya, KJ; Sledge, GW; Tormey, D, 1998) |
"Sixty-seven patients with advanced breast cancer were prospectively entered into a Phase II trial of cyclophosphamide 100 mg/m2 orally on days 1-14, methotrexate 40 mg/m2 intravenously (i." | 5.07 | A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer. ( Bishop, JF; Dipell, JF; Jeal, P; Laidlaw, CR; Olver, IN; Rischin, D; Zimet, A, 1992) |
" Our earlier study in breast cancer showed that second-line CAP (cyclophosphamide, adriamycin, cis-platinum) treatment was not cross-resistant to the CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) regimen and produced a 51% response rate." | 5.06 | cis-platinum-based alternating non-cross-resistant chemotherapy as a first-line treatment in metastatic breast cancer. A phase II study. ( Kolarić, K; Tomek, R, 1990) |
"A randomized trial was performed to determine relative efficacy and toxicity of two first-line combination chemotherapy regimens in women with metastatic breast cancer: CFP (cyclophosphamide, 5-fluorouracil, prednisone) and CMFP (cyclophosphamide, 5-fluorouracil, methotrexate, prednisone)." | 5.06 | Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer. ( Cullinan, SA; Ebbert, LP; Ingle, JN; Krook, JE; Mailliard, JA; Marschke, RF; Pfeifle, DM; Schaid, DJ; Votava, HJ; Windschitl, HE, 1989) |
"Ninety-seven eligible and evaluable women with metastatic breast cancer were placed on a prospective clinical protocol to evaluate the use of continuous cyclic therapy with dibromodulcitol, doxorubicin, vincristine, tamoxifen, and fluoxymesterone (DAVTH) v DAVTH alternating with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP); and the use of pretreatment and serial carcinoembryonic antigen (CEA) levels in these patients." | 5.06 | Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer. ( Chang, AY; Davis, TE; Falkson, G; Falkson, HC; Loprinzi, CL; Rasmussen, P; Tormey, DC, 1986) |
"The prospective controlled phase III clinical trial compared the therapeutic value of the cis-platinum - adriamycin - cyclophosphamide combination (CAP) and that of the combination of cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisolone (CMFVP) in untreated metastatic breast cancer." | 5.05 | CAP (cyclophosphamide, adriamycin, platinum) vs CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study. ( Cervek, J; Kolarić, K; Roth, A; Vukas, D, 1984) |
"Seventy patients with advanced metastatic breast cancer were treated with an oral drug regime of prednisone, cytomel, cytoxan, and methotrexate." | 5.05 | Treatment of breast cancer with oral four-drug chemotherapy. ( Foley, JF; Kessinger, MA; Lemon, HM, 1980) |
"In 1977 we reported our results of an ongoing randomized clinical trial evaluating early or delayed adjuvant chemotherapy utilizing 5-flourouracil, cytoxan and prednisone in premenopausal patients with recurrent or advanced breast cancer." | 5.05 | An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advances breast cancer undergoing oophorectomy: a later analysis. ( Ahmann, DL; Bisel, HF; Edmonson, JH; Green, SJ; Hahn, RG; Ingle, JN; Lee, RA, 1982) |
"One hundred fifty-five eligible women with metastatic breast cancer were randomly allocated to receive monthly cycles of either CMFP (cyclophosphamide, methotrexate, 5-fluorouracil, prednisone) or CAF (cyclophosphamide, doxorubicin, 5-fluorouracil), and 12 patients were studied to evaluate the effects of additional Corynebacterium parvum immunotherapy." | 5.05 | Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors. ( Cummings, FJ; Gelman, R; Horton, J, 1985) |
"We treated randomly 75 premenopausal patients with advanced breast cancer with combination chemotherapy (5-fluorouracil, cyclophosphamide and prednisone), either as an early adjunct to oophorectomy or as a delayed treatment upon appearance of progressive metastatic disease after operation." | 5.04 | An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy. ( Ahmann, DL; Bisel, HF; Edmonson, JH; Hahn, RG; Lee, RA; O'Connell, MJ, 1977) |
"A randomized clinical trial, involving approximately 100 patients, that compared two combination therapy regimens (5 FU, methotrexate, vincristine, cyclophosphamide with and without prednisone) in advanced breast cancer showed a significantly higher rate of response for the 5-drug therapy group (62." | 5.04 | Combination chemotherapy in breast cancer: a randomized study of 4 versus 5 drugs. ( Cornell, GN; Klotz, J; Madden, RE; Minton, JP; Ramirez, G; Strawitz, JG; Wilson, WL, 1975) |
"When added to androgen deprivation, therapies demonstrating improved survival, improved quality of life (QOL), and favorable benefit-harm balance include abiraterone acetate/prednisone, enzalutamide, and radium-223 ((223)Ra; for men with predominantly bone metastases)." | 4.90 | Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. ( Basch, E; Bennett, CL; Carducci, M; Chen, RC; Dusetzina, SB; Frame, JN; Garrels, K; Hotte, S; Kattan, MW; Loblaw, DA; Oliver, TK; Raghavan, D; Rumble, RB; Saad, F; Taplin, ME; Virgo, KS; Walker-Dilks, C; Williams, J; Winquist, E; Wootton, T, 2014) |
"To evaluate the association of the use of concomitant BRIs with overall survival (OS) and time to first SRE among patients with mCRPC and bone metastases receiving abiraterone acetate with prednisone as first-line therapy." | 4.02 | Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy. ( Alimohamed, NS; Bengala, C; Bryce, AH; Cigliola, A; Crivelli, F; Francini, E; Francini, G; Garcia-Foncillas, J; Gonzalez-Velez, M; Harshman, LC; Heng, DYC; Higano, CS; Lee-Ying, R; Montagnani, F; Moreno-Candilejo, I; Nuzzo, PV; Petrioli, R; Rosellini, P; Rubio-Perez, J; Shaw, GK; Sweeney, CJ; Zhang, L, 2021) |
"Clinical records of patients with pretreated advanced breast cancer and who were treated with the Metronomic-Cooper-type regimen consisting of weekly fixed doses of NPLD (30 mg IV) plus 5-Fluorouracil (5-FU) (500 mg IV) plus vincristine (0." | 3.79 | Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients. ( Ciruelos, E; Cortés-Funes, H; Dorta, M; Ghanem, I; Manneh, R; Manso, L; Mendiola, C; Sepúlveda, J; Valdiviezo, N; Vega, E, 2013) |
"Five responses (lung metastases, three; lymph node metastases, two) were observed in 23 patients with metastatic renal cell carcinoma who received recombinant interferon-alpha-2A (IFN) 18 X 10(6) U in three intramuscular doses each week combined with oral prednisone (10 to 20 mg daily)." | 3.68 | Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma. Reduced toxicity without reduction of the response rate--a phase II study. ( Fosså, SD; Gunderson, R; Moe, B, 1990) |
"21 patients with metastatic breast cancer, refractory to conventional agents, were treated with a combination of BCNU, vincristine, mitomycin-C and prednisone given every 4 weeks." | 3.67 | Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study. ( Anderson, P; DiBella, NJ; Fink, K; Garfield, D; Murphy, J; Speer, J, 1984) |
"Thirty-seven men with symptomatic bone metastases from prostate cancer that had progressed following earlier treatment with estrogens and/or orchidectomy were treated with low-dose prednisone (7." | 3.67 | Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. ( Gospodarowicz, M; Meakin, W; Panzarella, T; Rider, W; Stewart, L; Tannock, I, 1989) |
"One hundred and ten patients with stage IV breast cancer were treated with five-drug chemotherapy consisting of prednisone, cyclophosphamide, 5-fluorouracil, methotrexate, and vincristine." | 3.66 | Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer: effects on survival. ( Manni, A; Pearson, OH; Trujillo, JE, 1980) |
"The five-drug combination of fluorouracil imidazole carboxamide dimethyl triazeno, vincristine, bis-chloroethyl nitrosourea, and prednisone (FIVB + P) was given to 120 women with metastatic breast cancer." | 3.66 | A five-drug combination in the treatment of metastatic breast cancer. ( Falkson, G; Falkson, HC, 1981) |
"Combination chemotherapy consisting of cyclophosphamide, vincristine, prednisone, and procarbazine (COPP) was administered to 5 patients with invasive lymphoepithelial thymoma." | 3.66 | Combination chemotherapy in invasive thymoma role of COPP. ( Evans, WK; Feld, R; Phillips, MJ; Simpson, WJ; Thompson, DM, 1980) |
"Three patients with Hodgkin disease, eight with non-Hodgkin lymphoma, and one with chronic lymphocytic leukemia refractory to conventional combination chemotherapy were treated for remission induction with a new kinetically designed four-drug combination consisting of bleomycin, vincristine, adriamycin, and prednisone and given the acronym "BOAP." | 3.66 | A kinetically designed chemotherapeutic regimen for advanced refractory lymphoma patients. ( Braine, HG; Coltman, CA; Kerr, RO; Rossof, AH, 1978) |
"Forty-nine postmenopausal patients with advanced breast cancer were treated with a nonsteroidal antiestrogen, Nafoxidine." | 3.66 | Clinical trial of nafoxidine in advanced breast cancer. ( De Jager, RL; Krakoff, IH; Steinbaum, FL, 1978) |
"Cyclophosphamide, 5-fluorouracil, methotrexate, and prednisone were administered for 165, 28-day cycles to 33 patients with metastatic breast cancer." | 3.65 | Leucovorin in combination chemotherapy of breast cancer. ( Corder, MP; Flannery, EP; Herbst, KD; Justice, GR; Sheets, RF; Stone, WH, 1977) |
"Forty patients with metastatic breast cancer who had received no previous cytotoxic therapy were treated with a combination chemotherapy program CMF (P), which included methotrexate, 60 mg/m2, and 5-fluorouracil, 700 mg/m2 intravenously on the first and eighth days, in addition to cyclophosphamide, 100 mg/m2, and prednisone, 40 mg/m2, by mouth daily from the first to the fourteenth day of a 28-day cycle." | 3.65 | Combination chemotherapy for advanced breast cancer: response and effect on survival. ( Canellos, GP; Chabner, BA; DeVita, VT; Gold, GL; Schein, PS; Young, RC, 1976) |
"Twenty-five patients with advanced metastatic breast cancer were treated with the combination of methotrexate 60 mg/M(2) and 5-fluorouracil 700 mg/M(2) intravenously on the first and eighth days, and cyclophosphamide 100 mg/M(2) and prednisone 40 mg/M(2) by mouth daily for the first 14 days of a 28-day cycle." | 3.65 | Cyclical combination chemotherapy for advanced breast carcinoma. ( Canellos, GP; Chabner, BA; Devita, VT; Gold, GL; Schein, PS; Young, RC, 1974) |
" Grade 3/4 adverse events were reported in 24 (68." | 2.94 | Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. ( Fizazi, K; Fukasawa, S; Hashine, K; Kitani, S; Matsubara, N; Mundle, S; Ohtake, N; Shibayama, K; Shin, T; Suzuki, H; Tran, N, 2020) |
"The cumulative incidences of visceral metastases were calculated by the Kaplan-Meier method and compared using log-rank testing." | 2.90 | Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302. ( Antonarakis, ES; Carducci, MA; Denmeade, SR; Qiu, F; Teply, BA, 2019) |
"Apatorsen treated patients received a median of 19 infusions." | 2.87 | A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer. ( Chi, KN; Ellard, SL; Gingerich, JR; Gleave, ME; Hotte, SJ; Joshua, AM; Yu, EY, 2018) |
" The major adverse effects were bone marrow suppression, reduction of fibrinogen level, liver dysfunction, and digestive tract toxicities." | 2.87 | PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity. ( Deng, L; Gao, Y; Ke, X; Lin, N; Liu, W; Ping, L; Ren, H; Song, Y; Su, L; Tu, M; Wang, X; Xie, Y; Ying, Z; Zhang, C; Zhang, W; Zheng, W; Zhu, J, 2018) |
" Thus, salvage Ox-P chemotherapy for patients with relapsed or refractory MZL at the stated dosage and schedule showed moderate clinical activity and was considerable in very few selected patients (NCT01068392)." | 2.82 | A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial. ( Chae, YS; Eom, HS; Hong, J; Hong, JY; Kim, HJ; Kim, JS; Kim, SJ; Kim, WS; Lee, GW; Lee, S; Lee, SM; Oh, SY; Park, E; Park, J; Ryoo, HM; Suh, C; Won, JH; Yang, DH; Yoon, DH, 2016) |
"Cabozantinib is an inhibitor of kinases, including MET and vascular endothelial growth factor receptors, and has shown activity in men with previously treated metastatic castration-resistant prostate cancer (mCRPC)." | 2.82 | Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. ( Bergman, A; Bögemann, M; Cruciani, G; De Bono, J; De Giorgi, U; De Wit, R; Feyerabend, S; Fizazi, K; Hessel, C; Hoelzer, W; Houédé, N; Hussain, S; Krainer, M; Lam, E; Le Moulec, S; Mainwaring, P; Miller, K; Oudard, S; Polikoff, J; Ramies, D; Saad, F; Smith, M; Stenzl, A; Sternberg, C; Thiery-Vuillemin, A; Weitzman, A, 2016) |
"This was a phase I/II trial to determine the safety and efficacy of alisertib when given in combination with abiraterone plus prednisone (AP)." | 2.82 | A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone. ( Cristofanilli, M; Hoffman-Censits, JH; Kelly, WK; Kennedy, B; Kilpatrick, D; Leiby, B; Lewis, N; Lin, J; Mu, Z; Patel, SA; Sama, AR; Yang, H; Ye, Z, 2016) |
" Specific adverse events with abiraterone-prednisone were similar between the age subgroups." | 2.80 | Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer. ( Carles, J; Griffin, TW; Kheoh, T; Li, J; Molina, A; Mulders, PF; Rathkopf, DE; Ryan, CJ; Smith, MR; Van Poppel, H, 2015) |
"Visceral disease, non-nodal soft-tissue metastases predominantly involving the lung and liver, is a negative prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC)." | 2.79 | Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. ( de Bono, JS; Fizazi, K; Flaig, TW; Goodman, OB; Kheoh, T; Li, J; Molina, A; Mulders, PF; Scher, HI; Suttmann, H, 2014) |
"Treatment with abiraterone acetate and prednisone was well tolerated by patients who were treated for >2 yr." | 2.79 | Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). ( Beer, TM; Carles, J; de Bono, JS; de Souza, P; Efstathiou, E; Fizazi, K; Flaig, TW; Fradet, Y; Griffin, TW; Hainsworth, JD; Higano, CS; Kheoh, T; Logothetis, CJ; Mainwaring, P; Molina, A; Mulders, PF; North, S; Park, YC; Rathkopf, DE; Ryan, CJ; Saad, F; Scher, HI; Shore, ND; Small, EJ; Smith, MR; Taplin, ME; Todd, MB; Van Poppel, H; Yu, EY; Yu, MK, 2014) |
"Also, the Follicular Lymphoma International Prognostic Index (FLIPI) score increased in 18% (26 of 142) and decreased in 6% (9 of 142) of patients." | 2.78 | The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. ( Arcaini, L; Biasoli, I; Boccomini, C; Carella, AM; D'Arco, AM; Di Raimondo, F; Federico, M; Ferreri, AJ; Gaidano, G; Gallamini, A; Luminari, S; Mastronardi, S; Merli, F; Musto, P; Rusconi, C; Santoro, A; Spina, M; Versari, A; Zinzani, PL, 2013) |
" Intetumumab serum concentrations increased with repeated dosing and did not reach steady-state." | 2.78 | A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate c ( Bogdanova, N; Dawkins, F; de Boer, CJ; Dirix, L; Heidenreich, A; Rawal, SK; Schrijvers, D; Stenzl, A; Szkarlat, K; Wang, G; Welslau, M, 2013) |
"This phase 1/2 study assessed sunitinib combined with docetaxel (Taxotere) and prednisone in chemotherapy-naive metastatic, castration-resistant prostate cancer (mCRPC) patients." | 2.77 | Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. ( Chen, I; Chow Maneval, E; George, DJ; Harmon, CS; Hutson, TE; Kozloff, M; Liu, G; Logothetis, CJ; Mathew, P; Shore, ND; Wang, SL; Wilding, G; Zurita, AJ, 2012) |
"We performed a dose-escalation study to investigate the safety of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer (mCRPC)." | 2.77 | Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer. ( Canon, JL; Clausse, M; D'Hondt, L; Duck, L; Kerger, J; Machiels, JP; Mardjuadi, F; Medioni, J; Moxhon, A; Musuamba, F; Oudard, S, 2012) |
"These results suggest that the combination of ixabepilone and mitoxantrone is both feasible and active in castration-resistant prostate cancer and requires dosing with pegfilgrastim." | 2.76 | Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium. ( Beer, TM; Harzstark, AL; Liu, G; Pagliaro, LC; Rosenberg, JE; Ryan, CJ; Sharib, J; Small, EJ; Smith, DC; Weinberg, VK, 2011) |
" Most treatment-emergent adverse events (TEAEs) occurred in the 10-mg/kg intetumumab group." | 2.76 | A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. ( Chu, FM; Dreicer, R; Foster, B; Fracasso, PM; Lang, Z; Picus, J, 2011) |
"Prednisone was given orally at 60 mg/m(2) per day for five consecutive days within each 28-day cycle." | 2.75 | A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. ( Conley, BA; Dancey, J; Doroshow, JH; Figg, WD; Gardner, ER; Gutierrez, ME; Kummar, S; Melillo, G; Murgo, AJ; Sausville, EA, 2010) |
"Ultimately, patients with metastatic prostate cancer progress on androgen ablation therapy." | 2.72 | Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer. ( Borden, LS; Clark, PE; Hall, MC; Harmon, M; Lovato, J; M Mohler, R; Stindt, D; Torti, FM, 2006) |
" Abiraterone acetate in combination with prednisone was the first approved hormone therapy demonstrating survival benefit, and represents, to date, an alternative, or a second-line treatment after taxane-based chemotherapy, in addition to androgen-deprivation therapy, in hormone sensitive, and metastatic castration-resistant prostate cancer." | 2.66 | Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy. ( Manceau, C; Mourey, L; Ploussard, G; Pouessel, D, 2020) |
"Concerning bone metastases there was no difference between the two schedules in response rate, nor in the median remission duration (CAP 11, FAC 10 months)." | 2.66 | Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5-fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study. ( Kolarić, K; Potrebica, V; Vukas, D, 1989) |
"Body weight was the only risk factor found to be associated with statistically significant differences in survival." | 2.65 | Body weight and prognosis in breast cancer. ( Boyd, NF; Campbell, JE; Germanson, T; Meakin, JW; Sutherland, DJ; Thomson, DB, 1981) |
"Since in the treatment of advanced breast cancer chemotherapy and the various hormonal manipulations seem recently to have reached a plateau of effectiveness when used alone, it is widely assumed that the combination of both treatment modalities could improve therapeutic results." | 2.65 | [Simultaneous or sequential hormono/chemotherapy and a comparison of various polychemotherapies in the treatment of metastatic breast cancer]. ( Alberto, P; Beer, M; Brunner, KW; Cavalli, F; Jungi, WF; Martz, G; Mermillod, B; Obrecht, JP, 1982) |
"Patients with advanced breast carcinoma and no prior chemotherapy were prospectively evaluated to assess the induction capabilities of cyclophosphamide, methotrexate and 5-fluorouracil (CMF), Adriamycin and vincristine (AV), and CMF plus prednisone (CMFP)." | 2.65 | Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial. ( Band, PR; DeWys, W; Gelman, R; Perlia, C; Rice, MA; Rosenthal, SN; Sears, M; Tormey, DC, 1982) |
"However, since most patients with breast cancer present with local or regional disease but go on to die of disseminated cancer, major improvements in survival are most likely to occur by treating this neoplasm as a systemic disease through cobmining effective local therapy with systemic treatments." | 2.64 | Chemotherapy of disseminated breast cancer. Current status and prospects. ( Band, P; Bauer, M; Carbone, PP; Tormey, D, 1977) |
"The volume of metastases, as defined in the CHAARTED study for instance, could be an interesting predictive factor." | 2.55 | Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature. ( Albiges, L; Audenet, F; Barthelemy, P; Beuzeboc, P; Fléchon, A; Gravis, G; Irani, J; Linassier, C; Oudard, S; Rebillard, X; Richaud, P; Rouprêt, M; Rozet, F; Thiery Vuillemin, A; Timsit, MO; Vincendeau, S, 2017) |
"One patient experienced disease progression." | 2.50 | [Use of abiraterone acetate in the treatment of patients with metastatic castration resistant prostate cancer and no prior chemotherapy: 3 case reports and literature review]. ( Ma, H; Wan, B; Wang, JY; Wu, PJ; Zhu, G, 2014) |
"If metastatic prostate cancer progresses despite androgen suppression, the two main options in 2012 are either: palliative treatment with corticosteroids and external beam radiation therapy or radioisotope infusion; or docetaxel followed by abiraterone, which slightly prolongs survival but at a cost of sometimes serious adverse effects." | 2.49 | Second-line treatment of metastatic prostate cancer. Prednisone and radiotherapy for symptom relief. ( , 2013) |
"A systematic review was undertaken and an economic model constructed to evaluate the clinical effectiveness and cost-effectiveness of docetaxel (Taxotere, Sanofi-Aventis) in combination with prednisone/prednisolone for the treatment of metastatic hormone-refractory prostate cancer (mHRPC)." | 2.44 | A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. ( Birtle, A; Collins, R; Fenwick, E; Light, K; Norman, G; Palmer, S; Perard, R; Riemsma, R; Trowman, R, 2007) |
"In hormone-sensitive metastatic prostate cancer, androgen deprivation represents the first-line treatment." | 2.44 | Management of metastatic prostate cancer: the crucial role of geriatric assessment. ( Chaladaj, A; Droz, JP, 2008) |
"Visceral metastasis (VM) and a higher number of bone metastasis generally define high volume/risk in patients with metastatic castration-sensitive prostate cancer (mCSPC)." | 1.91 | Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer. ( Choueiri, TK; Gillessen, S; McKay, RR; Ürün, Y; Yekedüz, E, 2023) |
"Treatment with abiraterone acetate or enzalutamide is one of the approved approaches in men with metastatic castration-resistant prostate cancer (mCRPC) in the post-docetaxel setting." | 1.56 | Predictors of resistance to abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer in post-docetaxel setting: a single-center cohort study. ( Eterović, D; Omrčen, T; Vrdoljak, E, 2020) |
"Cabazitaxel is a treatment of metastatic castration-resistant prostate cancer (mCRPC) after docetaxel failure." | 1.51 | Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort. ( Balestra, A; Droz-Perroteau, C; Fizazi, K; Fourrier-Reglat, A; Guiard, E; Joly, F; Jove, J; Lacueille, C; Lamarque, S; Moore, N; Oudard, S; Rouyer, M; Tubach, F, 2019) |
"Fatigue was commonly linked to poor HRQoL and responses indicated that significantly fewer patients in the AAP group reported feeling usually tired or fatigued in the last week compared to the ENZ group (33% vs." | 1.51 | Fatigue, treatment satisfaction and health-related quality of life among patients receiving novel drugs suppressing androgen signalling for the treatment of metastatic castrate-resistant prostate cancer. ( Artenie, C; Dearden, L; Gater, A; Grant, L; Jackson, C; Mills, A; Shalet, N, 2019) |
" Pharmacokinetic evaluation was performed at two consecutive visits at least 4 weeks apart." | 1.51 | Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer. ( Arasaratnam, M; Bhatnagar, A; Crumbaker, M; Gurney, H; McKay, MJ; Molloy, MP, 2019) |
"Differentiated thyroid cancer is the most common endocrine malignancy with concomitant hematological malignancy in 7%." | 1.48 | Synchronous papillary thyroid cancer and non-Hodgkin lymphoma: Case report. ( Bochev, P; Cirocchi, R; Hristoskova, R; Mutafchiyski, VM; Philipov, A; Popivanov, GI; Tabakov, M, 2018) |
"Sarcopenia is known to be associated with poor clinical outcome in patients with diffuse large B-cell lymphoma (DLBCL)." | 1.46 | A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one. ( Go, SI; Kang, JH; Kang, MH; Kim, HG; Kim, HR; Lee, GW; Park, MJ; Song, HN, 2017) |
"Abiraterone is a well-tolerated and effective treatment modality for patients affected with metastatic castration-resistant prostate cancer." | 1.46 | Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: a retrospective study. ( Blasi, L; Cicero, G; De Luca, R; Dieli, F; Pavone, C; Pepe, A; Simonato, A, 2017) |
" All patients experienced at least one adverse event during induction, most commonly infusion-related reactions (58%), the majority of which were grade 1/2." | 1.46 | Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. ( Díaz, MG; Dreyling, M; Dyer, MJ; Grigg, A; Knapp, A; Lei, G; Marlton, P; Rule, S; Wassner-Fritsch, E, 2017) |
"Eplerenone is a nonsteroidal mineralocorticoid antagonist demonstrated to abrogate mineralocorticoid excess." | 1.46 | Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone. ( Agarwal, N; Alex, A; Bailey, E; Batten, J; Boucher, K; Gaston, D; Gill, D; Gupta, S; Hahn, A; Stenehjem, D, 2017) |
"Prednisone use was associated with a reduced risk of progression on docetaxel in the propensity score-weighted multivariable Cox model (P=0." | 1.43 | The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer. ( Antonarakis, ES; Denmeade, SR; Luber, B; Teply, BA, 2016) |
"Cabazitaxel/prednisone has been shown to prolong survival versus mitoxantrone/prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or after docetaxel." | 1.40 | Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. ( Bracarda, S; Climent, MA; Fossa, S; Heidenreich, A; Hitier, S; Mason, M; Ozen, H; Papandreou, C; Sengelov, L; Van Oort, I, 2014) |
"Periodontitis has been observed infrequently in bevacizumab-containing chemotherapy in clinical practice." | 1.39 | A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients. ( Akiyoshi, K; Hamaguchi, T; Hosokawa, A; Iwasa, S; Kato, K; Nakajima, TE; Nishitani, H; Ogawa, K; Shimada, Y; Sugiyama, T; Ueno, T; Yamada, Y, 2013) |
"Abiraterone was also associated with cardiac arrhythmias (7." | 1.38 | Abiraterone. After prostate cancer treatment failure: 4-month survival advantage. ( , 2012) |
"Considerations were Devic's disease versus metastases." | 1.36 | Breast lymphoma in Sjögren's syndrome complicated by acute monocular blindness. ( Molina, RM; Navarra, SV; Soldevilla, HF, 2010) |
"The incidence of PTS in breast cancer patients treated with a BCNU-containing HDC regimen can be remarkably high." | 1.31 | Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. ( Blume, KG; Cao, TM; Hu, WW; Johnston, LJ; Negrin, RS; Rizk, NW; Shizuru, JA; Stockerl-Goldstein, KE; Taylor, TL; Wong, RM, 2000) |
"Because thymoma is a chemosensitive tumor and frequently recurs in patients with Stage II or greater disease, chemotherapy carries a potential survival benefit and should be incorporated into the multimodality approach to prolong disease-free survival." | 1.29 | Thymoma. A retrospective study of 87 cases. ( Cox, JD; Hong, WK; Komaki, R; Lee, JS; Park, HS; Pollack, A; Putnam, JB; Shin, DM, 1994) |
"Neoadjuvant chemotherapy in Hodgkin's disease has improved survival time and tolerance to irradiation, allowing a lowering of the total doses used and the volumes irradiated." | 1.28 | [Radiotherapy with neoadjuvant chemotherapy]. ( Alapetite, C; Baillet, F; Dessard-Diana, B; Housset, M; Jacquillat, C; Michel-Langlet, P, 1989) |
"Chemotherapy results in metastatic breast cancer reached a plateau: Remission rate and duration are nearly equivalent for several regimens but not equitoxic." | 1.27 | [Vinblastine, 5-fluorouracil and prednisone (VFP) as "second-line" chemotherapy. Contribution to the problem of optimal therapy sequence in metastasizing breast carcinoma]. ( Hartlapp, JH; Illiger, HJ; Peiss, J; Vaupel, HA, 1983) |
"Nevertheless, because breast cancer is one of the most responsive of the solid tumors to cytotoxic drugs, appropriately chosen chemotherapy can relieve symptoms and prolong survival." | 1.27 | Chemotherapy of advanced breast cancer. A general survey. ( Loeb, V; Lyss, AP, 1984) |
"Distant metastases and chemotherapy in malignant thymoma are reviewed." | 1.27 | Malignant thymoma with distant metastases: a case report and review of the literature. ( Ichino, Y; Ishikawa, T; Obuchi, M; Suko, K, 1983) |
"Twenty-three patients with metastatic breast carcinoma were induced with a complex systemic therapy regimen in an attempt to ascertain if a complete remission rate greater than 50% could be obtained with intensive drug exposure." | 1.27 | Short term high density systemic therapy for metastatic breast cancer. ( Carbone, PP; Davis, TE; Kline, JC; Love, RR; Palta, M; Tormey, DC, 1985) |
" Reduction of the steroid dosage was followed by regression of the tumor." | 1.26 | Kaposi's sarcoma complicating corticosteroid therapy for temporal arteritis. ( Fam, AG; Leung, F; Osoba, D, 1981) |
" While earlier results suggested that adjuvant chemotherapy is especially effective in premenopausal women, newer studies and analyses indicate that appropriate dosage and consistent administration of chemotherapy are of decisive importance." | 1.26 | [Results of, and indications for adjuvant chemotherapy in breast cancer]. ( Brunner, KW; Goldhirsch, A; Joss, R; Sonntag, RW; Tschopp, L, 1981) |
"Breast cancer is the most common cause of cancer death in women in this country." | 1.26 | Modern approaches to the treatment of breast cancer. ( Knight, WA; McGuire, WL; Osborne, CK; Yochmowitz, MG, 1980) |
" The development of interstitial pneumopathy after this low bleomycin dosage may have been favored by a previous thorax irradiation 22 years earler for round cell sarcoma." | 1.26 | [Interstial pneumopathy after low dose bleomycin therapy]. ( Frey, F; Marone, C; Zimmermann, A, 1977) |
"Cases of disintegrating pulmonary metastases are presented." | 1.26 | [Confluent pulmonary deposits from carcinoma of the breast under cytostatic therapy (author's transl)]. ( Blechschmidt, CM; Schermuly, W, 1976) |
"A group of patients with metastatic breast cancer treated by a distinct drug regimen is analyzed with special respect to clinical and psychological problems." | 1.26 | [Experiences with drug therapy of advanced metastatic carcinoma of the breast (author's transl)]. ( Fernholz, HJ; Frik, W; Nüvemann, M, 1976) |
"Four patients suffering spinal cord compression resulting from epidural metastases were treated with adrenocorticosteroid hormones." | 1.26 | "Disappearing" spinal cord compression: oncolytic effect of glucocorticoids (and other chemotherapeutic agents) on epidural metastases. ( Cvitkovic, E; Howieson, J; Posner, JB, 1977) |
"The meningeal metastasis was treated by surgery and irradiation with orbital penetration; the lymph nodes were irradiated, and COPP polychemotherapy was given to treat the rest of the metastatic localizations." | 1.26 | [Extraskeletal manifestations of unusual localization in a case of myeloma (author's transl)]. ( Caballero, O; Martínez, J; Marty, ML; Mayans, J; Sanz, MA, 1979) |
"91 women with metastatic breast cancer, who received prior CTX-5FU or CTX-5FU-PRD, were treated in 3 consecutive clinical trials with either CTX-5FU-PRD-MTX-VCR, MTX-VCR, or MTX-VCR-PRD in order to elucidate whether the effectiveness of 5 drugs was due only to the newly added drugs (MTX-VCR +/- PRD) or whether the previously used drugs (CTX-5FU) were necessary as potentiating agents." | 1.26 | Potentiating role of previously administered agents in the combination chemotherapy of breast cancer. ( Nemoto, T; Rosner, D; Snyderman, M, 1979) |
"Soft tissue metastases may be more responsive than bony lesions." | 1.26 | Chemotherapy trial with comp-F regimen in advanced adenocarcinoma of prostate. ( Bergreen, PW; Buell, GV; Saiers, JH; Saiki, JH, 1978) |
"Seventy-two women with metastatic breast cancer were treated with multiple-agent chemotherapy." | 1.26 | Combination chemotherapy in the treatment of advanced breast cancer. ( Dao, TL; Nemoto, T; Rosner, D, 1976) |
"Osteoblastic bony metastases were observed in a case of medulloblastoma three years after surgery and radiation treatment." | 1.26 | Generalized osteoblastic bony metastases from medulloblastoma. ( DeLand, FH; Ho, EP; Lieber, A; Maruyama, Y, 1976) |
"Therapy for acute lymphocytic leukemia (ALL) has been less successful in adults than in children." | 1.26 | Remission induction in adult acute lymphocytic leukemia. Use of vincristine and prednisone alone. ( George, JN; Scavino, HF; Sears, DA, 1976) |
"Three cases of hepatocellular carcinoma are reported in young men who had been taking androgenic-anabolic steroids." | 1.25 | Androgen-induced hepatoma. ( Baird, PJ; Farrell, GC; Joshua, DE; Kronenberg, H; Perkins, KW; Uren, RF, 1975) |
"Although breast cancer presents as localized disease and is treated with local modalities, i." | 1.25 | Chemotherapy in the treatment strategy of breast cancer. ( Carbone, PP, 1975) |
"A patient had metastatic lymphosarcoma involving the right atrium and tricuspid valve in which functional tricuspid valve obstruction was relieved by chemotherapy." | 1.25 | Lymphosarcoma of the right atrium. Angiographic and hemodynamic documentation of response to chemotherapy. ( Garfein, OB, 1975) |
" Dosage adjustments were often necessary during the initial phases of therapy." | 1.25 | A controlled study in the use of combined drug therapy for metastatic breast cancer. ( Alberto, P; Brunner, KW; Martz, G; Obrecht, P; Senn, HJ; Sonntag, RW, 1975) |
"Seventeen patients with metastatic breast carcinoma were treated with a combination of 5-fluorouracil, methotrexate, vincristine, cyclophosphamide and prednisone." | 1.25 | Nonbacterial pneumonitis with multidrug antineoplastic therapy in breast carcinoma. ( Blom, J; Stutz, FH; Tormey, DC, 1973) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 250 (58.28) | 18.7374 |
1990's | 17 (3.96) | 18.2507 |
2000's | 21 (4.90) | 29.6817 |
2010's | 123 (28.67) | 24.3611 |
2020's | 18 (4.20) | 2.80 |
Authors | Studies |
---|---|
Saad, F | 15 |
Efstathiou, E | 5 |
Attard, G | 2 |
Flaig, TW | 7 |
Franke, F | 1 |
Goodman, OB | 3 |
Oudard, S | 11 |
Steuber, T | 1 |
Suzuki, H | 3 |
Wu, D | 1 |
Yeruva, K | 1 |
De Porre, P | 7 |
Brookman-May, S | 1 |
Li, S | 2 |
Li, J | 9 |
Thomas, S | 1 |
Bevans, KB | 1 |
Mundle, SD | 2 |
McCarthy, SA | 1 |
Rathkopf, DE | 8 |
Yekedüz, E | 1 |
McKay, RR | 1 |
Gillessen, S | 1 |
Choueiri, TK | 1 |
Ürün, Y | 1 |
George, DJ | 7 |
Thiery-Vuillemin, A | 3 |
Poulsen, MH | 1 |
Lagneau, E | 1 |
Ploussard, G | 2 |
Birtle, A | 2 |
Dourthe, LM | 1 |
Beal-Ardisson, D | 1 |
Pintus, E | 1 |
Trepiakas, R | 1 |
Lefresne, F | 1 |
Lukac, M | 1 |
Van Sanden, S | 2 |
Pissart, G | 1 |
Reid, A | 1 |
Rouyer, M | 1 |
Joly, F | 2 |
Fizazi, K | 20 |
Tubach, F | 1 |
Jove, J | 1 |
Lacueille, C | 1 |
Lamarque, S | 1 |
Guiard, E | 1 |
Balestra, A | 1 |
Droz-Perroteau, C | 1 |
Fourrier-Reglat, A | 1 |
Moore, N | 1 |
Khalaf, DJ | 2 |
Annala, M | 1 |
Taavitsainen, S | 1 |
Finch, DL | 2 |
Oja, C | 2 |
Vergidis, J | 2 |
Zulfiqar, M | 2 |
Sunderland, K | 2 |
Azad, AA | 1 |
Kollmannsberger, CK | 3 |
Eigl, BJ | 2 |
Noonan, K | 1 |
Wadhwa, D | 1 |
Attwell, A | 1 |
Keith, B | 1 |
Ellard, SL | 3 |
Le, L | 1 |
Gleave, ME | 3 |
Wyatt, AW | 1 |
Chi, KN | 7 |
Feyerabend, S | 3 |
Perualila, NJ | 1 |
Diels, J | 1 |
Ito, T | 1 |
Matsubara, N | 4 |
Özgüroğlu, M | 1 |
Rodriguez-Antolin, A | 1 |
Fein, L | 1 |
Alekseev, BY | 1 |
Sulur, G | 1 |
Protheroe, A | 2 |
Mundle, S | 2 |
Tran, N | 6 |
Shin, T | 1 |
Fukasawa, S | 2 |
Hashine, K | 1 |
Kitani, S | 1 |
Ohtake, N | 1 |
Shibayama, K | 1 |
Carretero-González, A | 1 |
Lora, D | 1 |
Manneh, R | 2 |
Lorente, D | 3 |
Castellano, D | 4 |
de Velasco, G | 1 |
Du, M | 1 |
Tian, Y | 1 |
Tan, W | 2 |
Wang, L | 6 |
Kilari, D | 1 |
Huang, CC | 1 |
Kohli, M | 2 |
Shore, N | 1 |
Higano, CS | 7 |
Sternberg, CN | 5 |
Tombal, B | 3 |
Miller, K | 3 |
Kalinovsky, J | 1 |
Jiao, X | 1 |
Tangirala, K | 1 |
Sartor, O | 4 |
Omrčen, T | 1 |
Eterović, D | 1 |
Vrdoljak, E | 1 |
Manceau, C | 1 |
Mourey, L | 2 |
Pouessel, D | 1 |
Fang, WY | 1 |
Wang, PF | 1 |
Fan, YC | 1 |
Shih, HJ | 1 |
Madan, RA | 2 |
Karzai, FH | 1 |
Al Harthy, M | 1 |
Petrylak, DP | 4 |
Kim, JW | 1 |
Arlen, PM | 1 |
Rosner, I | 1 |
Theoret, MR | 1 |
Cordes, L | 1 |
Bilusic, M | 1 |
Peer, CJ | 1 |
Dawson, NA | 1 |
Couvillon, A | 1 |
Hankin, A | 1 |
Williams, M | 1 |
Chun, G | 1 |
Owens, H | 1 |
Marte, JL | 1 |
Lee, MJ | 1 |
Tomita, Y | 1 |
Yuno, A | 1 |
Trepel, JB | 1 |
Lee, S | 3 |
Steinberg, SM | 2 |
Gulley, JL | 2 |
Figg, WD | 4 |
Dahut, WL | 2 |
Boerrigter, E | 1 |
Benoist, GE | 1 |
van Oort, IM | 1 |
Verhaegh, GW | 1 |
van Hooij, O | 1 |
Groen, L | 1 |
Smit, F | 1 |
Oving, IM | 1 |
de Mol, P | 1 |
Smilde, TJ | 1 |
Somford, DM | 1 |
Mehra, N | 1 |
Schalken, JA | 1 |
van Erp, NP | 1 |
Ternov, KK | 1 |
Nolsøe, AB | 1 |
Bratt, O | 1 |
Fode, M | 1 |
Lindberg, H | 1 |
Kistorp, C | 1 |
Palapattu, G | 1 |
Klausen, TW | 1 |
Sønksen, J | 1 |
Østergren, PB | 1 |
Pelloux-Prayer, R | 1 |
Schiele, P | 1 |
Gravis, G | 2 |
Kleinclauss, F | 1 |
Crehange, G | 1 |
Hennequin, C | 1 |
Morgans, AK | 1 |
Geoffrois, L | 1 |
Limat, S | 1 |
Nerich, V | 1 |
Francini, E | 1 |
Montagnani, F | 1 |
Nuzzo, PV | 1 |
Gonzalez-Velez, M | 1 |
Alimohamed, NS | 1 |
Rosellini, P | 1 |
Moreno-Candilejo, I | 1 |
Cigliola, A | 1 |
Rubio-Perez, J | 1 |
Crivelli, F | 1 |
Shaw, GK | 1 |
Zhang, L | 1 |
Petrioli, R | 1 |
Bengala, C | 1 |
Francini, G | 1 |
Garcia-Foncillas, J | 1 |
Sweeney, CJ | 1 |
Bryce, AH | 2 |
Harshman, LC | 1 |
Lee-Ying, R | 1 |
Heng, DYC | 1 |
Xiong, X | 1 |
Qiu, S | 1 |
Yi, X | 1 |
Xu, H | 1 |
Liao, D | 1 |
Lei, H | 1 |
Bai, S | 1 |
Peng, G | 1 |
Ai, J | 1 |
Yang, L | 1 |
Mostaghel, EA | 1 |
Marck, BT | 1 |
Kolokythas, O | 1 |
Chew, F | 1 |
Yu, EY | 4 |
Schweizer, MT | 1 |
Cheng, HH | 1 |
Kantoff, PW | 2 |
Balk, SP | 1 |
Taplin, ME | 6 |
Sharifi, N | 1 |
Matsumoto, AM | 1 |
Nelson, PS | 1 |
Montgomery, RB | 1 |
Cicero, G | 2 |
DE Luca, R | 2 |
Dorangricchia, P | 1 |
Dieli, F | 2 |
Smith, MR | 6 |
Mulders, PFA | 2 |
de Bono, JS | 17 |
Small, EJ | 11 |
Shore, ND | 5 |
Kheoh, T | 14 |
Todd, MB | 4 |
Yu, MK | 4 |
Ryan, CJ | 12 |
Go, SI | 1 |
Park, MJ | 1 |
Song, HN | 1 |
Kim, HG | 1 |
Kang, MH | 1 |
Kang, JH | 1 |
Kim, HR | 1 |
Lee, GW | 2 |
Struss, WJ | 1 |
Black, PC | 1 |
Scott, LJ | 1 |
Blasi, L | 1 |
Pepe, A | 1 |
Pavone, C | 1 |
Simonato, A | 1 |
Yamauchi, T | 1 |
Kinoshita, K | 1 |
Imamura, S | 1 |
Kamiya, K | 1 |
Dehm, SM | 1 |
Hillman, DW | 1 |
Sicotte, H | 1 |
Gormley, M | 1 |
Bhargava, V | 1 |
Jimenez, R | 1 |
Xie, F | 1 |
Yin, P | 1 |
Qin, S | 1 |
Quevedo, F | 1 |
Costello, BA | 1 |
Pitot, HC | 1 |
Ho, T | 1 |
Ye, Z | 2 |
Li, Y | 1 |
Eiken, P | 1 |
Vedell, PT | 1 |
Barman, P | 1 |
McMenomy, BP | 1 |
Atwell, TD | 1 |
Carlson, RE | 1 |
Ellingson, M | 1 |
Eckloff, BW | 1 |
Qin, R | 1 |
Ou, F | 1 |
Hart, SN | 1 |
Huang, H | 1 |
Jen, J | 1 |
Wieben, ED | 1 |
Kalari, KR | 1 |
Weinshilboum, RM | 1 |
Climent, MÁ | 2 |
Pérez-Valderrama, B | 1 |
Mellado, B | 1 |
Fernández Parra, EM | 1 |
Fernández Calvo, O | 1 |
Ochoa de Olza, M | 1 |
Muinelo Romay, L | 1 |
Anido, U | 1 |
Domenech, M | 1 |
Hernando Polo, S | 1 |
Arranz Arija, JÁ | 1 |
Caballero, C | 1 |
Juan Fita, MJ | 1 |
Sun, Y | 1 |
Lee, SK | 1 |
Oo, TH | 1 |
Rojas-Hernandez, CM | 1 |
Stein, CA | 1 |
Levin, R | 1 |
Given, R | 1 |
Nemeth, P | 1 |
Bosch, B | 1 |
Chapas-Reed, J | 1 |
Dreicer, R | 2 |
Hotte, SJ | 1 |
Gingerich, JR | 1 |
Joshua, AM | 3 |
Hussain, M | 1 |
Daignault-Newton, S | 1 |
Twardowski, PW | 1 |
Albany, C | 1 |
Stein, MN | 1 |
Kunju, LP | 1 |
Siddiqui, J | 1 |
Wu, YM | 1 |
Robinson, D | 1 |
Lonigro, RJ | 1 |
Cao, X | 1 |
Tomlins, SA | 1 |
Mehra, R | 1 |
Cooney, KA | 1 |
Montgomery, B | 2 |
Antonarakis, ES | 4 |
Shevrin, DH | 2 |
Corn, PG | 1 |
Whang, YE | 1 |
Smith, DC | 2 |
Caram, MV | 1 |
Knudsen, KE | 1 |
Stadler, WM | 1 |
Feng, FY | 1 |
Chinnaiyan, AM | 1 |
Amber, KT | 1 |
Valdebran, M | 1 |
Lu, Y | 1 |
De Feraudy, S | 1 |
Linden, KG | 1 |
Popivanov, GI | 1 |
Bochev, P | 1 |
Hristoskova, R | 1 |
Mutafchiyski, VM | 1 |
Tabakov, M | 1 |
Philipov, A | 1 |
Cirocchi, R | 1 |
Elkon, JM | 1 |
Millett, RL | 1 |
Millado, KF | 1 |
Lin, J | 2 |
Hamilou, Z | 1 |
Baciarello, G | 1 |
Thakur, MK | 1 |
Heilbrun, L | 2 |
Dobson, K | 1 |
Boerner, J | 1 |
Stark, K | 1 |
Smith, D | 2 |
Heath, E | 2 |
Fontana, J | 1 |
Vaishampayan, U | 2 |
Yan, X | 1 |
Zhou, M | 1 |
Lou, Z | 1 |
Mu, Q | 1 |
Sheng, L | 1 |
Zhang, P | 1 |
Wang, Y | 2 |
Ouyang, G | 1 |
Poorthuis, MHF | 1 |
Vernooij, RWM | 1 |
van Moorselaar, RJA | 1 |
de Reijke, TM | 1 |
Olmos, D | 2 |
Mateo, J | 2 |
Dolling, D | 1 |
Bianchini, D | 3 |
Seed, G | 2 |
Flohr, P | 2 |
Crespo, M | 2 |
Figueiredo, I | 2 |
Miranda, S | 2 |
Scher, HI | 11 |
Terstappen, LWMM | 1 |
Arays, R | 1 |
Wang, P | 1 |
Su, YJ | 1 |
Wang, PN | 1 |
Chang, H | 1 |
Shih, LY | 1 |
Lin, TL | 1 |
Kuo, MC | 1 |
Chuang, WY | 1 |
Wu, JH | 1 |
Tang, TC | 1 |
Hung, YS | 1 |
Dunn, P | 1 |
Kao, HW | 1 |
Boiché, M | 1 |
Conart, JB | 1 |
Angioi-Duprez, K | 1 |
Fenioux, C | 1 |
Louvet, C | 1 |
Charton, E | 1 |
Rozet, F | 2 |
Ropert, S | 1 |
Prapotnich, D | 1 |
Barret, E | 1 |
Sanchez-Salas, R | 1 |
Mombet, A | 1 |
Cathala, N | 1 |
Joulia, ML | 1 |
Molitor, JL | 1 |
Henriques, J | 1 |
Bonnetain, F | 1 |
Cathelineau, X | 1 |
Bennamoun, M | 1 |
Zheng, W | 1 |
Gao, Y | 1 |
Ke, X | 1 |
Zhang, W | 1 |
Su, L | 1 |
Ren, H | 1 |
Lin, N | 1 |
Xie, Y | 1 |
Tu, M | 1 |
Liu, W | 1 |
Ping, L | 1 |
Ying, Z | 1 |
Zhang, C | 1 |
Deng, L | 1 |
Wang, X | 1 |
Song, Y | 1 |
Zhu, J | 1 |
Kawaguchi, K | 1 |
Noguchi, H | 1 |
Enjo, K | 1 |
Todd, M | 1 |
Dearden, L | 1 |
Shalet, N | 1 |
Artenie, C | 1 |
Mills, A | 1 |
Jackson, C | 1 |
Grant, L | 1 |
Gater, A | 1 |
Grochtdreis, T | 1 |
König, HH | 1 |
Dobruschkin, A | 1 |
von Amsberg, G | 1 |
Dams, J | 1 |
Hakenberg, OW | 1 |
Perez-Gracia, JL | 1 |
Demkow, T | 2 |
Ali, T | 1 |
Caffo, O | 1 |
Heidenreich, A | 5 |
Schultze-Seemann, W | 1 |
Sautois, B | 1 |
Pavlik, I | 1 |
Qin, A | 1 |
Novosiadly, RD | 1 |
Shahir, A | 1 |
Ilaria, R | 1 |
Nippgen, J | 1 |
Halabi, S | 3 |
Dutta, S | 1 |
Tangen, CM | 1 |
Rosenthal, M | 1 |
Thompson, IM | 1 |
Araujo, JC | 1 |
Logothetis, C | 2 |
Quinn, DI | 1 |
Morris, MJ | 3 |
Eisenberger, MA | 2 |
Tannock, IF | 5 |
Kelly, WK | 3 |
Hahn, AW | 1 |
Gill, DM | 1 |
Poole, A | 1 |
Nussenzveig, RH | 1 |
Wilson, S | 1 |
Farnham, JM | 1 |
Stephenson, RA | 1 |
Cannon-Albright, LA | 1 |
Maughan, BL | 1 |
Agarwal, N | 2 |
Ivanov, N | 1 |
Fan, L | 1 |
Yang, Y | 1 |
Chi, C | 1 |
Ma, X | 1 |
Wang, R | 1 |
Gong, Y | 1 |
Zheng, H | 1 |
Pan, J | 1 |
Zhu, Y | 2 |
Dong, B | 1 |
Xue, W | 1 |
Mehta-Shah, N | 1 |
Ito, K | 1 |
Bantilan, K | 1 |
Moskowitz, AJ | 1 |
Sauter, C | 1 |
Horwitz, SM | 1 |
Schöder, H | 1 |
Smith, M | 2 |
Parker, C | 1 |
Ng, QS | 1 |
Boegemann, M | 1 |
Matveev, V | 1 |
Piulats, JM | 2 |
Zucca, LE | 1 |
Karyakin, O | 1 |
Kimura, G | 1 |
Nahas, WC | 1 |
Nolè, F | 1 |
Rosenbaum, E | 1 |
Kakehi, Y | 1 |
Zhang, A | 1 |
Krissel, H | 1 |
Teufel, M | 1 |
Shen, J | 1 |
Wagner, V | 1 |
Higano, C | 2 |
Długosz-Danecka, M | 1 |
Szmit, S | 1 |
Ogórka, T | 1 |
Skotnicki, AB | 1 |
Jurczak, W | 1 |
Hansen, AR | 1 |
Templeton, A | 1 |
Chen, E | 1 |
Evans, A | 1 |
Knox, J | 1 |
Prawira, A | 1 |
Sridhar, SS | 2 |
Tan, S | 1 |
Vera-Badillo, F | 2 |
Wouters, BG | 1 |
Teply, BA | 2 |
Qiu, F | 1 |
Carducci, MA | 2 |
Denmeade, SR | 2 |
Arasaratnam, M | 1 |
Crumbaker, M | 1 |
Bhatnagar, A | 1 |
McKay, MJ | 1 |
Molloy, MP | 1 |
Gurney, H | 2 |
Mannuel, H | 1 |
Liu, G | 3 |
Lara, P | 1 |
Monk, JP | 1 |
Flaig, T | 1 |
Zurita, A | 1 |
Mack, P | 1 |
Stella, P | 1 |
Bolton, S | 1 |
Hussain, A | 1 |
Al-Janadi, A | 1 |
Silbiger, D | 1 |
Usman, M | 1 |
Ivy, SP | 1 |
Ricciuti, B | 1 |
Dahlberg, SE | 1 |
Adeni, A | 1 |
Sholl, LM | 1 |
Nishino, M | 1 |
Awad, MM | 1 |
Zhao, J | 1 |
Zhang, M | 1 |
Liu, J | 2 |
Liu, Z | 1 |
Shen, P | 1 |
Nie, L | 1 |
Guo, W | 1 |
Cai, D | 1 |
Armstrong, CM | 1 |
Sun, G | 1 |
Chen, J | 2 |
Zhu, S | 1 |
Dai, J | 1 |
Zhang, H | 1 |
Zhao, P | 1 |
Zhang, X | 1 |
Yin, X | 1 |
Zhu, X | 1 |
Ni, Y | 1 |
Chen, N | 1 |
Zeng, H | 1 |
Castellan, P | 1 |
Castellucci, R | 1 |
Marchioni, M | 1 |
De Nunzio, C | 1 |
Tema, G | 1 |
Primiceri, G | 1 |
Schips, L | 1 |
Cindolo, L | 1 |
Keating, GM | 1 |
Luminari, S | 1 |
Biasoli, I | 1 |
Arcaini, L | 1 |
Versari, A | 1 |
Rusconi, C | 1 |
Merli, F | 1 |
Spina, M | 1 |
Ferreri, AJ | 2 |
Zinzani, PL | 2 |
Gallamini, A | 1 |
Mastronardi, S | 1 |
Boccomini, C | 1 |
Gaidano, G | 1 |
D'Arco, AM | 1 |
Di Raimondo, F | 1 |
Carella, AM | 1 |
Santoro, A | 1 |
Musto, P | 1 |
Federico, M | 1 |
Chau, CH | 1 |
Gao, R | 1 |
Sissung, TM | 1 |
Spencer, S | 1 |
Beatson, M | 1 |
Aragon-Ching, J | 1 |
Harzstark, AL | 1 |
Rosenberg, JE | 1 |
Weinberg, VK | 2 |
Sharib, J | 1 |
Pagliaro, LC | 1 |
Beer, TM | 4 |
Molina, A | 12 |
Mulders, PF | 5 |
Suttmann, H | 2 |
Delva, R | 1 |
Sevin, E | 1 |
Bompas, E | 1 |
Vedrine, L | 1 |
Ravaud, A | 1 |
Eymard, JC | 2 |
Tubiana-Mathieu, N | 1 |
Linassier, C | 2 |
Houede, N | 3 |
Guillot, A | 1 |
Ringensen, F | 1 |
Cojocarasu, O | 1 |
Valenza, B | 1 |
Leconte, A | 1 |
Lheureux, S | 1 |
Clarisse, B | 1 |
Michaelson, MD | 1 |
Ou, YC | 1 |
Sengeløv, L | 1 |
Ostler, P | 1 |
Stenzl, A | 3 |
Daugaard, G | 1 |
Jones, R | 1 |
Laestadius, F | 1 |
Ullèn, A | 1 |
Bahl, A | 1 |
Gschwend, J | 1 |
Maurina, T | 1 |
Chow Maneval, E | 2 |
Wang, SL | 2 |
Lechuga, MJ | 1 |
Paolini, J | 1 |
Chen, I | 2 |
Leibowitz-Amit, R | 1 |
Templeton, AJ | 2 |
Omlin, A | 1 |
Pezaro, C | 1 |
Atenafu, EG | 1 |
Keizman, D | 1 |
Seah, JA | 1 |
Knox, JJ | 1 |
Bracarda, S | 2 |
Mason, M | 1 |
Ozen, H | 1 |
Sengelov, L | 1 |
Van Oort, I | 1 |
Papandreou, C | 1 |
Fossa, S | 1 |
Hitier, S | 1 |
MARTINEZDIAZ, J | 1 |
Pytlík, R | 1 |
Belada, D | 1 |
Kubáčková, K | 1 |
Vášová, I | 1 |
Kozák, T | 1 |
Pirnos, J | 1 |
Bolomská, I | 1 |
Matuška, M | 1 |
Přibylová, J | 1 |
Campr, V | 1 |
Burešová, L | 1 |
Sýkorová, A | 1 |
Berková, A | 1 |
Klener, P | 1 |
Trněný, M | 1 |
Broccoli, A | 1 |
Pellegrini, C | 1 |
Celli, M | 1 |
Argnani, L | 1 |
Agostinelli, C | 1 |
Pileri, S | 1 |
Logothetis, CJ | 5 |
de Souza, P | 3 |
Mainwaring, P | 5 |
Hainsworth, JD | 2 |
North, S | 5 |
Fradet, Y | 1 |
Van Poppel, H | 3 |
Carles, J | 3 |
Griffin, TW | 5 |
Park, YC | 1 |
Jung, SH | 1 |
Yang, DH | 2 |
Ahn, JS | 1 |
Kim, YK | 1 |
Kim, HJ | 3 |
Lee, JJ | 1 |
Bellmunt, J | 2 |
Loriot, Y | 2 |
Ok, CY | 1 |
Xu-Monette, ZY | 1 |
Tzankov, A | 1 |
Manyam, GC | 1 |
Li, L | 1 |
Visco, C | 1 |
Montes-Moreno, S | 1 |
Dybkær, K | 1 |
Chiu, A | 1 |
Orazi, A | 1 |
Zu, Y | 1 |
Bhagat, G | 1 |
Richards, KL | 1 |
Hsi, ED | 1 |
Choi, WW | 1 |
van Krieken, JH | 1 |
Huh, J | 1 |
Zhao, X | 1 |
Ponzoni, M | 1 |
Bertoni, F | 1 |
Farnen, JP | 1 |
Møller, MB | 1 |
Piris, MA | 1 |
Winter, JN | 1 |
Medeiros, LJ | 1 |
Young, KH | 1 |
Ma, H | 1 |
Zhu, G | 1 |
Wan, B | 1 |
Wu, PJ | 1 |
Wang, JY | 1 |
Geynisman, DM | 1 |
Szmulewitz, RZ | 1 |
Plimack, ER | 1 |
Singal, R | 1 |
Ramachandran, K | 1 |
Gordian, E | 1 |
Quintero, C | 1 |
Zhao, W | 1 |
Reis, IM | 1 |
Basch, E | 2 |
Loblaw, DA | 1 |
Oliver, TK | 1 |
Carducci, M | 1 |
Chen, RC | 1 |
Frame, JN | 1 |
Garrels, K | 1 |
Hotte, S | 2 |
Kattan, MW | 1 |
Raghavan, D | 1 |
Walker-Dilks, C | 1 |
Williams, J | 1 |
Winquist, E | 4 |
Bennett, CL | 1 |
Wootton, T | 1 |
Rumble, RB | 1 |
Dusetzina, SB | 1 |
Virgo, KS | 1 |
Auchus, RJ | 1 |
Nguyen, S | 1 |
Patel, JN | 1 |
Jiang, C | 1 |
Hertz, DL | 1 |
Mulkey, FA | 1 |
Owzar, K | 1 |
Ratain, MJ | 1 |
Friedman, PN | 1 |
Mahoney, JF | 1 |
Kelley, MJ | 1 |
McLeod, HL | 1 |
Oki, Y | 1 |
Ewer, MS | 1 |
Lenihan, DJ | 1 |
Fisch, MJ | 1 |
Hagemeister, FB | 1 |
Fanale, M | 1 |
Romaguera, J | 1 |
Pro, B | 1 |
Fowler, N | 1 |
Younes, A | 1 |
Astrow, AB | 1 |
Huang, X | 1 |
Kwak, LW | 1 |
Samaniego, F | 1 |
McLaughlin, P | 1 |
Neelapu, SS | 1 |
Wang, M | 1 |
Fayad, LE | 1 |
Durand, JB | 1 |
Rodriguez, MA | 1 |
Aggarwal, RR | 1 |
Lin, AM | 1 |
Alumkal, J | 1 |
Graff, JN | 1 |
Nordquist, LT | 1 |
Herrera, I | 1 |
Larson, SM | 1 |
Matheny, SL | 1 |
Naini, V | 1 |
Burzykowski, T | 1 |
Lance, RS | 1 |
Gardner, TA | 1 |
Karsh, LI | 1 |
Fong, L | 1 |
McCoy, C | 1 |
DeVries, T | 1 |
Sheikh, NA | 1 |
GuhaThakurta, D | 1 |
Chang, N | 1 |
Redfern, CH | 1 |
Oh, SY | 1 |
Kim, WS | 1 |
Kim, JS | 1 |
Chae, YS | 1 |
Eom, HS | 1 |
Ryoo, HM | 1 |
Kim, SJ | 1 |
Yoon, DH | 1 |
Won, JH | 1 |
Hong, J | 1 |
Park, J | 1 |
Lee, SM | 1 |
Hong, JY | 1 |
Park, E | 1 |
Suh, C | 1 |
Chang, K | 1 |
Kong, YY | 1 |
Dai, B | 2 |
Ye, DW | 2 |
Qu, YY | 1 |
Jia, ZW | 1 |
Li, GX | 1 |
Davis, ID | 1 |
Schrijvers, D | 3 |
Stöckle, M | 1 |
Ohlmann, CH | 1 |
Meisel, A | 1 |
von Felten, S | 1 |
Vogt, DR | 1 |
Liewen, H | 1 |
de Wit, R | 5 |
de Bono, J | 2 |
Stenner-Liewen, F | 1 |
Tagawa, ST | 2 |
Posadas, EM | 1 |
Bruce, J | 1 |
Lim, EA | 1 |
Peng, W | 1 |
Maul, S | 1 |
Smit, JW | 1 |
Gonzalez, MD | 1 |
Nanus, DM | 1 |
Luber, B | 1 |
Pilon, D | 1 |
Queener, M | 1 |
Lefebvre, P | 1 |
Ellis, LA | 1 |
Fleisher, M | 1 |
Danila, DC | 1 |
Baeten, K | 1 |
McCormack, R | 1 |
Terstappen, LW | 1 |
Sternberg, C | 1 |
Le Moulec, S | 1 |
De Giorgi, U | 1 |
Krainer, M | 1 |
Bergman, A | 1 |
Hoelzer, W | 1 |
Bögemann, M | 1 |
Cruciani, G | 1 |
Hussain, S | 1 |
Lam, E | 1 |
Polikoff, J | 1 |
Ramies, D | 1 |
Hessel, C | 1 |
Weitzman, A | 1 |
Audenet, F | 1 |
Irani, J | 1 |
Timsit, MO | 1 |
Barthelemy, P | 1 |
Beuzeboc, P | 1 |
Fléchon, A | 3 |
Rebillard, X | 1 |
Richaud, P | 1 |
Rouprêt, M | 1 |
Thiery Vuillemin, A | 1 |
Vincendeau, S | 1 |
Albiges, L | 1 |
Sonpavde, G | 3 |
Pond, GR | 3 |
Kwon, ED | 1 |
Tsao, CK | 1 |
Sfakianos, J | 1 |
Liaw, B | 1 |
Gimpel-Tetra, K | 1 |
Kemeny, M | 1 |
Bulone, L | 1 |
Shahin, M | 1 |
Oh, WK | 1 |
Galsky, MD | 3 |
Takeuchi, T | 1 |
Yamaguchi, M | 1 |
Kobayashi, K | 1 |
Miyazaki, K | 1 |
Tawara, I | 1 |
Imai, H | 1 |
Ono, R | 1 |
Nosaka, T | 1 |
Tanaka, K | 1 |
Katayama, N | 1 |
Grigg, A | 1 |
Dyer, MJ | 1 |
Díaz, MG | 1 |
Dreyling, M | 1 |
Rule, S | 1 |
Lei, G | 1 |
Knapp, A | 1 |
Wassner-Fritsch, E | 1 |
Marlton, P | 1 |
Gill, D | 1 |
Gaston, D | 1 |
Bailey, E | 1 |
Hahn, A | 1 |
Gupta, S | 1 |
Batten, J | 1 |
Alex, A | 1 |
Boucher, K | 1 |
Stenehjem, D | 1 |
Patel, SA | 1 |
Sama, AR | 1 |
Hoffman-Censits, JH | 1 |
Kennedy, B | 1 |
Kilpatrick, D | 1 |
Yang, H | 1 |
Mu, Z | 1 |
Leiby, B | 1 |
Lewis, N | 1 |
Cristofanilli, M | 1 |
Ruether, D | 1 |
Ernst, S | 1 |
Cheng, T | 2 |
Perrotte, P | 1 |
Karakiewicz, P | 1 |
Machiels, JP | 2 |
Mazzeo, F | 1 |
Clausse, M | 2 |
Filleul, B | 1 |
Marcelis, L | 1 |
Honhon, B | 1 |
D'Hondt, L | 2 |
Dopchie, C | 1 |
Verschaeve, V | 1 |
Duck, L | 2 |
Verhoeven, D | 1 |
Jousten, P | 1 |
Bonny, MA | 1 |
Moxhon, AM | 1 |
Kerger, J | 2 |
Witjes, JA | 1 |
Ferrero, JM | 1 |
Falcon, S | 1 |
Calabrò, F | 1 |
James, N | 1 |
Bodrogi, I | 1 |
Harper, P | 1 |
Wirth, M | 1 |
Berry, W | 1 |
Petrone, ME | 1 |
McKearn, TJ | 1 |
Noursalehi, M | 1 |
George, M | 1 |
Rozencweig, M | 1 |
Buch-Hansen, TZ | 1 |
Bentzen, L | 1 |
Hansen, S | 1 |
Hoeyer, M | 1 |
Jensen, NV | 1 |
Saxe, C | 1 |
Sengeloev, L | 1 |
Kummar, S | 1 |
Gutierrez, ME | 1 |
Gardner, ER | 1 |
Melillo, G | 1 |
Dancey, J | 1 |
Sausville, EA | 1 |
Conley, BA | 1 |
Murgo, AJ | 1 |
Doroshow, JH | 1 |
Armstrong, AJ | 4 |
Eisenberger, M | 2 |
Chu, FM | 1 |
Picus, J | 1 |
Fracasso, PM | 1 |
Lang, Z | 1 |
Foster, B | 1 |
Eton, DT | 1 |
Beaumont, J | 1 |
Victorson, D | 1 |
Cella, D | 1 |
Soldevilla, HF | 1 |
Molina, RM | 1 |
Navarra, SV | 1 |
El Halim Mohamed Abu Hamar, A | 1 |
Mansour, S | 1 |
El Shebiney, M | 1 |
El Bary, NM | 1 |
Sadaka, E | 1 |
Maria, A | 1 |
Chu, L | 1 |
Jones, RJ | 1 |
Staffurth, JN | 1 |
Harland, S | 1 |
Hutson, TE | 2 |
Patterson, H | 1 |
Saleh, M | 1 |
Scholz, M | 1 |
Zivi, A | 1 |
Chieffo, N | 1 |
Haqq, CM | 2 |
Buckman, R | 1 |
Eigl, B | 1 |
Chi, K | 1 |
Czaykowski, P | 1 |
Wood, L | 1 |
Pollak, M | 1 |
Berry, S | 1 |
Lattouf, JB | 1 |
Mukherjee, SD | 2 |
Gleave, M | 1 |
Zurita, AJ | 1 |
Wilding, G | 1 |
Kozloff, M | 1 |
Mathew, P | 1 |
Harmon, CS | 1 |
Beltran, H | 1 |
Berruti, A | 1 |
Pia, A | 1 |
Terzolo, M | 1 |
Voog, E | 1 |
Davis, NB | 1 |
Qi, M | 1 |
Bandekar, R | 1 |
Vermeulen, JT | 1 |
Cornfeld, M | 1 |
Hudes, GR | 1 |
Wood, BA | 2 |
Leopold, L | 2 |
Mardjuadi, F | 1 |
Medioni, J | 1 |
Canon, JL | 1 |
Musuamba, F | 1 |
Moxhon, A | 1 |
Shen, YJ | 1 |
Bian, XJ | 1 |
Xie, HY | 1 |
Zhang, HL | 1 |
Zhang, SL | 1 |
Yao, XD | 1 |
Berry, WR | 1 |
Ogawa, K | 1 |
Ueno, T | 1 |
Kato, K | 1 |
Nishitani, H | 1 |
Akiyoshi, K | 1 |
Iwasa, S | 1 |
Nakajima, TE | 1 |
Hamaguchi, T | 1 |
Yamada, Y | 1 |
Hosokawa, A | 1 |
Sugiyama, T | 1 |
Shimada, Y | 1 |
Tolcher, A | 1 |
Lee, P | 1 |
Rosen, PJ | 1 |
Papadopoulos, KP | 1 |
Patnaik, A | 1 |
Jiao, J | 1 |
Pankras, C | 1 |
Kaiser, B | 1 |
Bernard, A | 1 |
Acharya, M | 1 |
Rawal, SK | 1 |
Szkarlat, K | 1 |
Bogdanova, N | 1 |
Dirix, L | 1 |
Welslau, M | 1 |
Wang, G | 1 |
Dawkins, F | 1 |
de Boer, CJ | 1 |
Pal, SK | 1 |
Hao, Y | 1 |
Rothman, M | 1 |
Gagnon, DD | 1 |
Cleeland, C | 1 |
Ng, S | 1 |
Gerritsen, WR | 1 |
Pantuck, A | 1 |
Park, Y | 1 |
Griffin, T | 1 |
Manso, L | 1 |
Valdiviezo, N | 1 |
Sepúlveda, J | 1 |
Ciruelos, E | 1 |
Mendiola, C | 1 |
Ghanem, I | 1 |
Vega, E | 1 |
Dorta, M | 1 |
Cortés-Funes, H | 1 |
Kim, YB | 1 |
Chang, SK | 1 |
Yang, WI | 1 |
Hahn, JS | 1 |
Koom, WS | 1 |
Shim, SJ | 1 |
Park, W | 1 |
Lee, KK | 1 |
Suh, CO | 1 |
Kim, GE | 1 |
Mak, YK | 1 |
Chan, CH | 1 |
Li, CK | 1 |
Lee, MP | 1 |
Tsang, YW | 1 |
Weiss, RB | 1 |
Woolf, SH | 1 |
Demakos, E | 1 |
Holland, JF | 2 |
Berry, DA | 1 |
Falkson, G | 5 |
Cirrincione, CT | 1 |
Robbins, A | 1 |
Bothun, S | 1 |
Henderson, IC | 1 |
Norton, L | 1 |
Rago, RP | 1 |
Einstein, A | 1 |
Lush, R | 1 |
Ko, YJ | 1 |
Henner, WD | 1 |
Bubley, G | 1 |
Merica, EA | 1 |
Garg, V | 1 |
Ette, E | 1 |
Harding, MW | 1 |
Dalton, WS | 1 |
Foley, MR | 1 |
Moshfeghi, DM | 1 |
Wilson, MW | 1 |
Haik, BG | 1 |
Pappo, AS | 1 |
Hill, DA | 1 |
SCHOYER, NH | 1 |
SCHMIDT, E | 1 |
SCHMIDT, FW | 1 |
ADAMS, JE | 1 |
GARDNER, B | 2 |
GRAHAM, WP | 1 |
GORDAN, GS | 1 |
LOKEN, HF | 1 |
THOMAS, AN | 1 |
TEAL, JS | 1 |
SCHOEN, D | 1 |
FEINE, U | 1 |
MCGOVERN, EL | 1 |
PERRIN, WE | 1 |
WILLAMO, HH | 2 |
CONKLIN, EF | 1 |
ALBANESE, AA | 1 |
LORENZE, EJ | 1 |
ORTO, LA | 1 |
SMULLYAN, I | 1 |
NISSEN-MEYER, R | 2 |
KARNOFSKY, DA | 1 |
NELSON, RS | 1 |
DEELIZALDE, R | 1 |
SJOERDSMA, A | 2 |
MELMON, KL | 2 |
GREENSPAN, EM | 1 |
LAMBERG, BA | 1 |
PELKONEN, R | 1 |
FRICK, MH | 1 |
RUDERMAN, NB | 1 |
HALL, TC | 1 |
MARTIN, DC | 1 |
RUBINI, M | 1 |
ROSEN, VJ | 1 |
MANNHEIMER, IH | 1 |
STRATFORD, EC | 1 |
TANAKA, KR | 1 |
Reichenberg, JS | 1 |
Sagar, S | 1 |
Davis, MD | 1 |
Borden, LS | 1 |
Clark, PE | 1 |
Lovato, J | 1 |
Hall, MC | 1 |
Stindt, D | 1 |
Harmon, M | 1 |
M Mohler, R | 1 |
Torti, FM | 1 |
Collins, R | 1 |
Fenwick, E | 1 |
Trowman, R | 1 |
Perard, R | 1 |
Norman, G | 1 |
Light, K | 1 |
Palmer, S | 1 |
Riemsma, R | 1 |
Escofet, X | 1 |
Khan, AZ | 1 |
Mazarani, W | 1 |
Woods, WG | 1 |
Garrett-Mayer, ES | 1 |
Yang, YC | 1 |
Ennishi, D | 1 |
Yokoyama, M | 1 |
Mishima, Y | 1 |
Watanabe, C | 1 |
Terui, Y | 1 |
Takahashi, S | 1 |
Takeuchi, K | 1 |
Ikeda, K | 1 |
Tanimoto, M | 1 |
Hatake, K | 1 |
Droz, JP | 1 |
Chaladaj, A | 1 |
Thuret, R | 1 |
Massard, C | 1 |
Gross-Goupil, M | 1 |
Escudier, B | 1 |
Di Palma, M | 1 |
Bossi, A | 1 |
de Crevoisier, R | 1 |
Chauchereau, A | 1 |
Blix, S | 1 |
Jacobsen, CD | 1 |
Moure, JM | 2 |
Ezrin, C | 1 |
Briant, TD | 1 |
Firestone, G | 1 |
Rosen, F | 1 |
Muirhead, W | 1 |
Manni, A | 2 |
Trujillo, JE | 1 |
Pearson, OH | 2 |
Moser, K | 1 |
Pohl, A | 1 |
Pezner, RD | 1 |
Bertrand, M | 1 |
Cecchi, GR | 1 |
Paladugu, RR | 1 |
Kendregan, BA | 1 |
Illiger, HJ | 1 |
Peiss, J | 1 |
Vaupel, HA | 1 |
Hartlapp, JH | 1 |
Kolarić, K | 3 |
Roth, A | 1 |
Vukas, D | 2 |
Cervek, J | 1 |
Hryniuk, W | 1 |
Bush, H | 1 |
Sledge, GW | 2 |
DiBella, NJ | 1 |
Garfield, D | 1 |
Fink, K | 1 |
Anderson, P | 1 |
Speer, J | 1 |
Murphy, J | 1 |
Lyss, AP | 1 |
Loeb, V | 1 |
Goodnough, LT | 1 |
Saito, H | 1 |
Jones, PK | 1 |
Schumm, F | 1 |
Brinkmann, A | 1 |
Fateh-Moghadam, A | 1 |
Ichino, Y | 1 |
Obuchi, M | 1 |
Suko, K | 1 |
Ishikawa, T | 1 |
Hirshaut, Y | 1 |
Kesselheim, H | 1 |
Sampi, K | 1 |
Honda, T | 1 |
Hattori, M | 1 |
Trishkina, EA | 1 |
Gershanovich, ML | 1 |
Pavlov, KA | 1 |
Danova, LA | 1 |
Labkovskiĭ, BM | 1 |
Cohen, M | 1 |
Hill, CA | 1 |
Cangir, A | 1 |
Sullivan, MP | 1 |
Brodeur, GM | 1 |
Williams, DL | 1 |
Look, AT | 1 |
Bowman, WP | 1 |
Kalwinsky, DK | 1 |
Boyd, NF | 1 |
Campbell, JE | 1 |
Germanson, T | 1 |
Thomson, DB | 1 |
Sutherland, DJ | 1 |
Meakin, JW | 1 |
Foley, JF | 1 |
Kessinger, MA | 1 |
Lemon, HM | 1 |
Leung, F | 1 |
Fam, AG | 1 |
Osoba, D | 1 |
Cavalli, F | 2 |
Alberto, P | 5 |
Jungi, F | 1 |
Brunner, K | 1 |
Martz, G | 8 |
Beer, M | 1 |
Jungi, WF | 2 |
Obrecht, JP | 1 |
Mermillod, B | 1 |
Brunner, KW | 8 |
Tormey, DC | 7 |
Gelman, R | 2 |
Band, PR | 1 |
Sears, M | 1 |
Rosenthal, SN | 1 |
DeWys, W | 1 |
Perlia, C | 1 |
Rice, MA | 1 |
Ahmann, DL | 3 |
Green, SJ | 1 |
Bisel, HF | 2 |
Ingle, JN | 2 |
Hahn, RG | 2 |
Lee, RA | 2 |
Edmonson, JH | 2 |
Falkson, HC | 2 |
Goldhirsch, A | 2 |
Joss, R | 1 |
Sonntag, RW | 3 |
Tschopp, L | 1 |
Smalley, RV | 3 |
Bartolucci, AA | 2 |
Evans, WK | 1 |
Thompson, DM | 1 |
Simpson, WJ | 1 |
Feld, R | 1 |
Phillips, MJ | 1 |
Osborne, CK | 2 |
Knight, WA | 1 |
Yochmowitz, MG | 1 |
McGuire, WL | 1 |
Gelber, RD | 1 |
Price, KN | 1 |
Castiglione, M | 1 |
Coates, AS | 1 |
Rudenstam, CM | 1 |
Collins, J | 1 |
Lindtner, J | 1 |
Hacking, A | 1 |
Marini, G | 1 |
Park, HS | 1 |
Shin, DM | 1 |
Lee, JS | 1 |
Komaki, R | 1 |
Pollack, A | 1 |
Putnam, JB | 1 |
Cox, JD | 1 |
Hong, WK | 1 |
Miyata, T | 1 |
Fujimoto, Y | 1 |
Fukushima, M | 1 |
Torisu, M | 1 |
Tanaka, M | 1 |
Knechtle, SJ | 1 |
Kalayoglu, M | 1 |
D'Alessandro, AM | 1 |
Pirsch, JD | 1 |
Hoffmann, RM | 1 |
Sollinger, HW | 1 |
Belzer, FO | 1 |
Bishop, JF | 2 |
Dewar, J | 1 |
Toner, G | 1 |
Tattersall, MH | 1 |
Olver, I | 1 |
Ackland, S | 1 |
Kennedy, I | 1 |
Goldstein, D | 1 |
Walpole, E | 1 |
Levi, J | 1 |
Stephenson, J | 1 |
Gelman, RS | 2 |
Pandya, KJ | 1 |
Tormey, D | 2 |
Cummings, FJ | 3 |
Abeloff, MD | 2 |
Karakuş, S | 1 |
Yalçin, S | 1 |
Güler, N | 1 |
Cöplü, L | 1 |
Ayhan, A | 1 |
Hartmann, JT | 1 |
Quietzsch, D | 1 |
Daikeler, T | 1 |
Kollmannsberger, C | 1 |
Mayer, F | 1 |
Kanz, L | 1 |
Bokemeyer, C | 1 |
Cao, TM | 1 |
Negrin, RS | 1 |
Stockerl-Goldstein, KE | 1 |
Johnston, LJ | 1 |
Shizuru, JA | 1 |
Taylor, TL | 1 |
Rizk, NW | 1 |
Wong, RM | 1 |
Blume, KG | 1 |
Hu, WW | 1 |
Ghate, JV | 1 |
Turner, ML | 1 |
Rudek, MA | 1 |
Dahut, W | 1 |
Dyer, V | 1 |
Pluda, JM | 1 |
Reed, E | 1 |
Laver, JH | 1 |
Mahmoud, H | 1 |
Pick, TE | 1 |
Hutchinson, RE | 1 |
Weinstein, HJ | 1 |
Schwenn, M | 1 |
Weitzman, S | 1 |
Murphy, SB | 1 |
Ochoa, S | 1 |
Shuster, JJ | 1 |
Farrell, GC | 1 |
Joshua, DE | 1 |
Uren, RF | 1 |
Baird, PJ | 1 |
Perkins, KW | 1 |
Kronenberg, H | 1 |
Just-Viera, JO | 1 |
Silva, JE | 1 |
Frey, F | 1 |
Marone, C | 1 |
Zimmermann, A | 1 |
Rossof, AH | 1 |
Kerr, RO | 1 |
Braine, HG | 1 |
Coltman, CA | 3 |
Wagner, HP | 1 |
Gailani, S | 1 |
Seon, BK | 1 |
Henderson, ES | 1 |
Au, WY | 1 |
Blechschmidt, CM | 1 |
Schermuly, W | 1 |
Schwartz, AD | 1 |
Lee, H | 1 |
Baum, ES | 1 |
Sterioff, S | 1 |
Rios, CN | 1 |
Zachary, JB | 1 |
Williams, GM | 1 |
Livingston, RB | 1 |
Nüvemann, M | 1 |
Fernholz, HJ | 1 |
Frik, W | 1 |
Carbone, PP | 4 |
Bauer, M | 1 |
Band, P | 1 |
Corder, MP | 1 |
Sheets, RF | 1 |
Stone, WH | 1 |
Flannery, EP | 1 |
Justice, GR | 1 |
Herbst, KD | 1 |
Senn, HJ | 6 |
Obrecht, P | 3 |
Maurice, P | 1 |
Carpenter, J | 2 |
Bartolucci, A | 1 |
Vogel, C | 1 |
Krauss, S | 1 |
Mouridsen, HT | 4 |
Palshof, T | 3 |
Muss, HB | 2 |
White, DR | 2 |
Cooper, MR | 2 |
Richards, F | 2 |
Spurr, CL | 2 |
Mauer, AM | 1 |
Frederiksen, PL | 2 |
Joergensen, ST | 1 |
Roesdahl, K | 1 |
Thomsen, J | 1 |
Stuart, JJ | 1 |
Jackson, DV | 1 |
Rhyne, L | 1 |
Posner, JB | 1 |
Howieson, J | 1 |
Cvitkovic, E | 1 |
Wiltshaw, E | 1 |
Allegra, JC | 1 |
Lippman, ME | 1 |
Dietz, R | 1 |
Tkocz, HJ | 1 |
Tsiliacos, SC | 1 |
Athanasiou, AE | 1 |
Wallace, EZ | 1 |
Rosman, PM | 1 |
Balthazar, A | 1 |
Sacerdote, A | 1 |
Sanz, MA | 1 |
Mayans, J | 1 |
Martínez, J | 1 |
Caballero, O | 1 |
Marty, ML | 1 |
Rosner, D | 5 |
Snyderman, M | 1 |
Nemoto, T | 5 |
Estapé, J | 1 |
Millá, A | 1 |
Prats, M | 1 |
Herranz, M | 1 |
Visa, J | 1 |
Buell, GV | 1 |
Saiers, JH | 1 |
Saiki, JH | 1 |
Bergreen, PW | 1 |
Diaz, R | 1 |
Dao, T | 1 |
Sponzo, R | 1 |
Cunningham, T | 1 |
Horton, J | 2 |
Simon, R | 1 |
Petersen, M | 1 |
Taylor, JD | 1 |
Steinbaum, FL | 1 |
De Jager, RL | 1 |
Krakoff, IH | 1 |
Bugarski, M | 1 |
Vuletić, L | 1 |
Boberić, J | 1 |
Milosavljević, A | 1 |
Dilparić, S | 1 |
Tomin, R | 1 |
Naumović, P | 1 |
Almog, C | 1 |
Pik, A | 1 |
Weisberg, D | 1 |
Herczeg, E | 1 |
Shellito, J | 1 |
Khandekar, JD | 1 |
McKeever, WP | 1 |
Vick, NA | 1 |
Sitarz, AL | 1 |
Santulli, TV | 1 |
Wigger, HJ | 1 |
Berdon, WE | 1 |
Haskell, CM | 1 |
Sparks, FC | 1 |
Graze, PR | 1 |
Korenman, SG | 1 |
Kane, RD | 2 |
Stocks, LH | 1 |
Paulson, DF | 2 |
O'Connell, MJ | 1 |
Hansen, M | 1 |
Osterlind, K | 1 |
Hansen, HH | 1 |
Mouridsen, H | 1 |
Brahm, M | 1 |
Rahbek, I | 1 |
Weller, SA | 1 |
Glatstein, E | 1 |
Kaplan, HS | 2 |
Rosenberg, SA | 2 |
Murphy, S | 1 |
Huguley, CM | 1 |
Barndt, J | 1 |
Dao, TL | 1 |
Mickey, DD | 1 |
Dalquen, P | 1 |
Bertel, O | 1 |
Staehelin, HB | 1 |
Ho, EP | 1 |
Lieber, A | 1 |
DeLand, FH | 1 |
Maruyama, Y | 1 |
Lozada, JA | 1 |
Grillo-López, A | 1 |
Vélez-Garciá, E | 1 |
Scavino, HF | 1 |
George, JN | 1 |
Sears, DA | 1 |
Mitchell, MS | 1 |
Gallmeier, WM | 1 |
Bruntsch, U | 2 |
Schmidt, CG | 2 |
Farmer, W | 1 |
Ravin, C | 1 |
Schachter, EN | 1 |
Lewis, RA | 1 |
Clark, RB | 1 |
Garfein, OB | 1 |
Ramirez, G | 3 |
Klotz, J | 1 |
Strawitz, JG | 1 |
Wilson, WL | 1 |
Cornell, GN | 1 |
Madden, RE | 1 |
Minton, JP | 1 |
Wollner, N | 2 |
Burchenal, JH | 2 |
Lieberman, PH | 2 |
Exelby, PR | 1 |
D'Angio, GJ | 1 |
Murphy, ML | 2 |
Exelby, P | 1 |
D'Angio, G | 1 |
Canellos, GP | 3 |
DeVita, VT | 3 |
Gold, GL | 2 |
Chabner, BA | 2 |
Schein, PS | 2 |
Young, RC | 3 |
Fosså, SD | 3 |
Lehne, G | 1 |
Gunderson, R | 2 |
Hjelmaas, U | 1 |
Holdener, EE | 1 |
Celsing, F | 1 |
Hast, R | 1 |
Stenke, L | 1 |
Hansson, H | 1 |
Pisa, P | 1 |
Rischin, D | 1 |
Olver, IN | 1 |
Laidlaw, CR | 1 |
Zimet, A | 1 |
Jeal, P | 1 |
Dipell, JF | 1 |
Jensen, JL | 1 |
Goel, R | 1 |
Venner, PM | 1 |
Spitzer, G | 1 |
Martino, S | 1 |
Samal, BA | 1 |
Redman, B | 1 |
Flaherty, L | 1 |
Kraut, M | 1 |
Simon, M | 1 |
Valdivieso, M | 1 |
Tomek, R | 1 |
Moe, B | 1 |
Gray, R | 1 |
Gilchrist, K | 1 |
Grage, T | 1 |
Wolter, J | 1 |
Woll, JE | 1 |
Kline, JC | 1 |
Palta, M | 1 |
Davis, TE | 2 |
Love, RR | 1 |
Yahalom, J | 1 |
Biran, S | 1 |
Sulkes, A | 1 |
Baillet, F | 1 |
Housset, M | 1 |
Dessard-Diana, B | 1 |
Jacquillat, C | 1 |
Michel-Langlet, P | 1 |
Alapetite, C | 1 |
Marschke, RF | 1 |
Schaid, DJ | 1 |
Krook, JE | 1 |
Mailliard, JA | 1 |
Cullinan, SA | 1 |
Pfeifle, DM | 1 |
Votava, HJ | 1 |
Ebbert, LP | 1 |
Windschitl, HE | 1 |
Tannock, I | 1 |
Gospodarowicz, M | 1 |
Meakin, W | 1 |
Panzarella, T | 1 |
Stewart, L | 1 |
Rider, W | 1 |
Schoen, HD | 1 |
Wendt, T | 1 |
Potrebica, V | 1 |
Taylor, R | 1 |
Tandan, R | 1 |
Roberts, J | 1 |
DiCostanzo, DP | 1 |
Sharma, K | 1 |
Fries, T | 1 |
Jakobsen, A | 1 |
Møller, KA | 1 |
Andersen, AP | 1 |
Brincker, H | 1 |
Dombernowsky, P | 1 |
Hansen, PV | 1 |
Hesselius, I | 1 |
Kjaer, M | 1 |
Friess, GG | 1 |
McCracken, JD | 1 |
Troxell, ML | 1 |
Pazdur, R | 1 |
Eyre, HJ | 1 |
Romero, A | 1 |
Rabinovich, MG | 1 |
Pérez, JE | 1 |
Macchiavelli, M | 1 |
Leone, BA | 1 |
Strauss, E | 1 |
Goldar, D | 1 |
Alvarez, LA | 1 |
Vallejo, C | 1 |
Loprinzi, CL | 1 |
Rasmussen, P | 1 |
Chang, AY | 1 |
Vogel, CL | 1 |
Raney, M | 1 |
Pretorius, FJ | 1 |
Petru, E | 1 |
Schmähl, D | 1 |
Lane, WW | 1 |
Carter, SK | 1 |
Schneck, SA | 1 |
Penn, I | 5 |
Stutz, FH | 3 |
Blom, J | 3 |
Sievers, DB | 1 |
Donovan, AJ | 2 |
Tashima, CK | 1 |
van der Werf-Messing, B | 1 |
Shehata, WM | 1 |
Hendrickson, FR | 1 |
Hindo, WA | 1 |
Jacobsson, S | 1 |
Linell, F | 1 |
Rausing, A | 1 |
Schell, HW | 1 |
Cressy, NL | 1 |
Stephens, PJ | 1 |
Hudson, P | 1 |
Mendoza, CB | 1 |
Gerwig, WH | 1 |
Watne, AL | 1 |
Gleason, TH | 1 |
Hamlin, WB | 1 |
De Souza e Silva, NA | 1 |
Wilson, DM | 1 |
Davis, HL | 3 |
Wiseley, AN | 1 |
Ansfield, FJ | 3 |
Farber, S | 1 |
Marks, IN | 1 |
Bank, S | 1 |
Louw, JH | 1 |
Shames, JM | 1 |
Dhurandhar, NR | 1 |
Blackard, WG | 1 |
Mitchell, ML | 1 |
Ernesti, M | 1 |
Raben, MS | 1 |
Scaliter, H | 1 |
Starzl, TE | 4 |
Porter, KA | 1 |
Brettschneider, L | 2 |
Bell, P | 1 |
Putnam, CW | 3 |
McGuire, RL | 1 |
Gorins, A | 1 |
Bloch-Michel, H | 1 |
Dussart, N | 1 |
Aristoff, H | 1 |
Ley, R | 1 |
Vanderhoeft, P | 1 |
Karkos, J | 1 |
Corman, J | 2 |
Groth, CG | 1 |
Halgrimson, CG | 2 |
Schroter, G | 1 |
Gustafsson, A | 1 |
Robertson, GL | 1 |
Bhoopalam, N | 1 |
Zelkowitz, LJ | 1 |
Tolloczko, T | 1 |
Wasiutyński, A | 1 |
Palva, T | 1 |
Palva, A | 1 |
Dammert, K | 1 |
Karma, P | 1 |
Mendes da Costa, P | 1 |
Jortay, A | 1 |
Noterman, J | 1 |
Byland, W | 1 |
Nagel, G | 1 |
Peterson, LJ | 1 |
Grimes, JH | 1 |
Dees, JE | 1 |
Anderson, EE | 1 |
Pouillart, P | 1 |
Schwarzenberg, L | 1 |
Mathé, G | 1 |
Schneider, M | 1 |
Jasmin, C | 1 |
Hayat, M | 1 |
Weiner, R | 1 |
de Vassal, F | 1 |
Amiel, JL | 1 |
Beyer, HP | 1 |
Fajbisowicz, S | 1 |
Mayr, AC | 1 |
Smith, P | 1 |
Nagel, GA | 2 |
Prout, MN | 1 |
McKenna, PJ | 1 |
Cole, DR | 1 |
Korbitz, BC | 2 |
Willoughby, ML | 1 |
Barsel', VA | 1 |
Matveev, BP | 1 |
Williams, R | 1 |
Smith, MG | 1 |
Booth, A | 1 |
Groth, C | 1 |
Melchert, F | 1 |
Brennan, MJ | 1 |
Stein, RS | 1 |
Moran, EM | 1 |
Desser, RK | 1 |
Miller, JB | 1 |
Golomb, HM | 1 |
Ultmann, JE | 1 |
Buckle, R | 1 |
Fairley, GH | 1 |
Freeman, JE | 1 |
Lokich, JJ | 1 |
Skarin, AT | 3 |
Höffken, K | 1 |
Hornung, G | 1 |
Becker, G | 1 |
Oproiu, A | 1 |
Goldenberg, IS | 1 |
McMahan, CA | 1 |
Escher, GC | 1 |
Volk, H | 1 |
Olson, KB | 1 |
Barb, U | 1 |
Vielberg, H | 1 |
Hoppe, D | 1 |
Bronsch, T | 1 |
Gudowski, J | 1 |
Lewis, MB | 1 |
Nunes, LB | 1 |
Powell, DE | 1 |
Shnider, BI | 1 |
Kaufman, S | 1 |
Goldstein, M | 1 |
Sugarbaker, PH | 1 |
Wilson, RE | 2 |
Spigel, SC | 1 |
Costanzi, JJ | 1 |
Pole, JG | 1 |
van Kaick, G | 1 |
Drings, P | 1 |
Fritsch, H | 1 |
Moskwa, G | 1 |
Lee, JM | 1 |
Lenhard, RE | 1 |
Baker, RR | 1 |
Steward, AM | 1 |
Nixon, D | 1 |
Zamcheck, N | 1 |
Aisenberg, A | 1 |
Andaloro, VA | 1 |
Babott, D | 1 |
Billund, JK | 1 |
Burton, JL | 1 |
Greaves, MW | 1 |
Walker, D | 1 |
Gill, TJ | 1 |
Corson, JM | 1 |
Greally, JF | 1 |
Theologides, A | 1 |
Kennedy, BJ | 1 |
Gamble, JF | 1 |
Fuller, LM | 1 |
Butler, JJ | 1 |
Shullenberger, CC | 1 |
Beck, W | 1 |
Barnard, CN | 1 |
Schrire, V | 1 |
Hammond, W | 1 |
Leb, DE | 1 |
Howell, RS | 1 |
Scott, WP | 1 |
Schaison, G | 1 |
Karb, K | 1 |
Reynolds, ES | 1 |
King, WW | 1 |
Cox, CE | 1 |
Boyce, WH | 1 |
Lleander, VC | 1 |
Goldstein, G | 1 |
Horsley, JS | 1 |
Shingleton, WW | 1 |
Sedransk, N | 1 |
Johnson, RO | 1 |
Moore, MR | 1 |
Bull, JM | 1 |
Jones, SE | 1 |
Gottlieb, JA | 1 |
Frei, E | 1 |
Luce, JK | 1 |
Arseneau, JC | 1 |
Sponzo, RW | 1 |
Levin, DL | 1 |
Schnipper, LE | 1 |
Bonner, H | 1 |
Johnson, RE | 1 |
Lee, CA | 1 |
Lloyd, HM | 1 |
Religa, H | 1 |
Sosin, A | 1 |
Czechowicz, Z | 1 |
Röthlisberger, C | 1 |
Donath, A | 1 |
Poretti, GG | 1 |
Zuppinger, A | 1 |
Gossart, R | 1 |
Kulakowski, S | 1 |
Achslogh, J | 1 |
Malherbe, A | 1 |
Bardana, EJ | 1 |
Pirofsky, B | 1 |
Májský, A | 1 |
Jakoubková, J | 2 |
Piro, AJ | 1 |
Aliapoulios, MA | 1 |
Moore, FD | 1 |
Finklestein, JZ | 1 |
Ekert, H | 1 |
Isaacs, H | 1 |
Higgins, G | 1 |
Abrahámová, J | 1 |
Havránková, N | 1 |
Wendel, H | 1 |
Kochan, E | 1 |
Kröger, W | 1 |
Walther, H | 1 |
Sharma, TC | 1 |
Huvos, AG | 1 |
Grabstald, H | 1 |
Wagle, DG | 1 |
Murphy, GP | 1 |
Ryan, SJ | 1 |
Frank, RN | 1 |
Green, WR | 1 |
Vansant, JH | 1 |
Payne, RL | 1 |
Wheeler, JR | 1 |
Harris, CC | 1 |
Smith, JP | 1 |
Boronow, RC | 1 |
Herter, FP | 1 |
Mulcare, RJ | 1 |
McCarthy, JG | 1 |
Gump, FE | 1 |
Ukai, M | 1 |
Buckley, K | 1 |
Wheeler, B | 1 |
Szreder, W | 1 |
Firat, D | 1 |
Olshin, S | 1 |
Kreiger, AE | 1 |
Meyer, D | 1 |
Smith, TR | 1 |
Riemer, K | 1 |
Neubauer, W | 1 |
Moccetti, T | 1 |
Mason, DT | 1 |
Stewart, JG | 1 |
Skinner, LG | 1 |
O'Connor, PJ | 1 |
Bethune, JE | 1 |
Berne, TV | 1 |
Schwarz, G | 1 |
Hoffmeister, W | 1 |
Loewe, KR | 1 |
Doorenbos, H | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cance[NCT02257736] | Phase 3 | 982 participants (Actual) | Interventional | 2014-11-30 | Active, not recruiting | ||
Prospective Multi-country Observational Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Patient-reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Patie[NCT02813408] | 226 participants (Actual) | Observational | 2016-05-03 | Completed | |||
A Randomized Phase II Study of Sequencing Abiraterone Acetate and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer[NCT02125357] | Phase 2 | 202 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
A Randomized Phase II Trial Comparing Biomarker Directed Therapy Versus Clinician's Choice of Enzalutamide or Docetaxel in Patients With Advanced Prostate Cancer Post Abiraterone[NCT04015622] | Phase 2 | 100 participants (Anticipated) | Interventional | 2020-10-07 | Recruiting | ||
A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC)[NCT01715285] | Phase 3 | 1,209 participants (Actual) | Interventional | 2013-02-12 | Completed | ||
A Phase III Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-naïve Subjects With Bone Predom[NCT02043678] | Phase 3 | 806 participants (Actual) | Interventional | 2014-03-30 | Active, not recruiting | ||
Phase I Non-Randomized, Unblinded, Single-Center Trial of Oral Telmisartan Alone or Combined With Selected Standard of Care Therapies for Prostate Cancer[NCT06168487] | Early Phase 1 | 42 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | ||
A Randomized Gene Fusion Stratified Phase 2 Trial of Abiraterone With or Without ABT-888 for Patients With Metastatic Castration-Resistant Prostate Cancer[NCT01576172] | Phase 2 | 159 participants (Actual) | Interventional | 2012-03-30 | Completed | ||
Phase I/II Trial of Epothilone Analog BMS-247550 (Ixabepilone), Mitoxantrone, and Prednisone in Hormone Refractory Prostate Cancer (HRPC) Patients Previously Treated With Chemotherapy[NCT00331344] | Phase 1/Phase 2 | 100 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
A Multicenter, Randomized, Double-Blind, Phase 3 Study Of Sunitinib Plus Prednisone Versus Prednisone In Patients With Progressive Metastatic Castration-Resistant Prostate Cancer After Failure Of A Docetaxel-Based Chemotherapy Regimen[NCT00676650] | Phase 3 | 873 participants (Actual) | Interventional | 2008-07-31 | Terminated (stopped due to Study A6181120 was prematurely discontinued due to futility on 27 September 2010. No new or unexpected safety issues were identified.) | ||
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer[NCT00887198] | Phase 3 | 1,088 participants (Actual) | Interventional | 2009-04-28 | Completed | ||
Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours Using the Quadratic Phenotypic Optimization Platform (QPOP) and an Artificial Intelligence-based Platform (CURATE.AI)[NCT05381038] | Phase 1/Phase 2 | 10 participants (Anticipated) | Interventional | 2022-06-30 | Not yet recruiting | ||
A Phase I/II Study of Azacitidine (Vidaza), Docetaxel and Prednisone for Patients With Hormone Refractory Metastatic Prostate Cancer Previously Treated With a Taxotere Containing Regimen.[NCT00503984] | Phase 1/Phase 2 | 22 participants (Actual) | Interventional | 2007-05-31 | Terminated (stopped due to Withdrawal of Funding) | ||
Phase 1b/2a Safety and Immunogenicity of the DNMT Inhibitor Azacitidine During Anti-Tuberculosis Therapy[NCT03941496] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2022-10-31 | Withdrawn (stopped due to The study was halted prematurely due to Bristol-Myers Squibb's (BMS) decision to withdraw support for this study.) | ||
A Phase II Study of Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma[NCT01068392] | Phase 2 | 42 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy[NCT00638690] | Phase 3 | 1,195 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib Upon Progression to Chemotherapy and Next Generation Hormonal Agents: a Phase II Study[NCT05265988] | Phase 2 | 32 participants (Anticipated) | Interventional | 2021-10-29 | Recruiting | ||
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100[NCT01605227] | Phase 3 | 1,028 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
A Pilot Study of Abiraterone Acetate in African American/Black Patients With Castration Resistant Prostate Cancer[NCT01735396] | Phase 2 | 11 participants (Actual) | Interventional | 2012-12-31 | Terminated (stopped due to poor accrual) | ||
An Open-Label, Multi-Centre, Randomised, Phase Ib Study to Investigate the Safety and Efficacy of RO5072759 Given in Combination With CHOP, FC or Bendamustine Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma[NCT00825149] | Phase 1 | 137 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
A Phase I/II Study of Alisertib in Combination With Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer After Progression on Abiraterone[NCT01848067] | Phase 1/Phase 2 | 9 participants (Actual) | Interventional | 2013-08-14 | Completed | ||
A Phase II Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis[NCT03114254] | Phase 2 | 17 participants (Actual) | Interventional | 2014-12-05 | Completed | ||
Development of Tissue Predictors of Abiraterone Benefit in Men With mCRPC[NCT03176381] | 110 participants (Actual) | Observational | 2017-05-05 | Completed | |||
F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer Treated by Abiraterone Acetate or Enzalutamide[NCT01981707] | Phase 2/Phase 3 | 12 participants (Actual) | Interventional | 2013-12-31 | Terminated (stopped due to enrollment default) | ||
Phase II Stereotactic Body Radiotherapy (SBRT) and Stereotactic Hypofractionated Radiotherapy (SHRT) for Oligometastatic Prostate Cancer[NCT01859221] | 39 participants (Actual) | Interventional | 2013-05-31 | Completed | |||
Prospective Pilot Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer[NCT04225910] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2020-01-01 | Not yet recruiting | ||
Phase II Randomized Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels[NCT02867020] | Phase 2 | 128 participants (Actual) | Interventional | 2017-10-11 | Completed | ||
A Single-center, Phase II Neoadjuvant Study of Abiraterone Acetate in the Treatment of Intraductal Carcinoma of the Prostate[NCT04736108] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-05-31 | Not yet recruiting | ||
A Phase I Study of Entinostat in Combination With Enzalutamide for Treatment of Patients With Castration-Resistant Prostate Cancer[NCT03829930] | Phase 1 | 6 participants (Actual) | Interventional | 2019-05-01 | Terminated (stopped due to Sponsor discontinued the drug) | ||
A Randomized Phase II Study of OGX-427 (a Second-Generation Antisense Oligonucleotide to Heat Shock Protein-27) in Patients With Castration Resistant Prostate Cancer Who Have Not Previously Received Chemotherapy for Metastatic Disease[NCT01120470] | Phase 2 | 74 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma[NCT03145285] | Phase 2 | 10 participants (Anticipated) | Interventional | 2017-04-18 | Active, not recruiting | ||
Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.[NCT04962919] | 590 participants (Anticipated) | Observational | 2020-01-14 | Recruiting | |||
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)[NCT01578655] | Phase 3 | 630 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
Title: A Pilot Study Evaluating the Safety and Feasibility of Custirsen (OGX-011) in Combination With Second Line Chemotherapy in Patients With Hormone Refractory Prostate Cancer[NCT00327340] | Phase 2 | 70 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.[NCT03103724] | Phase 2 | 68 participants (Actual) | Interventional | 2017-03-16 | Completed | ||
Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer: An Open-label, Randomized, Cross-Over Trial.[NCT04409288] | Phase 3 | 146 participants (Anticipated) | Interventional | 2020-07-20 | Recruiting | ||
A Phase I Trial of Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer (CRPC)[NCT03737370] | Phase 1 | 25 participants (Anticipated) | Interventional | 2018-01-30 | Recruiting | ||
An Open-label, Phase I/IIa Dose Escalation and Expansion Study to Determine the Safety and Clinical Activity of an Immune Priming Cell Therapy (INKmune) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)[NCT06056791] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2023-11-30 | Not yet recruiting | ||
Docetaxel and Estramustine Versus Mitoxantrone and Prednisone for Advanced, Hormone Refractory Prostate Cancer[NCT00004001] | Phase 3 | 770 participants (Actual) | Interventional | 1999-10-31 | Completed | ||
Evaluation of Dose-response, Pharmacodynamic and Pharmacokinetic Bioequivalence of Filgrastim in Healthy Male Volunteers After Single and Multiple-dose Subcutaneous Administration of the BK0023 Injectable Formulation vs. Neupogen®[NCT01933971] | Phase 1 | 102 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients[NCT00001384] | Phase 2 | 35 participants | Interventional | 1994-05-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The OS was defined as the time from randomization to date of death from any cause. (NCT02257736)
Timeframe: Up to 5 years and 10 months
Intervention | months (Median) |
---|---|
Placebo+ Abiraterone Acetate - Prednisolone | 33.71 |
Apalutamide + Abiraterone Acetate - Prednisolone | 36.17 |
The rPFS was defined as the time from randomization to the occurrence of one of the following: 1) a participant was considered to have progressed by bone scan if - a) the first bone scan with greater than or equal to (>=) 2 new lesions compared to baseline was observed in less than (<) 12 weeks from randomization and was confirmed by a second bone scan taken >=6 weeks later showing >=2 additional new lesions (a total of >=4 new lesions compared to baseline), b) the first bone scan with >=2 new lesions compared to baseline was observed in >=12 weeks from randomization and the new lesions were verified on the next bone scan >=6 weeks later (a total of >=2 new lesions compared to baseline); 2) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. (NCT02257736)
Timeframe: Up to 3 years and 4 months
Intervention | months (Median) |
---|---|
Placebo+ Abiraterone Acetate - Prednisolone | 16.59 |
Apalutamide + Abiraterone Acetate - Prednisolone | 23.98 |
Time to chronic opioid use was defined as the time from date of randomization to the first date of opioid use. (NCT02257736)
Timeframe: Up to 5 years and 10 months
Intervention | months (Median) |
---|---|
Placebo+ Abiraterone Acetate - Prednisolone | 53.26 |
Apalutamide + Abiraterone Acetate - Prednisolone | 46.98 |
Time to initiation of cytotoxic chemotherapy was defined as the time from date of randomization to the date of initiation of cytotoxic chemotherapy. (NCT02257736)
Timeframe: Up to 5 years and 10 months
Intervention | months (Median) |
---|---|
Placebo+ Abiraterone Acetate - Prednisolone | 34.23 |
Apalutamide + Abiraterone Acetate - Prednisolone | 36.11 |
"Time to pain progression: time from randomization to first date that participant either experienced an increase by 2 points from baseline in Brief Pain Inventory Short Form (BPI-SF) worst pain intensity item (item 3) or Case Report Form (CRF) pain, observed at 2 consecutive evaluations >=4 wks apart, or initiation of chronic opioids as defined in time to chronic opioid use, whichever occurred first. BPI-SF is a self-administered questionnaire developed to assess severity of pain and impact of pain on daily functions. Item 3(worst pain intensity) asks participants to rate worst pain in prior 7-days on a 0-10 numeric rating scale, where 0 indicates No pain and 10 indicates Pain as bad as you can imagine. A lower score is better.CRF pain refers to participant's response to global pain assessment How would you rate your pain over the past 7 days?with a scale of 0(No pain) to 10(Pain as bad as you can imagine),that is systematically reported and recorded on the eCRF." (NCT02257736)
Timeframe: Up to 5 years and 10 months
Intervention | months (Median) |
---|---|
Placebo+ Abiraterone Acetate - Prednisolone | 26.51 |
Apalutamide + Abiraterone Acetate - Prednisolone | 21.82 |
Overall survival was defined as the time from randomization to date of death from any cause. (NCT01715285)
Timeframe: Up to 66 months
Intervention | months (Median) |
---|---|
Abiraterone Acetate+Prednisone+ADT | 53.32 |
Placebo + ADT | 36.53 |
Radiographic PFS was defined as the time (in months) interval from randomization to the first date of radiographic progression or death. Radiographic progression included progression by bone scan (according to modified Prostate Cancer Working Group 2 [PCWG2] criteria), defined as at least 2 new lesions on bone scan and progression of soft tissue lesions by computed tomography (CT) or magnetic resonance imaging (MRI) (according to Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria). As per the RECIST 1.1 guideline, progression requires a 20 percent (%) increase in the sum of diameters of all target lesions and a minimum absolute increase of 5 millimeter (mm) in the sum as compared to nadir sum of diameter. (NCT01715285)
Timeframe: Up to 44 months
Intervention | Months (Median) |
---|---|
Abiraterone Acetate+Prednisone+ADT | 33.02 |
Placebo + ADT | 14.78 |
Time to initiation of chemotherapy was defined as the time (in months) interval from the date of randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer. (NCT01715285)
Timeframe: Up to 66 months
Intervention | months (Median) |
---|---|
Abiraterone Acetate+Prednisone+ADT | NA |
Placebo + ADT | 57.59 |
"Time to pain progression was defined as the time (in months) interval from randomization to the first date a participant experienced a greater than or equal to (>=) 30 percent (%) increase in Brief Pain Inventory-Short Form (BPI-SF) from baseline in the BPI-SF worst pain intensity (Item 3) observed at 2 consecutive evaluations (>=4) weeks apart. BPI-SF was an 11-item questionnaire, designed to assess severity and impact of pain on daily functions. Total score ranged from 0 to 10 with 0 representing no pain and 10 representing pain as bad as you can imagine." (NCT01715285)
Timeframe: Up to 66 months
Intervention | Months (Median) |
---|---|
Abiraterone Acetate+Prednisone+ADT | 47.41 |
Placebo + ADT | 16.62 |
Time to PSA progression was defined as the time (in months) interval from the date of randomization to the date of PSA progression, according to PCWG2 criteria. PCWG2 defines PSA progression as the date that a 25 percent (%) or greater increase and an absolute increase of 2 nanogram per milliliter (ng/mL) or more from the nadir is documented, which is confirmed by a second value obtained 3 or more weeks later. (NCT01715285)
Timeframe: Up to 66 months
Intervention | Months (Median) |
---|---|
Abiraterone Acetate+Prednisone+ADT | 33.31 |
Placebo + ADT | 7.43 |
Time to skeletal-related event was defined as the earliest of the following: clinical or pathological fracture, spinal cord compression, palliative radiation to bone, or surgery to bone. (NCT01715285)
Timeframe: Up to 66 months
Intervention | months (Median) |
---|---|
Abiraterone Acetate+Prednisone+ADT | NA |
Placebo + ADT | NA |
Time to subsequent therapy was defined as the time (in months) interval from the date of randomization to the date of initiation of subsequent therapy for prostate cancer. (NCT01715285)
Timeframe: Up to 66 months
Intervention | Months (Median) |
---|---|
Abiraterone Acetate+Prednisone+ADT | 54.87 |
Placebo + ADT | 21.22 |
Treatment-emergent additional primary malignancies were adverse events identified as additional primary malignancies that occurred after start of study treatment until the end of the treatment period. (NCT02043678)
Timeframe: From start of study treatment until 4 weeks after last study treatment, up to 65 months
Intervention | Participants (Count of Participants) |
---|---|
Radium-223 Dichloride + Abi/Pred | 26 |
Placebo + Abi/Pred | 25 |
Treatment-emergent fractures were adverse events identified as fractures that occurred after start of study treatment until the end of the treatment period. All bone fractures and bone-associated events (e.g., osteoporosis) were reported as either AEs, or SAEs if the criteria of SAE were met, regardless of the investigator's causality assessment. (NCT02043678)
Timeframe: From start of study treatment until 4 weeks after last study treatment, up to 65 months
Intervention | Participants (Count of Participants) |
---|---|
Radium-223 Dichloride + Abi/Pred | 107 |
Placebo + Abi/Pred | 49 |
OS was defined as the time (months) from the date of randomization to the date of death due to any cause. Subjects alive at the survival cut-off date were censored at the last date known to be alive. (NCT02043678)
Timeframe: From randomization until death from any cause, up to 67 months
Intervention | Months (Median) |
---|---|
Radium-223 Dichloride + Abi/Pred | 30.1 |
Placebo + Abi/Pred | 34.8 |
rPFS was defined as the time (months) from the date of randomization to the date of confirmed radiological progression or death (if death occurred before progression) based on independent assessment. (NCT02043678)
Timeframe: From randomization until the date of confirmed radiological progression or death, up to 47 months
Intervention | Months (Median) |
---|---|
Radium-223 Dichloride + Abi/Pred | 11.2 |
Placebo + Abi/Pred | 12.4 |
SSE-FS was defined as time (months) from randomization to the earliest of onset date of skeletal symptoms treated with external beam radiotherapy (EBRT), onset date of pathological bone fracture, onset date of spinal cord compression, procedure date of tumor-related orthopedic surgery, or death from any cause. Subjects who died without prior SSE and ≥ 13 weeks after the last SSE assessment are censored at the last SSE assessment date. Subjects alive at the survival cut-off date are censored at the last date known to be alive. Subjects with multiple events are only counted for the category in which the first event occurred. If multiple SSE (component events) occur on the same date for 1 subject, the subject is only counted into 1 category in the order of: spinal cord compression > bone fracture > orthopedic surgery > EBRT. (NCT02043678)
Timeframe: From randomization until first onset of on-study symptomatic skeletal event (SSE) or death, up to 47 months
Intervention | Months (Median) |
---|---|
Radium-223 Dichloride + Abi/Pred | 22.3 |
Placebo + Abi/Pred | 26.0 |
Time to cytotoxic chemotherapy is time (months) from randomization to the earliest date of the first cytotoxic chemotherapy. Participants who have not started cytotoxic chemotherapy during the study were censored at the last assessment date. (NCT02043678)
Timeframe: From randomization until the date of first cytotoxic chemotherapy, up to 47 months
Intervention | Months (Median) |
---|---|
Radium-223 Dichloride + Abi/Pred | 29.5 |
Placebo + Abi/Pred | 28.5 |
Time to opiate use for cancer pain was defined as the interval from the date of randomization to the date of opiate use. (NCT02043678)
Timeframe: From randomization until the date of opiate use, up to 47 months
Intervention | Months (Median) |
---|---|
Radium-223 Dichloride + Abi/Pred | 19.0 |
Placebo + Abi/Pred | 22.6 |
Time to pain progression was defined as the interval from randomization to the first date a subject experienced pain progression, assessed by BPI-SF (see Baseline Characteristics) and defined as: an increase of 2 or more points in the average worst pain score (WPS) from baseline observed at 2 consecutive evaluations >= 4 weeks apart or initiation of short- or long-acting opioid use for pain for subjects with WPS 0 at baseline; an increase of 2 or more points in the average WPS from baseline observed at 2 consecutive evaluations ≥ 4 weeks apart and an average WPS of ≥ 4 OR initiation of short- or long-acting opioid use for pain for subjects with WPS 1 to 3 at baseline. Subjects without pain progression at the end of study are censored at the last date known to have not progressed: the last evaluation date for pain scores or last visit when recorded opiate use, whichever is last. Subjects with no on-study assessment or no baseline assessment are censored at the date of randomization. (NCT02043678)
Timeframe: From randomization until the date of pain progression based on pain score, up to 47 months
Intervention | Months (Median) |
---|---|
Radium-223 Dichloride + Abi/Pred | 14.4 |
Placebo + Abi/Pred | 18.7 |
"An adverse event (AE) was any untoward medical occurrence (i.e., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a participant in the study. Any bleeding event occurring during the study was not documented as an AE because this event was planned to be captured in the assessment of efficacy. AEs that started after the treatment period were defined as post-treatment AEs. Drug-related AEs were those with reasonable causal relationship to the study treatment decided by the investigators." (NCT02043678)
Timeframe: After the treatment period, up to 46 months
Intervention | Participants (Count of Participants) | |||
---|---|---|---|---|
Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
Placebo + Abi/Pred | 3 | 3 | 3 | 0 |
Radium-223 Dichloride + Abi/Pred | 3 | 9 | 5 | 1 |
"An adverse event (AE) was any untoward medical occurrence (i.e., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a participant in the study. Any bleeding event occurring during the study was not documented as an AE because this event was planned to be captured in the assessment of efficacy. AEs that started after the treatment period were defined as post-treatment AEs. Drug-related AEs were those with reasonable causal relationship to the study treatment decided by the investigators." (NCT02043678)
Timeframe: After the treatment period, up to 46 months
Intervention | Participants (Count of Participants) | |||
---|---|---|---|---|
Any events | Any drug-related events | Any chemotherapy-related events | Any additional primary malignancies | |
Placebo + Abi/Pred | 133 | 9 | 34 | 7 |
Radium-223 Dichloride + Abi/Pred | 138 | 18 | 31 | 6 |
Post-treatment fractures were adverse events identified as fractures that occured after the end of the treatment period until participant died, was lost to follow-up, withdrew informed consent, actively objected to collection of further data, or was transitioned to the extended safety follow-up study. All bone fractures and bone-associated events (e.g., osteoporosis), were reported as either AEs, or SAEs if the criteria of SAE were met, regardless of the investigator's causality assessment. (NCT02043678)
Timeframe: After the treatment period, up to 46 months
Intervention | Participants (Count of Participants) | ||||||
---|---|---|---|---|---|---|---|
Lumbar vertebral fracture | Rib fracture | Spinal compression fracture | Thoracic vertebral fracture | Traumatic fracture | Osteoporotic fracture | Pathological fracture | |
Placebo + Abi/Pred | 1 | 1 | 1 | 1 | 2 | 0 | 13 |
Radium-223 Dichloride + Abi/Pred | 0 | 0 | 0 | 0 | 6 | 6 | 12 |
Post-treatment blood and lymphatic system disorders were adverse events identified as blood and lymphatic system disorders that occurred after the end of the treatment period until participant died, was lost to follow-up, withdrew informed consent, actively objected to collection of further data, or was transitioned to the extended safety follow-up study. (NCT02043678)
Timeframe: After the treatment period, up to 46 months
Intervention | Participants (Count of Participants) | ||||||
---|---|---|---|---|---|---|---|
Anaemia | Bone marrow failure | Febrile neutropenia | Leukopenia | Neutropenia | Pancytopenia | Thrombocytopenia | |
Placebo + Abi/Pred | 4 | 0 | 8 | 0 | 3 | 1 | 2 |
Radium-223 Dichloride + Abi/Pred | 5 | 1 | 5 | 1 | 8 | 0 | 2 |
"An adverse event (AE) was any untoward medical occurrence (i.e., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a participant in the study. A serious adverse event (SAE) was any untoward medical occurrence that at any dose was resulting in death, was lifethreatening, requires hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity. AEs or SAEs occurring after start of study treatment until the end of the treatment period were defined as treatment-emergent AEs (TEAEs) or serious TEAEs. Drug-related TEAEs or serious TEAEs were those with reasonable causal relationship to the study treatment decided by the investigators." (NCT02043678)
Timeframe: From start of study treatment until the end of the treatment period, up to 65 months
Intervention | Participants (Count of Participants) | |||||
---|---|---|---|---|---|---|
Any TEAE | Any drug-related TEAE | Radium-223/Placebo-related TEAE | Any serious TEAE | Any drug-related serious TEAE | Radium-223/Placebo-related serious TEAE | |
Placebo + Abi/Pred | 387 | 271 | 92 | 172 | 29 | 7 |
Radium-223 Dichloride + Abi/Pred | 382 | 265 | 92 | 175 | 32 | 11 |
"An adverse event (AE) was any untoward medical occurrence (i.e., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a participant in the study. A serious adverse event (SAE) was any untoward medical occurrence that at any dose was resulting in death, was lifethreatening, requires hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity. AEs or SAEs occurring after start of study treatment until the end of the treatment period were defined as treatment-emergent AEs (TEAEs) or serious TEAEs. Radium-223/placebo-related TEAEs or serious TEAEs were those with reasonable causal relationship to radium-223 or placebo decided by the investigators." (NCT02043678)
Timeframe: From start of study treatment until the end of the treatment period, up to 65 months
Intervention | Participants (Count of Participants) | ||||||
---|---|---|---|---|---|---|---|
TEAE - Grade 1 | TEAE - Grade 2 | TEAE - Grade 3 | TEAE - Grade 4 | Serious TEAE - Grade 2 | Serious TEAE - Grade 3 | Serious TEAE - Grade 4 | |
Placebo + Abi/Pred | 53 | 24 | 13 | 2 | 0 | 5 | 2 |
Radium-223 Dichloride + Abi/Pred | 44 | 28 | 19 | 1 | 3 | 8 | 0 |
50% or greater decline in PSA from baseline. (NCT01576172)
Timeframe: Up to 3 years
Intervention | Participants (Count of Participants) |
---|---|
Arm I (Abiraterone Acetate and Prednisone) | 46 |
Arm II (Abiraterone Acetate, Prednisone, and Veliparib) | 55 |
Grade 4 or greater toxicity graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 at least possibly related to treatment. (NCT01576172)
Timeframe: 30 days after completion of study treatment
Intervention | Participants (Count of Participants) |
---|---|
Arm I (Abiraterone Acetate and Prednisone) | 1 |
Arm II (Abiraterone Acetate, Prednisone, and Veliparib) | 3 |
Overall response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT01576172)
Timeframe: Up to 3 years
Intervention | Participants (Count of Participants) |
---|---|
Arm I (Abiraterone Acetate and Prednisone) | 18 |
Arm II (Abiraterone Acetate, Prednisone, and Veliparib) | 24 |
Time from randomization to disease progression or death. (NCT01576172)
Timeframe: Up to 42 months
Intervention | months (Median) |
---|---|
Arm I (Abiraterone Acetate and Prednisone) | 10.1 |
Arm II (Abiraterone Acetate, Prednisone, and Veliparib) | 11.0 |
Change in PSA from baseline to 12 weeks (NCT01576172)
Timeframe: 12 weeks
Intervention | ng/ml (Mean) |
---|---|
Arm I (Abiraterone Acetate and Prednisone) | -41.1 |
Arm II (Abiraterone Acetate, Prednisone, and Veliparib) | -52.9 |
Cohorts of 3 patients will be enrolled at each dose level; if 1 dose limiting toxicity (DLT) is observed then the cohort will be expanded to 6 patients. If a second DLT is observed, the previous dose level will be considered the maximum tolerated dose (MTD). If all observed DLT are due to neuropathy (specific to ixabepilone), then we would consider the previous dose level of Ixabepilone the MTD for that drug, and escalate mitoxantrone hydrochloride as described above to a maximum dose of 12 mg/m^2. Toxicities will be tabulated by grade for each dose cohort and overall for all patients accrued to the phase I study. (NCT00331344)
Timeframe: Course 1 (first 21 days)
Intervention | Participants (Count of Participants) |
---|---|
Phase I Group I | 0 |
Phase Group II | 0 |
Phase I Group III | 0 |
Phase I Group IV | 1 |
Phase I Group V | 2 |
Phase I Group VI | 2 |
Phase I Group Va | 0 |
Phase I Group VIa | 1 |
"Descriptive statistics will be calculated to characterize the disease and treatment factors including the proportion responding with a 95% confidence interval. If accrual is completed and more than 15 of 58 patients show > 50% Prostate Specific Antigen (PSA) declines after 3 courses, then the null hypothesis of a 20% response proportion will be rejected. PSA declines for individual patients will be plotted in the form of a waterfall diagram of maximal PSA declines.~58 patients were enrolled for phase II, two were ineligible so 56 patients were analyzed." (NCT00331344)
Timeframe: Every 3 courses until cancer progression/excessive toxicity or death
Intervention | Participants (Count of Participants) |
---|---|
Treatment (Combination Chemotherapy) | 25 |
This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) v3.0 for adverse event monitoring and reporting. The cumulative grade 3 or higher adverse events for all dose levels are noted below and in the table of adverse events. (NCT00331344)
Timeframe: Every 21 days until cancer progression/excessive toxicity or death
Intervention | Adverse Events (above threshold) (Number) |
---|---|
Phase I Treatment (Groups I-VIa) | 62 |
Measured from the start of protocol therapy until RECIST (Response Evaluation Criteria In Solid Tumors Criteria) v1.0 progression. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00331344)
Timeframe: Every 3 months until cancer progression/excessive toxicity or death
Intervention | months (Median) |
---|---|
Treatment (Combination Chemotherapy) | 4.4 |
OS is the duration from randomization to death. For participants who were alive, overall survival was censored at the last contact. OS (in months) calculated as (date of death minus [-] date of randomization plus [+] 1) divided (/) 30.4. (NCT00676650)
Timeframe: Baseline up to 32 months
Intervention | months (Median) |
---|---|
Sunitinib and Prednisone | 13.1 |
Placebo and Prednisone | 11.8 |
OR defined as the percent (%) of participants with confirmed Complete Response (CR) (disappearance of all target lesions) or Partial Response (PR) (>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions) according to Response Evaluation Criteria in Solid Tumors (RECIST), relative to the full analysis population. Confirmed responses were those that persist on repeat imagining study >= 4 weeks after initial documentation of response. (NCT00676650)
Timeframe: Baseline, every 8 weeks up to 123 weeks
Intervention | percentage of participants (Number) |
---|---|
Sunitinib and Prednisone | 6.1 |
Placebo and Prednisone | 1.8 |
PFS is the period from randomization until disease progression or death on study. PFS is censored on the date of last tumor assessment documenting absence of progressive disease. PFS (weeks) calculated as (first event date - randomization date + 1)/7.02 (NCT00676650)
Timeframe: Baseline, every 8 weeks up to 123 weeks
Intervention | weeks (Median) |
---|---|
Sunitinib and Prednisone | 24.1 |
Placebo and Prednisone | 17.9 |
Overall survival is defined as the time from randomization to date of death from any cause. (NCT00887198)
Timeframe: From randomization (Day 1) up to end of study (Month 60)
Intervention | Months (Median) |
---|---|
Abiraterone Acetate + Prednisone (AAP) | 34.66 |
Placebo | 30.29 |
The rPFS was defined as the time from randomization to the occurrence of one of the following: 1) a participant was considered to have progressed by bone scan if - a) the first bone scan with greater than or equal to (>=) 2 new lesions compared to baseline was observed in less than (<) 12 weeks from randomization and was confirmed by a second bone scan taken >=6 weeks later showing >=2 additional new lesions (a total of >=4 new lesions compared to baseline), b) the first bone scan with >=2 new lesions compared to baseline was observed in >=12 weeks from randomization and the new lesions were verified on the next bone scan >=6 weeks later (a total of >=2 new lesions compared to baseline); 2) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI); 3) death from any cause. (NCT00887198)
Timeframe: From randomization (Day 1) up to first radiographic progression or cutoff date (Month 18)
Intervention | Months (Median) |
---|---|
Abiraterone Acetate + Prednisone (AAP) | NA |
Placebo | 8.28 |
The time interval from the date of randomization to the first date at which there was at least a 1 grade change (worsening) in the ECOG performance status grade. Participants who had no deterioration in ECOG performance status grade at the time of the analysis were censored at the last known date of no deterioration. ECOG is a 5-point scale, where 0=Fully active, 1=Ambulatory, carry out work of sedentary nature, 2=Ambulatory, capable of all self-care, 3=Capable of limited self-care, confined to bed or chair more than 50% of waking hours, 4=Completely disabled, no self-care, totally confined to bed or chair, 5=Dead. Participants with no assessment were censored at the date of randomization. (NCT00887198)
Timeframe: From randomization (Day 1) up to first radiographic progression or cutoff date (Month 18)
Intervention | Months (Median) |
---|---|
Abiraterone Acetate + Prednisone (AAP) | 12.29 |
Placebo | 10.87 |
The time interval from the date of randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer. Participants who had no cytotoxic chemotherapy administration at the time of analysis were censored at the last known date when no cytotoxic chemotherapy was administered. Participants with no assessment were censored at the date of randomization. (NCT00887198)
Timeframe: From randomization (Day 1) up to initiation of cytotoxic chemotherapy or cutoff date (Month 18)
Intervention | Months (Median) |
---|---|
Abiraterone Acetate + Prednisone (AAP) | 25.17 |
Placebo | 16.82 |
The time interval from the date of randomization to the date of opiate use for cancer pain. Participants who have no opiate use at the time of analysis were censored at the last known date of no opiate use for cancer pain. Participants with no assessment were censored at the date of randomization. (NCT00887198)
Timeframe: From randomization (Day 1) up to first opiate use or end of study (Month 60)
Intervention | Months (Median) |
---|---|
Abiraterone Acetate + Prednisone (AAP) | 33.38 |
Placebo | 23.39 |
The time interval from the date of randomization to the date of PSA progression as defined in the protocol-specific prostate cancer Working Group 2 (PCWG2) criteria. A participant was considered to have a PSA progression if the PSA level had a 25 percent (%) or greater increase from nadir and an absolute increase of 2 nanogram/milliliter ((ng/mL) or more, which is confirmed by a second value obtained in 3 or more weeks. Participants who had no PSA progression at the time of the analysis were censored at the last known date of no PSA progression. Participants with no on-study PSA assessment or no baseline PSA assessment were censored at the date of randomization. (NCT00887198)
Timeframe: From randomization (Day 1) up to date of PSA progerssion or cutoff date (Month 18)
Intervention | Months (Median) |
---|---|
Abiraterone Acetate + Prednisone (AAP) | 11.07 |
Placebo | 5.55 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state. (NCT00887198)
Timeframe: From first dose of study drug up to 30 days after the last dose of study drug
Intervention | Participants (Number) | |
---|---|---|
With Treatment-Emergent Adverse Events | With Treatment-Emergent Serious Adverse Events | |
Abiraterone Acetate + Prednisone (AAP) | 541 | 208 |
Placebo | 524 | 148 |
Placebo to Abiraterone Acetate | 93 | 39 |
Length of time from the date of first observation of complete response (CR) or partial response (PR) to the date of first observation of disease progression, according to prostate-specific antigen (PSA) response according to Prostate Cancer Working Group 1 (PCWG1) criteria. PSA response according to PCWG1 is defined as an least 50 percent decline in PSA level from baseline that was maintained for at least three weeks. (NCT00503984)
Timeframe: Up to 4.5 years.
Intervention | weeks (Median) |
---|---|
All Study Participants Achieving PSA Response | 20.5 |
Number of participants achieving prostate-specific antigen (PSA) response according to Prostate Cancer Working Group 1 (PCWG1) criteria. PSA response according to PCWG1 is defined as an least 50 percent decline in PSA level from baseline that was maintained for at least three weeks. (NCT00503984)
Timeframe: Up to 4.5 years.
Intervention | participants (Number) |
---|---|
Phase 1: Level 1 - 75 Aza + 60 Doc | 0 |
Phase 1: Level 2 - 75 Aza + 75 Doc | 1 |
Phase 1: Level 3 - 100 Aza + 75 Doc | 2 |
Phase 1: Level 4 - 150 Aza + 75 Doc | 4 |
Phase 2 - Aza + Doc Initial RPTD | 3 |
Phase 2 - Aza + Doc Reduced RPTD | 0 |
(NCT00503984)
Timeframe: Up to 4.5 years
Intervention | participants (Number) |
---|---|
Level 1 - 75 Aza + 60 Doc | 3 |
Level 2 - 75 Aza + 75 Doc | 4 |
Level 3 - 100 Aza + 75 Doc | 3 |
Level 4 - 150 Aza + 75 Doc | 12 |
The time from the date of initiation of study treatment until date of death from any cause. (NCT00503984)
Timeframe: Up to 4.5 years.
Intervention | months (Median) |
---|---|
All Study Participants | 19.5 |
The time from the date of start of treatment until the first documented or confirmed disease progression, or death related to prostate cancer, whichever is earlier. (NCT00503984)
Timeframe: Up to 4.5 years
Intervention | months (Median) |
---|---|
All Study Participants | 4.9 |
"Number of participants achieving Complete Response (CR) or Partial Response to protocol therapy according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.0 Criteria. Per RECIST 1.0 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; " (NCT00503984)
Timeframe: Up to 4.5 years
Intervention | participants (Number) | |
---|---|---|
Complete Response (CR) | Partial Response (PR) | |
Phase 1: Level 1 - 75 Aza + 60 Doc | 0 | 0 |
Phase 1: Level 3 - 100 Aza + 75 Doc | 1 | 0 |
Phase 1: Level 4 - 150 Aza + 75 Doc | 0 | 1 |
Phase 2 - Aza + Doc Initial RPTD | 0 | 1 |
Determination of a safe and potentially efficacious phase II dose of azacitidine in combination with docetaxel and prednisone that can be used for the treatment of hormone refractory metastatic prostate cancer. (NCT00503984)
Timeframe: Up to 1.5 years
Intervention | mg/m2 (Number) | |||
---|---|---|---|---|
Initial RPTD Azacitidine (mg/m2) | Initial RPTD Docetaxel (mg/m2) | Reduced RPTD Azacitidine (mg/m2) | Reduced RPTD Docetaxel (mg/m2) | |
Phase 1 - Aza + Doc | 150 | 75 | 75 | 75 |
Determination of a safe and potentially efficacious phase II dose of azacitidine in combination with docetaxel and prednisone that can be used for the treatment of hormone refractory metastatic prostate cancer. (NCT00503984)
Timeframe: Up to 1.5 years
Intervention | mg (Number) | |
---|---|---|
Initial RPTD Prednisone (mg) | Reduced RPTD Prednisone (mg) | |
Phase 1 - Aza + Doc | 5 | 5 |
A prostate-specific antigen (PSA) response was defined as a >=50% decline from baseline. (NCT00638690)
Timeframe: Up to 12 months
Intervention | Participants (Number) |
---|---|
Abiraterone Acetate | 232 |
Placebo | 22 |
Overall survival is defined as the time interval from the date of randomization to the date of death from any cause. (NCT00638690)
Timeframe: Up to 60 months
Intervention | Days (Median) |
---|---|
Abiraterone Acetate | 450.0 |
Placebo | 332.0 |
Radiographic progression-free survival is based on imaging studies according to modified Response Evaluation Criteria in Solid Tumors (RECIST): baseline lymph node size must be >=2.0 cm to be considered a target lesion; progression on bone scans with >=2 new lesions not consistent with tumor flare, confirmed on a second scan >=6 weeks later that shows >=1 additional new lesion. (NCT00638690)
Timeframe: Up to 11 months
Intervention | Days (Median) |
---|---|
Abiraterone Acetate | 171.0 |
Placebo | 110.0 |
The time interval from the date of randomization to the date of the prostate-specific antigen (PSA) progression as defined in the protocol-specific Prostate Specific Antigen Working Group (PSAWG) criteria, namely, a PSA level of at least 5 ng/ml that has risen on at least 2 successive occasions, at least 2 weeks apart. (NCT00638690)
Timeframe: Up to 12 months
Intervention | Days (Median) |
---|---|
Abiraterone Acetate | 309.0 |
Placebo | 200.0 |
BSR is defined as >=30% reduction in the bone scan lesion area (BSLA) compared with baseline. Confirmation of bone scan was not required for response or progression. Bone scans were evaluated by an independent radiology facility (IRF) for response. (NCT01605227)
Timeframe: BSR was measured at the end of Week 12 as determined by the IRF
Intervention | percentage of participants (Number) |
---|---|
Cabozantinib | 42 |
Prednisone | 3 |
The primary analysis of OS is defined as the time from randomization to death due to any cause. Participants that had not died or were permanently lost to follow-up were censored at the last known date alive. Median OS was calculated using Kaplan-Meier estimates. Analysis for OS was performed after 614 events had occurred. (NCT01605227)
Timeframe: OS was measured from the time of randomization until 614 events, approximately 24 months after study start
Intervention | months (Median) |
---|---|
Cabozantinib | 11.0 |
Prednisone | 9.8 |
The exploratory analysis of PFS is the time from randomization to date of first documented radiographic progression (bone and/or soft tissue) according to the investigator's assessment or death. PFS was defined per mRECIST 1.1 and included evaluation of measurable, nonmeasurable, target and nontarget lesions. A Kaplan-Meier analysis was performed to estimate the median duration. (NCT01605227)
Timeframe: Duration of PFS was defined as time from the date of randomization to earlier of date of radiographic progression (bone/andor soft tissue) according to the investigator's assessment or death, assessed for up to approximately 24 months
Intervention | months (Median) |
---|---|
Cabozantinib | 5.6 |
Prednisone | 2.8 |
The primary objective of this study is to determine a correlation between inherited genetic polymorphisms and antitumor activity (as defined by a decline in PSA of ≥ 30%) in AA patients with castration-resistant prostate cancer treated with Abiraterone. The primary endpoint is the percent change in PSA from baseline to 12 weeks. A decline of ≥ 30% will be correlated with germline SNPs. (NCT01735396)
Timeframe: baseline and 12 weeks
Intervention | Participants (Count of Participants) |
---|---|
Abiraterone Acetate | 9 |
To determine the safety of abiraterone Adverse events as defined by CTCAE v4. Number of participants with serious adverse events grade 4 or 5 (NCT01735396)
Timeframe: up to 12 weeks
Intervention | Participants (Count of Participants) |
---|---|
Abiraterone Acetate | 0 |
Post-treatment changes in measurable disease by RECIST - Response Evaluation Criteria in Solid Tumors Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions (NCT01735396)
Timeframe: up to 12 weeks
Intervention | Participants (Count of Participants) | |
---|---|---|
PR | SD | |
Abiraterone Acetate | 9 | 1 |
Compared between the two patient subsets using the nonparametric Mann-Whitney test. A comparison of CTC counts between baseline and at progression for those who have progressed will be carried out using either a paired t test or the nonparameteric Wilcoxon matched pairs test. (NCT01848067)
Timeframe: Baseline up to 3 months
Intervention | Participants (Count of Participants) |
---|---|
Treatment (Alisertib, Abiraterone Acetate, Prednisone) | 3 |
Summarized with descriptive statistics. (NCT01848067)
Timeframe: Up to 21 days
Intervention | Participants (Count of Participants) |
---|---|
Treatment (Alisertib, Abiraterone Acetate, Prednisone) | 2 |
PSA or prostate specific antigen is a marker for prostate cancer. A PSA response was defined as a decrease in PSA values of ≥ 50% relative to baseline on two or more consecutive measurements that were 4-6 weeks apart. (NCT00327340)
Timeframe: PSA was evaluated at screening, on Day 1 of each cycle, at the end of treatment visit and during off-treatment follow up (up to 27 months)
Intervention | percentage of participants (Number) |
---|---|
OGX-011 / Mitoxantrone/Prednisone | 17 |
OGX-011 / Docetaxel/Prednisone | 31 |
Time to pain progression was defined as the time (months) from the first dose of OGX-011 to the first documentation of pain or analgesic progression or initiation of palliative radiation therapy. Pain response was defined as either a decrease of at least two points on the 11-point Worst Pain Scale, without an increase in analgesic level, maintained for at least two consecutive measurements approximately three weeks apart -or- a decrease in analgesic level, without an increase in pain score, maintained for at least two consecutive measurements approximately three weeks apart. (NCT00327340)
Timeframe: Enrollment until pain progression (up to 21 months)
Intervention | months (Number) |
---|---|
OGX-011 + Mitoxantrone + Prednisone | 5.2 |
OGX-011 + Docetaxel + Prednisone | 7.2 |
Serum clusterin samples were collected prior to receiving OGX-011 loading dose 1, prior to study treatment on Day 1 of each cycle, and at the end of treatment. PSA was evaluated at screening, on Day 1 of each cycle, at the end of treatment visit, and during off-treatment follow-up. PSA response was defined in the protocol as a decrease in PSA of ≥ 50% relative to baseline on two or more consecutive measurements 4-6 weeks apart. (NCT00327340)
Timeframe: Enrollment until disease progression (up to 13 months)
Intervention | percentage of participants (Number) | |
---|---|---|
Minimum clusterin level < or = to 45 mcg/mL | Minimum clusterin level > 45 mcg/mL | |
OGX-011 + Docetaxel + Prednisone | 24 | 7 |
OGX-011 + Mitoxantrone + Prednisone | 22 | 4 |
"Safety and tolerability were based on Adverse Events (AE) and Serious Adverse Events (SAE) graded using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE).~The CTCAE has 5 grades with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1=Mild AE; Grade 2=Moderate AE; Grade 3=Severe AE; Grade 4=Life-threatening or disabling AE; and Grade 5=Death related to AE." (NCT00327340)
Timeframe: Subjects were followed for safety from enrollment for up to 8 months (9 three-week cycles plus 30 days after end of treatment)
Intervention | percentage of participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Percent of Subjects with Serious Adverse Events | Percent of Subjects with Grade 5 Adverse Events | Percent of Subjects with Grade 4 Adverse Events | Percent of Subjects with Grade 3 Adverse Events | Percent of Subjects with Grade 2 Adverse Events | Percent of Subjects with Grade 1 Adverse Events | Percent of Subjects who Discontinued Study Drug | |
OGX-011 + Docetaxel + Prednisone | 26 | 4 | 15 | 52 | 98 | 100 | 17 |
OGX-011 + Mitoxantrone + Prednisone | 26 | 13 | 26 | 70 | 83 | 100 | 22 |
32 reviews available for prednisone and Metastase
Article | Year |
---|---|
Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy.
Topics: Abiraterone Acetate; Androgen Antagonists; Animals; Antineoplastic Combined Chemotherapy Protocols; | 2020 |
Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis.
Topics: Androstenes; Benzamides; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednison | 2021 |
Steroid switch after progression on abiraterone plus prednisone in patients with metastatic castration-resistant prostate cancer: A systematic review.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Neoplasm Metastasis; Pred | 2021 |
Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.
Topics: Abiraterone Acetate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxe | 2017 |
Treatment of Castration-naive Metastatic Prostate Cancer.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined | 2017 |
Second-line therapy in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel: A systematic review of nine randomized controlled trials.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Surviv | 2017 |
Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review.
Topics: Aged; Antineoplastic Agents; Bias; Cost-Benefit Analysis; Humans; Male; Middle Aged; Mitoxantrone; N | 2018 |
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Black People; Clinical Trials, Phase III as Topic; D | 2019 |
A drug safety evaluation of abiraterone acetate in the treatment of prostate cancer.
Topics: Abiraterone Acetate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; | 2019 |
Cabazitaxel: a guide to its use in hormone-refractory metastatic prostate cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Europe; | 2013 |
Second-line treatment of metastatic prostate cancer. Prednisone and radiotherapy for symptom relief.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 2013 |
[Use of abiraterone acetate in the treatment of patients with metastatic castration resistant prostate cancer and no prior chemotherapy: 3 case reports and literature review].
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progressio | 2014 |
Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.
Topics: Abiraterone Acetate; Androstadienes; Benzamides; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitri | 2014 |
Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer.
Topics: Androstenes; Antineoplastic Agents, Hormonal; Disease Progression; Humans; Male; Neoplasm Metastasis | 2014 |
Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature.
Topics: Age Factors; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease Progressi | 2017 |
Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Clinical Trials as Topic; Docetaxel; Drug Administratio | 2010 |
Primary NK/T cell lymphoma of the testis. A case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamide; Doxorubici | 2003 |
[ENDOCRINE TREATMENT OF METASTASISED MAMMARY CARCINOMA].
Topics: Anabolic Agents; Androgens; Breast; Breast Neoplasms; Castration; Estrogens; Female; Humans; Hypophy | 1963 |
ENDOCRINE TREATMENT OF METASTASISED MAMMARY CARCINOMA.
Topics: Anabolic Agents; Androgens; Breast; Breast Neoplasms; Castration; Estrogens; Female; Humans; Hypophy | 1963 |
A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer.
Topics: Antineoplastic Agents; Docetaxel; Drug Therapy, Combination; Glucocorticoids; Humans; Male; Models, | 2007 |
Chemotherapy in hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease P | 2008 |
Management of metastatic prostate cancer: the crucial role of geriatric assessment.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docet | 2008 |
[Recent developments in chemotherapy of malignant diseases].
Topics: Anthraquinones; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 1982 |
The importance of dose intensity in chemotherapy of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Re | 1984 |
The importance of dose intensity in chemotherapy of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Re | 1984 |
The importance of dose intensity in chemotherapy of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Re | 1984 |
The importance of dose intensity in chemotherapy of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Re | 1984 |
Spontaneous rupture of splenic angiosarcoma: a case report of chemotherapeutic approach and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1993 |
Chemotherapy of solid tumors. Recent advances.
Topics: Adult; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Bronchogenic; Carcinom | 1976 |
[The state of hormone and chemotherapy in breast neoplasms].
Topics: Androgens; Brain Neoplasms; Breast Neoplasms; Castration; Cyclophosphamide; Doxorubicin; Drug Therap | 1978 |
Autotransplantation in solid tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1991 |
[Carcinoid: problems of pathology, biochemistry and therapy].
Topics: Angiotensin II; Animals; Blood Pressure; Cyclophosphamide; Fluorouracil; Guinea Pigs; Histocytochemi | 1971 |
[Hormone therapy of renal cancer].
Topics: Acetates; Adenocarcinoma; Animals; Caproates; Castration; Cricetinae; Drug Synergism; Female; Femora | 1972 |
Corticosteroids in the treatment of solid tumors.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Brain Edema; Brain Neoplasms; Breast Neoplasms; Chil | 1973 |
Ectopic PTH syndrome, pseudohyperparathyroidism; hypercalcaemia of malignancy.
Topics: Adenocarcinoma; Adenoma; Alkaline Phosphatase; Bone and Bones; Bone Resorption; Calcium; Carcinoma; | 1974 |
119 trials available for prednisone and Metastase
Article | Year |
---|---|
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
Topics: Abiraterone Acetate; Aged; Androgen Receptor Antagonists; Antineoplastic Combined Chemotherapy Proto | 2021 |
Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2020 |
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzam | 2019 |
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzam | 2019 |
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzam | 2019 |
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzam | 2019 |
Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia; | 2019 |
Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivatio
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents; Correlation of Data; Double-Blind | 2020 |
Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Do | 2020 |
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2021 |
Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer.
Topics: Adrenal Cortex; Adult; Aged; Aged, 80 and over; Androgens; Androstenes; Antineoplastic Agents, Hormo | 2021 |
The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Docetaxel; Drug Resistan | 2017 |
A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone.
Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Prolifer | 2018 |
Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug | 2017 |
Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Gastro | 2018 |
A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Endpoint Determination; HSP27 Heat | 2018 |
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles | 2018 |
Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer.
Topics: Administration, Intravenous; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progressi | 2018 |
Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; | 2018 |
PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers; Cyclophospham | 2018 |
Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian | 2018 |
Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2019 |
Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Hu | 2019 |
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Abiraterone Acetate; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone N | 2019 |
Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Disease Progress | 2019 |
Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2019 |
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kallikre | 2019 |
The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 2013 |
Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Fre | 2013 |
Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Epothilones; Hum | 2011 |
Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal | 2014 |
Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Eto | 2015 |
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Di | 2014 |
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
Topics: Abiraterone Acetate; Aged; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Che | 2014 |
Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic | 2015 |
Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle | 2015 |
Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle | 2015 |
Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle | 2015 |
Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle | 2015 |
Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle | 2015 |
Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle | 2015 |
Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle | 2015 |
Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle | 2015 |
Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle | 2015 |
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2015 |
Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2015 |
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doce | 2015 |
Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 2015 |
A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antigen-Presenting Cells; Antineoplastic Combined Chem | 2015 |
Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Dis | 2015 |
A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Resista | 2016 |
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
Topics: Abiraterone Acetate; Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic | 2016 |
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androstenols; Antineoplastic Combined Chemother | 2016 |
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androstenols; Antineoplastic Combined Chemother | 2016 |
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androstenols; Antineoplastic Combined Chemother | 2016 |
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androstenols; Antineoplastic Combined Chemother | 2016 |
Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Granulocyte Colony | 2016 |
Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Di | 2016 |
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Sur | 2016 |
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Sur | 2016 |
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Sur | 2016 |
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Sur | 2016 |
Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Black People; Humans; Mal | 2016 |
A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase | 2016 |
The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male; | 2008 |
Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Ch | 2008 |
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy P | 2009 |
Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic A | 2010 |
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance | 2010 |
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Mitoxantrone; Neoplas | 2010 |
A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2011 |
Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer.
Topics: Aged; Alopecia; Anemia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoc | 2010 |
TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Castration; Cell Line, Tumor; Disease-Free Survival; | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clusterin; Docetaxel; Drug | 2011 |
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clusterin; Docetaxel; Drug | 2011 |
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clusterin; Docetaxel; Drug | 2011 |
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clusterin; Docetaxel; Drug | 2011 |
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doce | 2012 |
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Pr | 2012 |
Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Gossypol; Hu | 2013 |
Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; D | 2012 |
[Docetaxel plus prednisone versus mitoxantrone plus prednisone as first-line chemotherapy for metastatic hormone-refractory prostate cancer: long-term effects and safety].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Mitoxant | 2012 |
Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Gossypol; Humans; | 2012 |
Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Area Under Curv | 2013 |
A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate c
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2013 |
Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Castration; Docetaxel; Fatigue; Humans; Male; Neoplasm Metastas | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot | 2013 |
Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cause of Deat | 2003 |
Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under | 2003 |
Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administr | 2006 |
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Humans; Kinetics; Mal | 2007 |
CAP (cyclophosphamide, adriamycin, platinum) vs CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical T | 1984 |
Breast cancer 1984: state of the art.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Tr | 1984 |
Body weight and prognosis in breast cancer.
Topics: Adult; Aged; Body Height; Body Weight; Breast Neoplasms; Castration; Female; Hormones; Humans; Menst | 1981 |
Treatment of breast cancer with oral four-drug chemotherapy.
Topics: Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosph | 1980 |
Hormono-chemotherapy versus hormonotherapy followed by chemotherapy in the treatment of disseminated breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Chlorambucil; Clinical Trials as Topic; Doxorubicin; Drug A | 1980 |
[Simultaneous or sequential hormono/chemotherapy and a comparison of various polychemotherapies in the treatment of metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Castration; Chlorambucil; Clinical Trials as T | 1982 |
Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubic | 1982 |
An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advances breast cancer undergoing oophorectomy: a later analysis.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Castration; Clinical Trials as Topic; Cyclophosphami | 1982 |
Effect of systemic adjuvant treatment on first sites of breast cancer relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adju | 1994 |
A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1997 |
Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosph | 1998 |
Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Infusion Pumps | 1999 |
Drug-induced lupus associated with COL-3: report of 3 cases.
Topics: Administration, Topical; Aged; Anti-Inflammatory Agents; Clobetasol; Female; Follow-Up Studies; Gluc | 2001 |
Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non Hodgkin's lymphoma: a Pediatric Oncology Group study.
Topics: Adolescent; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; D | 2001 |
Chemotherapy of disseminated breast cancer. Current status and prospects.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Dr | 1977 |
Combined chemo- and hormonal therapy in advanced breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Castration; Chlorambucil; Clinical Trials as Topic; Cycloph | 1977 |
A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project.
Topics: Agranulocytosis; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; | 1977 |
Chemotherapy of metastatic breast cancer in postmenopausal women: a controlled trial of cyclophosphamide versus a five-drug combination of cyclophosphamide, vincristine, methotrexate, 5-fluorouracil and prednisone.
Topics: Aged; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphami | 1977 |
Combination chemotherapy in advanced breast cancer.: a randomized trial comparing a three-vs a five-drug program.
Topics: Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Double-Blind Method; Drug Therapy, Com | 1977 |
Activity of adriamycin in metastatic breast cancer resistant to a combination regimen with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prdnisone.
Topics: Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Resista | 1978 |
Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer: a randomized trial.
Topics: Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Do | 1978 |
Chemotherapy in the management of extramedullary plasmacytoma.
Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; | 1978 |
Combination chemotherapy for metastatic breast cancer: comparison of multiple drug therapy with 5-fluorouracil, cytoxan and prednisone with adriamycin or adrenalectomy.
Topics: Adrenalectomy; Aged; Bone Marrow; Breast Neoplasms; Cyclophosphamide; Digestive System; Doxorubicin; | 1978 |
An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy.
Topics: Adult; Age Factors; Breast Neoplasms; Castration; Cyclophosphamide; Drug Therapy, Combination; Evalu | 1977 |
[Cytostatic treatment of metastasizing breast cancer. A prospective controlled comparison between single drug and multiple drug chemotherapy].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Comb | 1977 |
Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Adminis | 1976 |
[Chemotherapy of metastasizing breast cancers. Indications and results].
Topics: Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fema | 1975 |
Combination chemotherapy in breast cancer: a randomized study of 4 versus 5 drugs.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Methotrexate; Middle | 1975 |
Recombinant interferon alpha-2A combined with prednisone in metastatic renal-cell carcinoma: treatment results, serum interferon levels and the development of antibodies.
Topics: Antibody Formation; Carcinoma, Renal Cell; Female; Humans; Interferon alpha-2; Interferon-alpha; Int | 1992 |
A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1992 |
Autotransplantation in solid tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1991 |
Phase II study of deoxydoxorubicin in previously untreated metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1990 |
cis-platinum-based alternating non-cross-resistant chemotherapy as a first-line treatment in metastatic breast cancer. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1990 |
Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorour | 1990 |
Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cl | 1989 |
Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5-fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1989 |
Medroxyprogesterone acetate and prednisone in advanced breast cancer. A randomized trial.
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Injec | 1986 |
Alternating versus sequential therapy in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1987 |
Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoembryonic Antigen; Clinical | 1986 |
Age as a prognostic factor in recurrent breast cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined | 1986 |
A randomized study of intensive versus moderate chemotherapy programs in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1987 |
Adjuvant chemotherapy for breast cancer. Implications of clinical trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Tr | 1985 |
Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; C | 1985 |
[Study of the metastasizing carcinoma of the breast (author's transl)].
Topics: Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Hum | 1973 |
[Control studies on the cytostatic combination therapy in metastasizing breast carcinoma].
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Synergism; | 1973 |
Combination chemotherapy of lymphomas other than Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Bone Marrow; Bone Marrow Cells; Cyclophosphamide; Drug Therapy, Combination | 1974 |
Sequential radiotherapy and chemotherapy in the treatment of Hodgkin's disease. A progress report.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzoates; Child; Drug Combinations; Female; Follow- | 1972 |
279 other studies available for prednisone and Metastase
Article | Year |
---|---|
Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined | 2023 |
Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.
Topics: Abiraterone Acetate; Absorptiometry, Photon; Aged; Antineoplastic Combined Chemotherapy Protocols; B | 2019 |
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docet | 2019 |
Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (CRPC): a post hoc analysis of two randomized clinical trials.
Topics: Androstenes; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male | 2020 |
Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Adult; Aged; Anti-Inflammatory Agents; Biomarkers, Tumor; Cell-Free Nucleic Aci | 2020 |
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzami | 2020 |
Predictors of resistance to abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer in post-docetaxel setting: a single-center cohort study.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined | 2020 |
Clinical Experience of Steroid Switch from Prednisone to Dexamethasone in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate.
Topics: Abiraterone Acetate; Antineoplastic Agents; Dexamethasone; Drug Substitution; Glucocorticoids; Human | 2021 |
Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment.
Topics: Abiraterone Acetate; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Case-Control Studies; Di | 2021 |
Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer.
Topics: Abiraterone Acetate; Cost-Benefit Analysis; Docetaxel; Hormones; Humans; Male; Markov Chains; Neopla | 2021 |
Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Coho | 2021 |
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Topics: Abiraterone Acetate; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols | 2017 |
A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2017 |
Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Castration; Diseas | 2017 |
Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: a retrospective study.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hum | 2017 |
High-dose chemotherapy with autologous stem cell transplantation following systemic chemotherapy, prophylactic intrathecal methotrexate, and radiotherapy prevents relapse and improves the outcome of advanced stage primary testicular lymphoma even with car
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Autografts; | 2017 |
Management of Immune-mediated Cytopenias in the Era of Cancer Immunotherapy: A Report of 4 Cases.
Topics: Anemia, Hemolytic; Antibodies, Monoclonal, Humanized; CTLA-4 Antigen; Drug-Related Side Effects and | 2018 |
Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma.
Topics: Administration, Oral; Administration, Topical; Aged, 80 and over; Antibodies, Monoclonal, Humanized; | 2018 |
Synchronous papillary thyroid cancer and non-Hodgkin lymphoma: Case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Clinical Decision-Making; Cycl | 2018 |
Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer.
Topics: Abiraterone Acetate; Androstenes; Anti-Inflammatory Agents; Docetaxel; Drug Therapy, Combination; Hu | 2018 |
Diffuse large B-cell lymphoma with concurrent hepatitis B virus infection in the MabThera era: Unique clinical features and worse outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2018 |
A case of pembrolizumab-induced localized organizing pneumonia.
Topics: Antibodies, Monoclonal, Humanized; Brain; Cryptogenic Organizing Pneumonia; Drug-Related Side Effect | 2018 |
Extranodal NK/T-cell lymphoma, nasal type: Clinical features, outcome, and prognostic factors in 101 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2018 |
[Severe panuveitis in a metastatic cutaneous melanoma patient treated with vemurafenib].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Huma | 2018 |
Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Asymptomatic D | 2019 |
Fatigue, treatment satisfaction and health-related quality of life among patients receiving novel drugs suppressing androgen signalling for the treatment of metastatic castrate-resistant prostate cancer.
Topics: Abiraterone Acetate; Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemothera | 2019 |
Germline Variant in
Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease | 2019 |
Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Antigens, Differentiation; Antineoplastic Agents; Antineoplastic Combined | 2019 |
Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 2019 |
The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cyclophosphamide; Doxorubic | 2019 |
Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Prot | 2019 |
Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lu | 2019 |
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
Topics: Aged; Aldo-Keto Reductase Family 1 Member C3; Androstenes; Antineoplastic Combined Chemotherapy Prot | 2019 |
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androgen Antagonists; Androstadienes; Biomarkers, Tumo | 2014 |
Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Compassionate Use T | 2014 |
[ON HODGKIN'S DISEASE. PERSONAL EXPERIENCE].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Aziridines; Biopsy; Chlorambucil; Classification; Hodg | 1964 |
Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmu | 2015 |
Single-agent lenalidomide is effective in the treatment of a heavily pretreated and refractory angioimmunoblastic T-cell lymphoma patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cycl | 2014 |
Serum lactate dehydrogenase with a systemic inflammation score is useful for predicting response and survival in patients with newly diagnosed diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2015 |
Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Corticosteroids and prostate cancer: friend or foe?
Topics: Adrenal Cortex Hormones; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; | 2015 |
Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Cou | 2015 |
The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free S | 2016 |
Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Clinical Tri | 2016 |
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Clinical Trials as Topic; H | 2016 |
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Topics: Abiraterone Acetate; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplas | 2017 |
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Topics: Abiraterone Acetate; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplas | 2017 |
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Topics: Abiraterone Acetate; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplas | 2017 |
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Topics: Abiraterone Acetate; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplas | 2017 |
Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Clinical Trials, Phase III as Topic; Humans; Kaplan-Meier Est | 2017 |
MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2017 |
Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bend | 2017 |
Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone.
Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Eplerenone; Humans; Male; | 2017 |
Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Anxiety; Area Under | 2010 |
Breast lymphoma in Sjögren's syndrome complicated by acute monocular blindness.
Topics: Aged; Blindness; Breast Neoplasms; Combined Modality Therapy; Diagnosis, Differential; Female; Human | 2010 |
Current and emerging treatment modalities for metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Epidemiologic | 2011 |
Expanding treatment options for metastatic prostate cancer.
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Hum | 2011 |
Metronomic cyclophosphamide and methotrexate for breast cancer: enhanced efficacy by adding dalteparin and low-dose prednisone?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Combined Modality T | 2011 |
Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Enzyme Inhibitors; Humans | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Adrenocorticotropic Hormone; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Combine | 2011 |
Abiraterone. After prostate cancer treatment failure: 4-month survival advantage.
Topics: Androstenes; Androstenols; Drug Interactions; Humans; Male; Neoplasm Metastasis; Prednisone; Prostat | 2012 |
A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Abiraterone and its place in the treatment of metastatic CRPC.
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Castration; Clinical Tria | 2013 |
Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 2013 |
Clinical profiles of human immunodeficiency virus-associated lymphoma in Hong Kong.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Ac | 2003 |
Orbital inflammatory syndromes with systemic involvement may mimic metastatic disease.
Topics: Blepharoptosis; Bone Diseases; Child; Diagnosis, Differential; Exophthalmos; Female; Glucocorticoids | 2003 |
[Lost time].
Topics: Breast Neoplasms; Humans; Neoplasm Metastasis; Prednisone | 1962 |
[ENZYME DETERMINATIONS IN THE SERUM IN LIVER DISEASES. FUNCTION PATTERNS AS A MEANS OF DIAGNOSIS].
Topics: Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Bilirubin; Cholecystitis; C | 1963 |
LEUKEMOGENIC THYMOMA: REPORT OF A UNIQUE CASE.
Topics: Adolescent; Bone Marrow; Chlorothiazide; Humans; Leukemia; Mediastinal Neoplasms; Neoplasm Metastasi | 1963 |
CALCIUM AND PHOSPHATE METABOLISM IN PATIENTS WITH DISSEMINATED BREAST CANCER: EFFECT OF ANDROGENS AND OF PREDNISONE.
Topics: Androgens; Blood Chemical Analysis; Bone and Bones; Breast; Breast Neoplasms; Calcium; Calcium, Diet | 1963 |
[CAVERN FORMATION IN LUNG METASTASES].
Topics: Caves; Cyclophosphamide; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Physiology; Prednisone | 1963 |
TREATMENT OF INOPERABLE CARCINOMA WITH NEWER CHEMOTHERAPEUTIC AGENTS: REPORT OF THREE CASES.
Topics: Bone Neoplasms; Breast Neoplasms; Humans; Methotrexate; Neoplasm Metastasis; Prednisone; Retroperito | 1963 |
SOME UNUSUAL COMPLICATIONS OF METASTATIC CARCINOMA OF THE BREAST.
Topics: Breast Neoplasms; Esophageal Diseases; Esophageal Neoplasms; Esophageal Stenosis; Gastrointestinal H | 1964 |
NUTRITIONAL AND METABOLIC EFFECTS OF SOME NEWER STEROIDS. III. STANOZOLOL.
Topics: Amputation, Surgical; Anabolic Agents; Blood Chemical Analysis; Dexamethasone; Diabetic Neuropathies | 1964 |
PROPHYLACTIC ENDOCRINE TREATMENT IN CARCINOMA OF THE BREAST.
Topics: Androgens; Breast Neoplasms; Castration; Cortisone; Estrogens; Female; Humans; Mastectomy; Menopause | 1964 |
ENDOCRINE TREATMENT OF BREAST CANCER.
Topics: Anabolic Agents; Androgens; Breast Neoplasms; Castration; Estrone; Female; Humans; Menopause; Nandro | 1964 |
NONSURGICAL TREATMENT OF PULMONARY CANCER.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Agen | 1964 |
HEPATITIS AND--MALIGNANT NEOPLASIA.
Topics: Biopsy; Drug Therapy; Hepatic Encephalopathy; Hepatitis; Hepatitis A; Humans; Hydrocortisone; Hyperb | 1964 |
SEVERE FLUSHING REACTIONS RESPONSIVE TO STEROIDS IN PATIENTS WITH BRONCHIAL CARCINOID.
Topics: Bronchial Neoplasms; Chlorpromazine; Chromatography; Diagnosis, Differential; Humans; Hydroxyindolea | 1964 |
REGRESSION OF METASTATIC HEPATOMEGALY FROM MAMMARY CARCINOMA. CYTOTOXIC COMBINATION CHEMOTHERAPY WITH 5-FU.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Hepatomegaly; Humans; L | 1964 |
HYPERCALCAEMIA IN RENAL CARCINOMA. REPORT OF A CASE.
Topics: Alkaline Phosphatase; Blood; Bone Neoplasms; Calcium; Carcinoma; Carcinoma, Renal Cell; Electrocardi | 1964 |
USE OF GLUCOCORTICOIDS IN THE PALLIATIVE TREATMENT OF METASTATIC BRAIN TUMORS.
Topics: Brain Neoplasms; Dexamethasone; Drug Therapy; Geriatrics; Glucocorticoids; Humans; Hydrocortisone; M | 1965 |
CADAVERIC RENAL HOMOTRANSPLANTATION WITH INADVERTENT TRANSPLANTATION OF CARCINOMA.
Topics: Antineoplastic Agents; Azathioprine; Carcinoma, Bronchogenic; Drug Therapy; Humans; Immunosuppressiv | 1965 |
HYPERCALCEMIA OF BREAST CANCER; MANAGEMENT WITH CORTICOSTEROIDS.
Topics: Adrenal Cortex Hormones; Breast Neoplasms; Calcium; Carcinoma; Drug Therapy; Geriatrics; Humans; Hyp | 1965 |
MICROANGIOPATHIC HEMOLYTIC ANEMIA IN METASTATIC CARCINOMA. REPORT OF A CASE AND BIOCHEMICAL STUDIES.
Topics: Anemia, Hemolytic; Bone Marrow Cells; Breast Neoplasms; Chemical Phenomena; Chemistry; Clinical Enzy | 1965 |
[Hormone-refractory metastatic prostate carcinoma -- combination improves survival].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antine | 2005 |
Painful purpuric plaques on edematous hands.
Topics: Administration, Oral; Aged; Carcinosarcoma; Edema; Hand; Humans; Male; Neoplasm Metastasis; Pain; Pa | 2005 |
Lessons to be learned: a case study approach. Lateral aberrant thyroid tissue: is it always malignant?
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxor | 2007 |
Rituximab plus CHOP as an initial chemotherapy for patients with disseminated MALT lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2007 |
The postchemotherapy PSA surge syndrome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineo | 2008 |
Intravascular coagulation, a possible accelerating effect of prednisone.
Topics: Aged; Blood Coagulation Disorders; Blood Coagulation Factors; Blood Platelets; Factor IX; Factor V; | 1966 |
The electroencephalogram in hypercalcemia.
Topics: Adult; Aged; Alkaline Phosphatase; Breast Neoplasms; Diethylstilbestrol; Electroencephalography; Est | 1967 |
The endocrine aspects of trans-sphenoidal hypophysectomy.
Topics: Adrenal Glands; Breast Neoplasms; Cortisone; Diabetes Mellitus; Diabetic Retinopathy; Female; Humans | 1967 |
[Medical treatment of tumors].
Topics: Antineoplastic Agents; Humans; Neoplasm Metastasis; Neoplasms; Prednisone | 1967 |
Hormonal treatment of hypercalcemia caused by bone metastases.
Topics: Aged; Bone Neoplasms; Breast Neoplasms; Diethylstilbestrol; Female; Humans; Hypercalcemia; Middle Ag | 1967 |
Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer: effects on survival.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, C | 1980 |
Steroid-withdrawal radiation pneumonitis in cancer patients.
Topics: Adenocarcinoma; Aged; Breast Neoplasms; Carcinoma, Small Cell; Combined Modality Therapy; Dexamethas | 1984 |
[Vinblastine, 5-fluorouracil and prednisone (VFP) as "second-line" chemotherapy. Contribution to the problem of optimal therapy sequence in metastasizing breast carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration S | 1983 |
Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmu | 1984 |
Chemotherapy of advanced breast cancer. A general survey.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Mo | 1984 |
Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation Tests; Breast Neoplasms; Cy | 1984 |
[Antibody-controlled cytostatic therapy of malignant thymoma with concomitant myasthenia gravis].
Topics: Acetylcholine; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Azathioprine; Cyclophosph | 1984 |
Malignant thymoma with distant metastases: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Cyclophosphamide; F | 1983 |
Prolonged remissions of metastatic breast cancer achieved with a six-drug regimen of relatively low toxicity.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast | 1983 |
[Combination chemotherapy for advanced diffuse non-Hodgkin's lymphomas in relapse following local radiotherapy].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxo | 1983 |
[Comparative evaluation of the results of mono- and polychemotherapy of disseminated forms of breast cancer using the CMFVP program and anthracycline antibiotics (carminomycin and adriamycin)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carubicin; Cyclophosphamide; Dauno | 1983 |
Thymic rebound after treatment of childhood tumors.
Topics: Child; Child, Preschool; Diagnosis, Differential; Female; Humans; Hypertrophy; Infant; Male; Mediast | 1980 |
Near-haploid acute lymphoblastic leukemia: a unique subgroup with a poor prognosis?
Topics: Acute Disease; Adolescent; Bone Marrow Examination; Brain Neoplasms; Child; Daunorubicin; Female; Ha | 1981 |
Kaposi's sarcoma complicating corticosteroid therapy for temporal arteritis.
Topics: Aged; Female; Giant Cell Arteritis; Humans; Immunosuppression Therapy; Kidney Transplantation; Neopl | 1981 |
A five-drug combination in the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; | 1981 |
[Results of, and indications for adjuvant chemotherapy in breast cancer].
Topics: Adult; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; | 1981 |
Variations in responsiveness and survival of clinical subsets of patients with metastatic breast cancer to two chemotherapy combinations.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; F | 1980 |
Combination chemotherapy in invasive thymoma role of COPP.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Co | 1980 |
Modern approaches to the treatment of breast cancer.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Menstru | 1980 |
Thymoma. A retrospective study of 87 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 1994 |
Should abdominal cluster transplantation be abandoned?
Topics: Adult; Azathioprine; Child; Cyclosporine; Drug Therapy, Combination; Duodenum; Female; Gastrointesti | 1993 |
Angiocentric T-cell lymphoma of the lung mimicking metastatic carcinoma. Case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Doxorubic | 1998 |
Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemot | 2000 |
Androgen-induced hepatoma.
Topics: Adult; Anabolic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Cortisone; Cryptorchidism; Hemogl | 1975 |
Esophageal carcinoma. The value of staging in long-term survival.
Topics: Administration, Oral; Cyclophosphamide; Esophageal Neoplasms; Esophagus; Female; Fluorouracil; Follo | 1975 |
[Interstial pneumopathy after low dose bleomycin therapy].
Topics: Bleomycin; Female; Hematopoiesis; Humans; Middle Aged; Neoplasm Metastasis; Prednisone; Pulmonary Fi | 1977 |
A kinetically designed chemotherapeutic regimen for advanced refractory lymphoma patients.
Topics: Adolescent; Adult; Aged; Bleomycin; Doxorubicin; Drug Administration Schedule; Female; Hodgkin Disea | 1978 |
[Chemotherapy of malignant skeletal tumors (author's transl)].
Topics: Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Humans; Lymphoma; Melphalan; Multiple Myeloma; N | 1979 |
Kappa light chain--myeloma associated with adult Fanconi syndrome: response of the nephropathy to treatment of myeloma.
Topics: Adult; Bence Jones Protein; beta 2-Microglobulin; Bone Neoplasms; Fanconi Syndrome; Female; Humans; | 1978 |
Calcitonin treatment of hypercalcemia due to parathyroid carcinoma. Synergistic effect of prednisone on long-term treatment of hypercalcemia.
Topics: Adult; Bone Resorption; Calcitonin; Calcium; Drug Synergism; Humans; Hypercalcemia; Male; Neoplasm M | 1975 |
[Confluent pulmonary deposits from carcinoma of the breast under cytostatic therapy (author's transl)].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Female; H | 1976 |
Leukemia in children with Wilms tumor.
Topics: Acute Disease; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Female; Humans | 1975 |
Neoplasia in kidney transplant recipients.
Topics: Adult; Azathioprine; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophosphamide; Female; Huma | 1975 |
[Experiences with drug therapy of advanced metastatic carcinoma of the breast (author's transl)].
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Car | 1976 |
Leucovorin in combination chemotherapy of breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Humans; Le | 1977 |
Current treatment of acute leukemia.
Topics: Bone Marrow Transplantation; Child; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Lymphoid; Le | 1978 |
"Disappearing" spinal cord compression: oncolytic effect of glucocorticoids (and other chemotherapeutic agents) on epidural metastases.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dexamethasone; Dysgerminoma; Epidural Space; Humans; | 1977 |
Chemotherapy for breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; F | 1979 |
[The period of time between operation and irradiation of a mamma carcinoma and its cytostatic treatment (author's transl)].
Topics: Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; | 1979 |
Treatment and survival in advanced breast cancer.
Topics: Breast Neoplasms; Estradiol Congeners; Female; Humans; Neoplasm Metastasis; Prednisone; Research Des | 1979 |
Adrenocortical carcinoma in a patient with systemic lupus erythematosus treated with azathioprine.
Topics: Adrenal Cortex Neoplasms; Azathioprine; Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; Ne | 1979 |
[Extraskeletal manifestations of unusual localization in a case of myeloma (author's transl)].
Topics: Female; Humans; Immunoglobulin G; Lymphatic Metastasis; Melphalan; Middle Aged; Multiple Myeloma; Ne | 1979 |
Potentiating role of previously administered agents in the combination chemotherapy of breast cancer.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Synergism; Drug Therapy, Comb | 1979 |
[Association of VCR-5FU-CYCLO-PDN in the treatment of disseminated carcinoma of the breast (author's transl)].
Topics: Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Evaluation Studies a | 1979 |
Sequence for developing optimal combination chemotherapy of metastatic breast cancer.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Methotr | 1979 |
Chemotherapy trial with comp-F regimen in advanced adenocarcinoma of prostate.
Topics: Adenocarcinoma; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Hu | 1978 |
Chemotherapy of solid tumors.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Drug Therapy, Combination; Humans; Male; Neoplasm Metas | 1978 |
Clinical trial of nafoxidine in advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Drug Hypersensitivity; Drug Therapy, Combination; Female; Humans; Mid | 1978 |
Treatment of hepatic metastases from breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; F | 1978 |
Regression of malignant thymoma with metastases after treatment with adrenocortical steroids.
Topics: Female; Humans; Middle Aged; Neoplasm Metastasis; Prednisone; Thymoma; Thymus Neoplasms | 1978 |
Invasive thymoma responsive to oral corticosteroids.
Topics: Administration, Oral; Humans; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Metastasis; Pleural | 1978 |
Complete maturation of neuroblastoma with bone metastases in documented stages.
Topics: Bone Neoplasms; Child, Preschool; Cyclophosphamide; Female; Ganglioneuroma; Humans; Infant; Mercapto | 1975 |
Systemic therapy for metastatic breast cancer.
Topics: BCG Vaccine; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Estrogens; Female; Fluor | 1977 |
Multiple drug chemotherapy regimen for patients with hormonally-unresponsive carcinoma of the prostate: a preliminary report.
Topics: Administration, Oral; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Drug The | 1977 |
Combination chemotherapy with CCNU, melphalan, methotrexate, and prednisone (CAMP) in 35 patients with advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Therapy, Combinatio | 1977 |
Initial relapses in previously treated Hodgkin's disease. I. Results of second treatment.
Topics: Female; Hodgkin Disease; Humans; Male; Mechlorethamine; Neoplasm Metastasis; Neoplasm Recurrence, Lo | 1976 |
[Preliminary experiences in the treatment of metastatic mamma carcinoma by polychemotherapy-according to Cooper (author's transl)].
Topics: Breast Neoplasms; Cyclophosphamide; Drug Combinations; Drug Therapy, Combination; Female; Fluorourac | 1976 |
Combination chemotherapy in the treatment of advanced breast cancer.
Topics: Adrenalectomy; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Co | 1976 |
Serial carcinoembryonic antigen assays in patients with metastatic carcinoma of prostate being treated with chemotherapy.
Topics: Acid Phosphatase; Adenocarcinoma; Carcinoembryonic Antigen; Drug Therapy, Combination; Fluorouracil; | 1976 |
[Primary (?) retroperitoneal seminoma with multiple metastases and elevated serum alkaline phosphatase (author's transl)].
Topics: Adrenal Gland Neoplasms; Alkaline Phosphatase; Cyclophosphamide; Dysgerminoma; Humans; Male; Middle | 1976 |
Generalized osteoblastic bony metastases from medulloblastoma.
Topics: Adult; Bone Neoplasms; Brain Neoplasms; Cyclophosphamide; Humans; Male; Medulloblastoma; Neoplasm Me | 1976 |
Combination chemotherapy for disseminated carcinoma of the breast.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Com | 1975 |
Remission induction in adult acute lymphocytic leukemia. Use of vincristine and prednisone alone.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Drug Administration Schedule; Drug Therapy, Combination; F | 1976 |
Chemotherapy of breast cancer.
Topics: Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Hu | 1975 |
Hyperlucent lung after radiation therapy.
Topics: Angiography; Bone Neoplasms; Breast Neoplasms; Chlorambucil; Dyspnea, Paroxysmal; Female; Humans; Lu | 1975 |
Chemotherapy in the treatment strategy of breast cancer.
Topics: Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Hu | 1975 |
Infiltrative retinopathy in systemic lymphoma.
Topics: Cobalt; Cyclophosphamide; Eye Neoplasms; Female; Fluorescein Angiography; Fundus Oculi; Humans; Ison | 1975 |
Lymphosarcoma of the right atrium. Angiographic and hemodynamic documentation of response to chemotherapy.
Topics: Adult; Angiocardiography; Cardiac Catheterization; Coronary Circulation; Heart Atria; Heart Neoplasm | 1975 |
A controlled study in the use of combined drug therapy for metastatic breast cancer.
Topics: Age Factors; Antineoplastic Agents; Breast Neoplasms; Chlorambucil; Cyclophosphamide; Drug Therapy, | 1975 |
Non-Hodgkin's lymphoma in children.
Topics: Adolescent; Asparaginase; Bone Marrow; Brain Neoplasms; Carmustine; Child; Child, Preschool; Cycloph | 1975 |
Editorial: Major advance in breast-cancer therapy.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil | 1976 |
Non-Hodgkin's lymphoma in children. A comparative study of two modalities of therapy.
Topics: Adolescent; Antineoplastic Agents; Asparaginase; Carmustine; Child; Child, Preschool; Cyclophosphami | 1976 |
Combination chemotherapy for advanced breast cancer: response and effect on survival.
Topics: Adult; Bone Neoplasms; Breast Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Li | 1976 |
Extramedullary progression of multiple myeloma following GM-CSF treatment--grounds for caution?
Topics: Cytokines; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Melphalan; Middle | 1992 |
The effect of corticosteroid administration on bleomycin lung toxicity.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; | 1990 |
Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma. Reduced toxicity without reduction of the response rate--a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Evaluation; | 1990 |
Short term high density systemic therapy for metastatic breast cancer.
Topics: Altretamine; Antineoplastic Agents; Bleomycin; Breast Neoplasms; Combined Modality Therapy; Doxorubi | 1985 |
[Treatment of metastatic breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neoplasms; Cyclophosphamide; Dacar | 1986 |
[Radiotherapy with neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Doxorub | 1989 |
Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.
Topics: Aged; Analgesics; Androgens; Humans; Male; Middle Aged; Neoplasm Metastasis; Pain; Prednisone; Prosp | 1989 |
[The effect of chemotherapy on survival time in advanced breast carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carmustine; Combined Mo | 1989 |
Disseminated thymoma and myasthenia gravis: dramatic response to prednisone.
Topics: Combined Modality Therapy; Female; Humans; Middle Aged; Myasthenia Gravis; Neoplasm Metastasis; Pred | 1989 |
Effect of initial resection of small-cell carcinoma of the lung: a review of Southwest Oncology Group Study 7628.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma, Small Cell; Combined Modalit | 1985 |
Multiple drug intensification after cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) induction in metastatic breast cancer: a Southeastern Cancer Study Group phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Flu | 1987 |
On the relevance of "second-line" cytotoxic chemotherapy in patients with metastatic breast cancer resistant to standard combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorour | 1986 |
De-novo brain tumours in renal-transplant recipients.
Topics: Adolescent; Adult; Azathioprine; Brain; Brain Neoplasms; Cadaver; Follow-Up Studies; Humans; Immunos | 1971 |
Current concepts in the treatment of advanced breast cancer.
Topics: Adrenalectomy; Adult; Androgens; Breast Neoplasms; Castration; Estrogens; Female; Fluorouracil; Huma | 1972 |
Hemangiosarcoma and pathologic rupture of the spleen.
Topics: Bleomycin; Female; Hemangiosarcoma; Humans; Middle Aged; Neoplasm Metastasis; Prednisone; Splenectom | 1973 |
Palliative treatment of mammary cancer. Response of soft tissue, pleural and pulmonary disease.
Topics: Adrenalectomy; Adult; Age Factors; Aged; Breast Neoplasms; Castration; Cyclophosphamide; Dexamethaso | 1973 |
Association of malignant melanoma and malignant lymphoma.
Topics: Biopsy; Cyclophosphamide; Lymphatic Metastasis; Lymphoma; Melanoma; Neoplasm Metastasis; Neoplasm Re | 1973 |
The treatment of pulmonary metastases of malignant teratoma of the testis.
Topics: Chlorambucil; Dactinomycin; Humans; Lung Neoplasms; Male; Methotrexate; Neoplasm Metastasis; Pneumon | 1973 |
Rapid fractionation technique and re-treatment of cerebral metastases by irradiation.
Topics: Brain Neoplasms; Dexamethasone; Female; Humans; Male; Neoplasm Metastasis; Palliative Care; Predniso | 1974 |
Florid keratoacanthomas in a kidney transplant recipient. Case report.
Topics: Azathioprine; Carcinoma, Squamous Cell; Dactinomycin; Graft Rejection; Humans; Immunosuppression The | 1974 |
Management of far-advanced carcinoma of the lung.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Aged; Alkylating Agents; Brain Neoplasms; Carcinoma; Carcin | 1966 |
Spontaneous rupture of the spleen on plasma cell leukemia.
Topics: Bence Jones Protein; Blood Protein Electrophoresis; Bone Marrow Examination; Diagnosis, Differential | 1969 |
Dermatofibrosarcoma protuberans with metastases treated with methotrexate.
Topics: Chemotherapy, Cancer, Regional Perfusion; Chin; Facial Neoplasms; Fibrosarcoma; Humans; Male; Methot | 1970 |
Disseminated toxoplasmosis in the compromised host. A report of five cases.
Topics: Adult; Aged; Anemia, Hemolytic, Autoimmune; Autopsy; Azathioprine; Brain; Breast Neoplasms; Female; | 1974 |
Hypercalcemia associated with chronic lymphocytic leukemia. Treatment with mithramycin.
Topics: Bone Neoplasms; Diuretics; Humans; Hypercalcemia; Kidney; Leukemia, Lymphoid; Lung; Lymphoma, Non-Ho | 1973 |
Hypercalcemia complicating breast cancer. Clinical features and management.
Topics: Adrenalectomy; Bone Neoplasms; Breast Neoplasms; Diet Therapy; Female; Humans; Hydrocortisone; Hyper | 1973 |
Chemotherapy in the treatment of leukemia and Wilms' tumor.
Topics: Aminopterin; Antineoplastic Agents; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Leuk | 1966 |
Islet cell tumor of the pancreas with reversible watery diarrhea and achylorhydraia.
Topics: Achlorhydria; Adenoma, Islet Cell; Adult; Diarrhea; Gastric Acidity Determination; Gastric Juice; Hu | 1967 |
Insulin-secreting bronchial carcinoid tumor with widespread metastases.
Topics: Adult; Blood Glucose; Bronchi; Bronchial Neoplasms; Carcinoma, Adenoid Cystic; Diazoxide; Female; Gl | 1968 |
Control of hypoglycemia with diazoxide and hormones.
Topics: Adenoma, Islet Cell; Adrenocorticotropic Hormone; Aged; Benzothiadiazines; Blood Glucose; Diazoxide; | 1968 |
Clinical and pathologic observations after orthotopic transplantation of the human liver.
Topics: Adolescent; Adult; Alkaline Phosphatase; Azathioprine; Bilirubin; Blood Proteins; Carcinoma, Hepatoc | 1969 |
[Therapeutic possibilities in metastatic cancer of the breast with hypercalcaemia. (Apropos of 2 cases)].
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adult; Bone Neoplasms; Breast Neoplasms; Castration; Cyc | 1969 |
[Bronchial carcinoid. Apropos of 5 cases, one of which was a carcinoid syndrome].
Topics: Adenoma; Adult; Aged; Antineoplastic Agents; Bronchial Neoplasms; Carcinoid Tumor; Carcinoma, Adenoi | 1969 |
Personal experience with orthotopic liver transplantation.
Topics: Adolescent; Antilymphocyte Serum; Biliary Tract Diseases; Bilirubin; Carcinoma, Hepatocellular; Chil | 1972 |
Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone.
Topics: Adolescent; Adult; Arginine; Blood; Carcinoma, Small Cell; Cyclophosphamide; Humans; Leukemia, Lymph | 1973 |
Diazoxide, encorton and streptozotocin in the treatment of malignant betacytoma.
Topics: Adenoma, Islet Cell; Adult; Autopsy; Diazoxide; Female; Glucose; Humans; Hypoglycemia; Liver Neoplas | 1974 |
Malignant lymphoma invading the facial nerve.
Topics: Child; Cochlear Nerve; Colon; Electric Stimulation; Facial Nerve; Facial Paralysis; Female; Humans; | 1974 |
[Diagnostic problems raised by tumors of the skull. A propos 2 cases (author's transl)].
Topics: Aged; Biopsy; Cyclophosphamide; Diagnosis, Differential; Frontal Bone; Humans; Immunoelectrophoresis | 1974 |
[Hormone therapy and chemotherapy of metastasizing breast cancer. Experiences of the Basle Oncology Center, 1969-72].
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Castration; Cyclophosphamide; Drug Therapy, Comb | 1974 |
Hormonal therapy in metastatic hypernephroma.
Topics: Adenocarcinoma; Adult; Aged; Bone Neoplasms; Female; Humans; Kidney Neoplasms; Lung Neoplasms; Male; | 1974 |
[Clinical trial of chemotherapeutic combinations based on the notion of attempted cellular synchronization. Preliminary administration of an antimitotic followed by the use of cycle-dependent or phase dependent product(s)].
Topics: Amino Sugars; Anthraquinones; Antineoplastic Agents; Asparaginase; Cyclophosphamide; Daunorubicin; D | 1972 |
[1st experiences with Adriamycin, a new cytotoxic antibiotic, in combination chemotherapy of malignant tumors].
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma; Drug Synergism; F | 1972 |
Acute leukemia complicating metastatic breast cancer.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Chlorambucil; Cyclophosphamide; Female; Fluorouracil | 1973 |
Combination chemotherapy in disseminated carcinoma of the breast.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Evaluation Stu | 1974 |
Blood and neoplastic diseases. Acute lymphoblastic leukaemia.
Topics: Arachnoid; Asparaginase; Brain Neoplasms; Cerebrospinal Fluid; Child; Cyclophosphamide; Daunorubicin | 1974 |
Liver transplantation: a clinical and immunological appraisal.
Topics: Adult; Animals; Autoantibodies; Azathioprine; Biliary Fistula; Cell Migration Inhibition; Complement | 1972 |
Eight- to ten-year follow-up in early cases of renal homotransplantation.
Topics: Adolescent; Adult; Azathioprine; Blood Group Incompatibility; Carcinoma, Basal Cell; Carcinoma, Baso | 1973 |
Blood and neoplastic diseases. Treatment of the lymphomas.
Topics: Alopecia; Bone Marrow; Cyclophosphamide; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Follicular; Ne | 1974 |
[Theory and practice of systemic cancer therapy].
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cyclophosphamide; Family Practice; Female; H | 1972 |
Five-drug combination chemotherapy for disseminated adenocarcinoma.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Drug | 1972 |
[Treatment of Hodgkin's disease of the stomach].
Topics: Adult; Cyclophosphamide; Female; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Metastasis; Pr | 1973 |
[On the use of isotope hypophysectomy with yttrium 90 in mammary neoplasms].
Topics: Breast Neoplasms; Cortisone; Humans; Mastectomy; Neoplasm Metastasis; Pituitary Irradiation; Postope | 1973 |
Nonbacterial pneumonitis with multidrug antineoplastic therapy in breast carcinoma.
Topics: Adenocarcinoma; Adrenalectomy; Adult; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Huma | 1973 |
Secondary chemotherapy of advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Chlorambucil; Female; Humans; Hydrocortisone; Middle Aged; Neoplasm M | 1973 |
[Iatrogenic diabetic coma. Contribution to adverse effects of cytostatic therapy].
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Diabetic Coma; Female; Fluorouracil; Huma | 1973 |
[Significance of ( 85 Sr) radioisotope bone scanning in the early diagnosis of bone metastases and possibilities of their therapy].
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Castration; Cobalt Isotopes; Female; | 1973 |
Extra-axial spread of medulloblastoma.
Topics: Autopsy; Brain Neoplasms; Carmustine; Cranial Fossa, Posterior; Femoral Neoplasms; Humans; Liver Neo | 1973 |
Combination chemotherapy in disseminated carcinoma of the breast.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Synergism; Female; Fluorouracil; Humans; Metho | 1973 |
Thrombocytopenia from metastatic carcinoma of the breast. Effective managements of patients with this complication.
Topics: Adrenalectomy; Aged; Blood Cell Count; Blood Platelets; Bone Marrow; Bone Neoplasms; Breast Neoplasm | 1973 |
Disseminated breast carcinoma. Treatment with combination chemotherapy.
Topics: Adenocarcinoma; Adult; Breast Neoplasms; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Fem | 1973 |
[Cytostatic combination therapy in metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; F | 1973 |
Childhood leukaemia presenting in the central nervous system.
Topics: Autopsy; Brain Neoplasms; Child; Child, Preschool; Daunorubicin; Humans; Leukemia; Male; Mercaptopur | 1973 |
[Cooper's combination chemotherapy of metastasizing breast carcinoms].
Topics: Adult; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Male; Methotrexate; Middle | 1973 |
An evaluation of five drug combination chemotherapy in the management of recurrent carcinoma of the breast.
Topics: Administration, Oral; Adult; Aged; Blood Cell Count; Breast Neoplasms; Cyclophosphamide; Drug Therap | 1974 |
Cyclical combination chemotherapy for advanced breast carcinoma.
Topics: Adrenalectomy; Adult; Alopecia; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Castration; Cyclophos | 1974 |
[Carcinoma of the male breast].
Topics: Breast Neoplasms; Carcinoma; False Negative Reactions; Humans; Male; Mastectomy; Middle Aged; Neopla | 1974 |
Carcinoembryonic antigen in breast cancer patients: serum levels and disease progress.
Topics: Adrenalectomy; Adult; Aged; Breast Neoplasms; Carcinoembryonic Antigen; Castration; Cyclophosphamide | 1974 |
Testicular involvement in plasma-cell leukemia.
Topics: Allopurinol; Cyclophosphamide; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; N | 1974 |
[Letter: Prednisone treatment of breast cancer with metastases].
Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Carcinoma; Female; Femoral Neoplasms; Humans; Neoplas | 1974 |
Azathioprine for pemphigus and pemphigoid--a 4 year follow-up.
Topics: Adult; Aged; Anemia; Azathioprine; Bone Neoplasms; Drug Evaluation; Drug Hypersensitivity; Female; F | 1974 |
Leiomyosarcoma in a renal allograft recipient treated with immunosuppressive drugs.
Topics: Adenocarcinoma; Adult; Age Factors; Autopsy; Azathioprine; Histocompatibility; Humans; Immunosuppres | 1971 |
Apparent chemotherapeutic cure of malignant lymphoma.
Topics: Adult; Antineoplastic Agents; Cyclophosphamide; Diagnosis, Differential; Histological Techniques; Hu | 1971 |
Combined chemotherapy and radiotherapy for advanced Hodgkin's disease and reticulum cell sarcoma: a preliminary report.
Topics: Adolescent; Adult; Aged; Blood Cell Count; Cyclophosphamide; Female; Hodgkin Disease; Humans; Lympho | 1971 |
Hemodynamic studies in two long-term survivors of heart transplantation.
Topics: Adult; Angiography; Antilymphocyte Serum; Aorta; Autopsy; Azathioprine; Blood Pressure; Cardiac Cath | 1971 |
Malignant lymphomas in transplantation patients.
Topics: Adolescent; Adult; Antilymphocyte Serum; Azathioprine; Brain Neoplasms; Female; Humans; Immunosuppre | 1969 |
Carcinoma of the testis in a renal transplant recipient.
Topics: Adult; Azathioprine; Cell Transformation, Neoplastic; Humans; Immunosuppressive Agents; Kidney Trans | 1971 |
Fluoride therapy for pain in malignant bone disease.
Topics: Adult; Aged; Analgesia; Bone Neoplasms; Breast Neoplasms; Estrogens; Fluorides; Fluoxymesterone; Hum | 1968 |
[The practitioner's approach to acute hypercalcemia].
Topics: Acute Disease; Animals; Bone Neoplasms; Calcitonin; Diet Therapy; Edetic Acid; Humans; Hypercalcemia | 1969 |
Acute leukemia terminating in histiocytic medullary reticulosis.
Topics: Adolescent; Autopsy; Bone Marrow Examination; Erythrocytes; Histiocytes; Humans; Kidney; Leukemia, L | 1972 |
Pseudohyperparathyroidism and seminoma.
Topics: Acute Disease; Adult; Blood Urea Nitrogen; Calcium; Diagnosis, Differential; Dysgerminoma; Humans; H | 1972 |
The phase II study: some reflections, particularly concerning disseminated breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carmustine; Cyclohexanes; Cyclophosphamide; Female; Fluorou | 1972 |
Chemotherapy in the management of metastatic cancer of unknown primary site.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Chlorambucil; Cyclopho | 1972 |
Chemotherapy of breast carcinoma.
Topics: Adult; Amines; Breast Neoplasms; Chlorambucil; Cyclophosphamide; Female; Fluorouracil; Humans; Imida | 1972 |
An evaluation of the management of patients with cerebral metastases from malignant melanoma.
Topics: Adult; Aged; Amides; Brain; Brain Neoplasms; Coma; Dexamethasone; Evaluation Studies as Topic; Femal | 1972 |
Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy.
Topics: Adolescent; Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Drug-Related S | 1972 |
Bone collagen and calcium metabolism in normocalcemic and hypercalcemic patients with breast cancer.
Topics: Adult; Alkaline Phosphatase; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Calcium; Collagen; Co | 1971 |
[Case of thyroid lymphosarcoma].
Topics: Aged; Female; Humans; Lymphoma, Non-Hodgkin; Neoplasm Metastasis; Prednisone; Radiography, Thoracic; | 1971 |
[Studies on calcium metabolism in humans with the aid of a whole body counter. Whole body retention of Ca47 in the healthy and in patients with tumors and other diseases].
Topics: Adult; Age Factors; Aged; Bone Diseases; Bone Neoplasms; Calcium; Calcium Isotopes; Cortisone; Femal | 1971 |
Five-drug therapy for advanced breast cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans | 1971 |
[Hemangiopericytoma with metastases. Effect of prednisone treatment].
Topics: Brain Diseases; Buttocks; Child, Preschool; Cysts; Hemangiopericytoma; Humans; Infant; Infant, Newbo | 1971 |
Autoimmune hemolytic anemia and ulcerative colitis: a multisystem immunodeficiency disease?
Topics: Adolescent; Adult; Anemia, Hemolytic, Autoimmune; Antibodies, Anti-Idiotypic; Blood Cell Count; Bloo | 1970 |
A simultaneous modification of A agglutinogen of erythrocytes and loss of specific platelet antigens in a patient with gall bladder carcinoma.
Topics: Agglutination Tests; Antigens; Blood Group Antigens; Blood Platelets; Erythrocytes; Female; Gallblad | 1969 |
Evaluation of adrenalectomy and hypophysectomy in the treatment of metastatic cancer of the breast.
Topics: Adrenalectomy; Breast Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Hypophysectomy; Ne | 1969 |
Bone marrow metastases in children with solid tumors.
Topics: Bone Marrow Diseases; Bone Marrow Examination; Bone Neoplasms; Child; Cyclophosphamide; Dactinomycin | 1970 |
Combined chemotherapy of epithelial tumours.
Topics: Breast Neoplasms; Cobalt Isotopes; Cyclophosphamide; Dactinomycin; DNA, Neoplasm; Female; Humans; Ma | 1970 |
[Clinical aspects of malignant pleurisy].
Topics: Adult; Aged; Biopsy; Diagnosis, Differential; Female; Humans; Male; Mesothelioma; Middle Aged; Neopl | 1970 |
[Hypercalcemia syndrome in bronchial carcinoma without skeletal metastasizing].
Topics: Bronchial Neoplasms; Carcinoma, Squamous Cell; Cardiac Glycosides; Female; Humans; Hypercalcemia; Hy | 1970 |
Retroperitoneal malignant mesenchymoma.
Topics: Adult; Aortography; Child, Preschool; Cyclophosphamide; Dactinomycin; Female; Humans; Male; Melphala | 1971 |
Hormonal therapy in advanced renal cell carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Bone Neoplasms; Brain Neoplasms; Female; Humans; Hydroxyprogesterones; | 1971 |
Bilateral inflammatory pseudotumors of the ciliary body.
Topics: Administration, Topical; Anti-Inflammatory Agents; Atropine; Biopsy; Ciliary Body; Diagnosis, Differ | 1971 |
Treatment of advanced cancer of the breast with 5-fluorouracil.
Topics: Adult; Aged; Breast Neoplasms; Castration; Cobalt Isotopes; Female; Fluorouracil; Humans; Mastectomy | 1971 |
Malignancy during methotrexate and steroid therapy for psoriasis.
Topics: Adult; Carcinoma, Squamous Cell; Humans; Immunosuppression Therapy; Lung Neoplasms; Male; Methotrexa | 1971 |
[The present position of hormone treatment of metastasizing cancer diseases].
Topics: Breast Neoplasms; Estrogens; Female; Gonadal Steroid Hormones; Humans; Male; Neoplasm Metastasis; Pr | 1967 |
Hypercalcemia accompanying ovarian mesonephroma without skeletal metastasis.
Topics: Alkaline Phosphatase; Calcium; Electroencephalography; Female; Humans; Hydrocortisone; Hypercalcemia | 1968 |
A radioisotopic method for determining optimum non-surgical therapy for advanced cancer. II. Clinical experience.
Topics: Adenocarcinoma; Breast Neoplasms; Diethylstilbestrol; Female; Fluorouracil; Fluoxymesterone; Gastroi | 1968 |
Effect of artificially induced abacterial erysipelas and of chronic aseptic abscess on human and experimental neoplasms.
Topics: Abscess; Adult; Aged; Amylases; Anemia; Animals; Breast Neoplasms; Child; Erysipelas; Eye Neoplasms; | 1968 |
Treatment of metastatic carcinoma of the female breast with combination of hormones and other chemotherapy.
Topics: Breast Neoplasms; Cyclophosphamide; Diethylstilbestrol; Female; Fluorouracil; Humans; Neoplasm Metas | 1968 |
Metastatic carcinoma to the choroid with choroidal detachment. A case presenting as uveal effusion.
Topics: Carcinoma; Choroid; Choroid Neoplasms; Eye Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neop | 1969 |
[Possibilities of treatment of meningeal dissemination in leukemia and malignant tumors in adults].
Topics: Adult; Brain Neoplasms; Female; Humans; Injections, Spinal; Intracranial Pressure; Leukemia; Male; M | 1969 |
Distinctive clinical and therapeutic aspects of the syndrome associated with bronchial carcinoid tumors.
Topics: Adenoma; Adult; Aortic Valve Stenosis; Bronchial Neoplasms; Carcinoid Tumor; Electrocardiography; Fe | 1965 |
Hormone therapy in metastatic breast cancer: clinical response and urinary gonadotrophins.
Topics: Aged; Anabolic Agents; Breast Neoplasms; Diethylstilbestrol; Female; Gonadotropins; Humans; Neoplasm | 1965 |
Hypercalcemia in patients with advanced mammary cancer and osseous metastases. Effect of hormone therapy and schedule of treatment.
Topics: Adult; Bone Neoplasms; Breast Neoplasms; Calcium; Estradiol; Female; Humans; Hypercalcemia; Middle A | 1966 |
[A previously unknown mechanism of the development of hypercalcemias in leukemia].
Topics: Aged; Calcium; Female; Humans; Hypercalcemia; Hyperparathyroidism; Leukemia; Neoplasm Metastasis; Pa | 1966 |
[Conservative hormonal treatment of metastatic mammary cancer].
Topics: Breast Neoplasms; Estrogens; Female; Humans; Nandrolone; Neoplasm Metastasis; Ovary; Prednisone; Rad | 1966 |